Yu, SM, 73P(ab)
Yu, Y-M, 230P(ab)
Yuan, A, 97P(ab), 98P(ab)
Yuasa, H, 242P(ab)
Yuille, D, 70P(le)
Yokhiro, M, 134P(ab)
Yun, E, 24P(ab)
Yun, L, 7P(ab)
Yun Ryo, U, 244P(ab)
Zachoval, R, 200P(ab)
Zagni, P, 231P(ab)
Zajac, JM, 163P(ab)
Zaknun, I, 2062
Zalberg, J, 107P(ab)
Zalutsky, MR, 644, 38P(ab)
Zambuto, GF, 1862
Zamora, PO, 42P(ab), 72P(ab), 129P(ab), 183P(ab)
Zanzi, I, 31P(ab)
Zanzone, P, 714, 25P(ab), 142P(ab), 714(br)
Zapf, A-O, 85P(ab)
Zaret, BL, 180, 1078, 131P(ab)
Zarnegar, K, 122P(ab)
Zasadny, KR, 5P(ab), 83P(ab), 214P(ab), 226P(ab)
Zea-Ponce, Y, 167, 525, 1175, 1182, 10P(ab), 31P(ab), 99P(ab), 118P(ab), 151P(ab), 164P(ab)
Zedlick, D, 108P(ab)
Zeiger, LS, 171P(ab)
Zeigler, SI, 3P(ab), 70P(ab), 46P(ab), 119P(ab)
Zhang, J, 100, 48P(ab), 214P(ab)
Zhang, JJ, 86P(ab), 90P(ab), 122P(ab), 127P(ab), 198P(ab)
Zhang, M, 837
Zhang, S, 151P(ab)
Zhang, Y, 172P(ab)
Zhang, YZ, 144P(ab)
Zhao, QH, 103P(ab), 192P(ab), 230P(ab)
Zhao, XD, 173P(ab)
Zhao, X-M, 982
Zheng, M, 143P(ab), 208P(ab)
Zhong, G-R, 829
Zhou, H, 142P(ab)
Zhu, J, 859
Zhu, N, 186P(ab)
Zhu, Y, 77P(ab)
Ziegler, S, 1747, 47P(ab), 75P(ab), 76P(ab), 82P(ab), 95P(ab), 140P(ab), 198P(ab)
Zielger, SL, 3P(ab), 70P(ab), 165P(ab)
Ziessman, HA, 64P(ab)
Zilleruelo, G, 34P(ab)
Zimmerman, RA, 191P(ab)
Zimmerman, RE, 60P(ab), 96P(ab), 270P(ab)
Zini, JM, 195P(ab)
Zinke, M, 82P(ab)
Zinn, KR, 850, 1818, 9P(ab), 92P(ab), 217P(ab)
Zipes, D, 137P(ab)
Zoboli, S, 44P(ab), 243P(ab)
Zoccarato, O, 58
Zogbhi, S, 99P(ab), 118P(ab), 248P(ab)
Zogbhi, SS, 167, 1175, 1182, 10P(ab), 31P(ab)
Zubal, G, 248P(ab)
Zubal, IG, 684, 1602, 46P(ab), 119P(ab)
Zubieta, JK, 20P(ab), 98P(ab), 99P(ab), 115P(ab), 237P(ab)
Zuccaro, W, 160P(ab)
Zuckier, LS, 1659, 2345, 55P(ab), 103P(ab), 161P(ab)
Zuger, J, 197P(ab), 199P(ab)
Zubieta, JK, 21P(ab)
Zukerberg, B, 131P(ab), 245P(ab)
Zukerberg, BW, 1514, 369(ed), 5P(ab), 95P(ab)
Zurakowski, D, 32P(ab)
Zuretti, AR, 73P(ab)
Ankylosing spondylitis, Paget’s disease/rheumatoid arthritis and, 125I Sm EDTMP for palliation, 1417

**Antibodies**
chimeric human-mouse IgG, shuffled constant region exons, structural factors of IgG half-life, 161P(ab)
design pitfall, radioimmunoconjugates, metabolizable ester bond, 158P(ab)
detection, 111In chimeric negative-charged-ZZD3 PL-F(ab)2, 133P(ab)
negative-charged modified dose, regulation of in vivo T/N ratio, atherosclerotic lesion imaging, 158P(ab)
99mTc-labeled chimeric ZZD3 Fab, experimental atherosclerotic lesion localization, 138P(ab)
99mTc photolabeling, preclinical testing, 160P(ab)

**Anti-CEA-antibodies**, targeting, liver metastases of colorectal cancer, 8P(ab)

**Anti-chelate body response**, 90Y-labeled HMFG1 MAb, ovarian cancer therapy, 746

**Antigranulocyte antibody**, 90mTc-labeled, bone marrow scintigraphy, 1800

**Antisense probes**
BCL2 oligodeoxynucleotide, 90Y-labeled, tumor cell killing by, 212P(ab)
sцинтиграфия, breast cancer oncogene, 201P(ab)

**Arterial瘤**
B-cell, embolism, hepatocellular carcinoma, 90mTc HIDA hepatobiliary scans, 1590
innominate stenosis, hemodynamic carotid transient ischemic attacks due to, cerebral blood flow and perfusion reserve capacity in, Doppler ultrasonography and SPECT, 1268
pulmonary, stenosis endovascular stenting, pulmonary 99mTc MAA сцинтиграфия, 2006
ventilation-perfusion mismatch, 1608
renal, stenosis, captopril renography, nuclear medicine physician interpretation, 2192

**Arthritis**
adjuvant, 99mTc anti-CD4 Fab fragment imaging, rats, 2268
rheumatoid, anklosing spondylitis/Paget’s disease and, 111In Sm EDTMP for palliation, 1417

**Artherosclerosis**
edoendothelin derivatives for imaging of, 102P(ab)
lesion imaging, effect of high and low dose ZZD3 antibody, 158P(ab)

**Atom bomb**
RFER management change, 13N(5)
35th anniversary, 17N(6)
ATP, glycolytic, radiolabeled 2-deoxyglucose uptake, 39P(ab)

**Atrioventricular node**, adrenergic activity, MIBG as index, 1096

**Attenuation correction**
accuracy, movement during PET imaging, 670 adaptive PET whole-body segmented evaluation of, 104P(ab)
initial clinical results, 105P(ab)
AsF sampling in SPECT, attenuation maps obtained, noise characteristics analysis, 169P(ab)

**A2F transmission scan**
cardiac SPECT, 40P(ab)
rationales for sequential application, 169P(ab)
breast, defect size measurement and, myocardial SPECT, 40P(ab)

**Brennstrahlung SPECT imaging, body contour determination and validation, 171P(ab)**
cardiac SPECT coronary heart disease, 132P(ab)
fast sequential SPECT/TCT data acquisition method, 169P(ab)
99mTc teboroxime, liver-heart artifact, 133 without transmission measurement, 506 clinical PET scans, thorax model database, construction, 185P(ab)
collimated scanning line source, fast data in TCT, 41P(ab)
combined scatter compensation 111In with energy spectrum fitting, 60P(ab)
201Tl cardiac SPECT, 60P(ab)
dual-head SPECT system, nonuniform sources, transmission imaging, 170P(ab)
ement-based, myocardial SPECT studies, 18P(ab)
fast sequential scanning SPECT system, effect of registration error between transmission and emission scans, 174P(ab)
iterative Chang algorithm, SPECT in large females, 40P(ab)
multilead SPECT system, 11P(ab)
myocardial perfusion SPECT, technical maturation, art becoming science, 905 myocardial tracer distribution effect, 201Tl cardiac SPECT, simultaneous transmission-emission, 921 quantitative SPECT, dual fanbeam gamma-ray transmission data acquisition, proposal, 172P(ab)
simultaneous transmission-emission SPECT, myocardial perfusion images, 12P(ab)
SPECT heart, EM-IntraSPECT method, 50P(ab)
activity and quantitative analysis, 46P(ab)
myocardial, comparison, 50P(ab), 51P(ab)
nonuniform, projection domain method, 50P(ab)
simultaneous transmission emission, 46P(ab)
Tc-MIBI and Tc-MIBI normal database variability, 45P(ab)
SPECT and x-ray CT imaging system combined, animal studies, 18P(ab)
99mTc sestamibi perfusion imaging, STEF and parallel hole SPECT comparison, PET validation, 169P(ab)

**Benzodiazepine receptors**
TCT, data from scanning line source, uniformity correction and calibration method, 173P(ab)
three-dimensional iterative reconstruction for, SPECT, 29P(ab)
transmission CT of head, with SPECT system and line source collimator, 328
use of hollow source and TEW scatter, improved TCT, 166P(ab)
whole-body PET, simultaneous emission and transmission measurements, 1680

**Autism**, functional deficits, 99mTc HMFP AO SPECT, 1156

**Automated alignment**
sizing and, three-dimensional templates, myocardial stress and rest 99mTc sestamibi SPECT, image registration algorithm, 1115
SPECT, three-dimensional transaxial myocardial perfusion, 1107

**Automatic image registration, MRI and PET**, brain images, 1307

**Autonomic nervous system**, modulation of cardiac function, PET measurements, 37P(ab)

**Autoradiography**
breast cancer, FDG intratumoral distribution, inflammatory cells and, 1854
double-tracer 3H and 14C using imaging plates, myocardial metabolic rat studies, 518
125I BMIPP and 201Tl comparison, myocardial hyperperfusion, 1645
film, comparison with new digital radioimager, radionuclide imaging, 169P(ab)
125I VIP in vitro receptor, VIP-R content in human tumors, 1846
radioisotintigraphy and, 99mTc sestamibi and 11C deoxyglucose, breast tumors in ne-nu transgenic mice, 1862

**Autoregulation**, V/Q match and, lung, 5P(ab)

**Avidin**
chase, tumors targeted by MAb biotinylation through, improved targeting of radiolabeled streptavidin, 837
chase repetition, excretion of radiolabeled biotinylated MAbs, 143P(ab)
111In in streptavidin and, human breast tumor xenograft, localization, 186P(ab)

**Azidobifuridine**, labeled, for imaging tumor proliferation, 208P(ab)

**B**

**Barium studies**, esophageal motor functions and gastroesophageal reflux, effect of endoscopic variceal sclerotherapy on, 1363

**Bayesian reconstruction**, EM algorithm, Gibb prior regularization of, weighting factor for, 8P(ab)

**Benzamidines**, dopamine D2 receptors of, extravascular binding effects, 256P(ab)

**Benzodiazepine**
children with epilepsy, 11C flumazenil PET, 83P(ab)
surface charge relationship, ligand and receptor, investigation, 155P(ab)

**Benzodiazepine binding sites**, peripheral, PET, microgliosis, Alzheimer’s disease, 2207

**Benzodiazepine receptors**
binding, ligand transport and, simple quantification by 125I iomazenil SPECT, 1201

---

Subject Index  •  1995

2415
Beta-adrenergceptors

brain concentration, 13C flumazenil PET, parameter and index images, 1462

123I iodobenzamid, SPECT measurement, reproducibility, 167
11C flumazenil, delayed PET activity and distribution volume after, 257P(ab)
CNS, 123I io-dobetaznid studies of, 6P(ab)

Peripherally-type
IPK, lesioned brain area detection, 143P(ab) transient ischemic brain, 68P(ab)

Beta-adrenergceptors
assessment, PET and 11C carazolol, 142P(ab) 
54C(carazolol) canine myocardial, lateral sympathetic reinervation and normalization, density after denervation, 1726(8)
54C(carazolol) canine myocardial density, reinervation and normalization after cardiac denervation, PET, 136P(ab)
54C(carazolol) cardiac, fluorocarazolol PET evaluation, 59P(ab) muscarinic and, canine myocardial, after denervation, PET, 140B

Beta-camera, intraoperative, 110P(ab)

Beta oxidation, septal, glucose utilization and, left bundle branch block, F18 FDG PET, 2056

Biliary atresia, diagnostic accuracy in, hepatic rejection index of DISIDA, 74P(ab)

Binding domain, BPV-1 E2 protein, structure, binding to DNA targets, 225(8)

Binding potential, determination, unsuitability of pseudoequilibrium methods, 179P(ab)

Biochemistry, revealing in a single image, 32N(9)

Biodistribution
dosimetry and
131I IDEX SPECT, for cholergic muscarinic neuroreceptors, 1332
44N polyoxon IGF, normal subjects, 2372
123I labeled anti-Tac disulfide stabilized Fv fragments, IL-2a receptor-positive tumor xenografts, 160P(ab)
preparation and, 13Y lipiodol, rats after hepatic arterial injection, 163P(ab)

Biokinetics
radiation dosimetry, 11O water bolus administration, blood flow PET, 651 radiodiode, 131I therapy capsules, 79P(ab)
Biotin, new 125I DOTA-, characterization for pretargeting, 154P(ab)
Bisphosphonate, dilemma, 70S(5)e reply, 70S(5)e

Bladder, therapeutic 131I MIBG, dosimetric models and S factors, children, 1530(8)

Bleomycin, radiochemotherapy and, 1531(8)

Block detectors, BGO PET, electron contribution to images, 175P(ab)

Blood, venous, sampling, calibrated standard input functions and, cerebral blood flow measurement, 123I IMP SPECT, 2339

Blood-brain barrier
breakdown, after RMP-7, 198P(ab) neutral amino acid transport, aging effect on, 44F Phe PET, 1232 permeability, central nervous system tumors, somatomedin receptor 111In DTPA-D-Phe-1-octreotide scintigraphy, 403

Blood-brain transport, regional striatal, decarboxylase activity and, 11F DOPA PET, Parkinson's disease, 1226

Blood flow
penis, 125I RBC washing time-activity curves, 55P(ab)
PET evaluation, 13O water bolus administration, 651
201TI and, comparison to myocardial 133I Tc teboroxime uptake during hyperemia, dogs with coronary stenosis, 476

Blood flow, cerebral
Alzheimer's disease, intellectual decline, parietal perfusion deficit prediction by, 1347
123I Tc HMPAO SPECT, three-dimensional surface cortical perfusion display, 690
24F Tracer PET, assessment of reserve, acetazolamide loading SPECT with double injection, 243P(ab) baseline, morning versus midday differences, 128P(ab)
caudate, low flow to, chest pain and, 244P(ab)
arteriovenous malformation, 13O water PET activation studies, delayed data acquisition, 2149
capillaries, electroencephalographic therapy, 125I Tc HMPAO SPECT study of, 244P(ab), 248P(ab)

Diazom, 123I Tc HMPAO SPECT, transcranial Doppler and, internal carotid artery stenosis, 243P(ab)
dimension after caffeine ingestion, effect on imaging, 245P(ab) distribution volume and, rapid calculation using 123I IMP and dynamic SPECT, 531 estimation of, 11Cu PTSM and three-dimensional compartment model in, 128P(ab)
glucose metabolism and, spontaneous epileptiform, 256P(ab)

high-resolution SPECT, hippocampal perfusion assessment, neoplastic syndromes, 1126

IMP IMP SPECT, calibrated standard input function and venous blood sampling, 2339
reproducibility and normal values, 239P(ab)
impaired cognitive function, ICBF imaging with 15O HMPAO, 108P(ab)
improved regional, chronic cocaine polydrug users treated with buprenorphine, 125I Tc HMPAO SPECT, 1211
ipsapirone challenge effects, depression, 247P(ab)

massive intracerebral calcifications, evaluation in, 125I Tc HMPAO SPECT, 610 measurement microsphere and 2-compartment model with 123I IMP and SPECT, 257P(ab)
123I Tc ECD compared with 13O water PET, 254P(ab)
125I Tc ECD on microsphere model, 254P(ab)
metabolism and, cats, high-resolution PET, application of clinical camera to experimental studies, 484
perfusion reserve capacity and, hemodynamic carotid transient ischemic attacks, innominate artery stenosis, Doppler ultrasound and SPECT, 1268
peripheral and global, acute intracerebral hemorrhage, SPECT study, 52P(ab)
postprostactectomy dysuria, 123I IMP SPECT in, 246P(ab)
post-traumatic stress disorder, PET and script-driven imagery use in, 42P(ab)
quantitation, clinical routine studies, 234(8) regional, after light therapy, seasonal affective disorder, 43P(ab)
sentence ambiguity effects, 13O water PET study, 250P(ab)
sequential measurement, double-injection method, 123I IMP SPECT, 1339 during sleep, 123I Tc ECD SPECT, 245P(ab)
SPECT, reproducible kinetic phantom for study, 173P(ab)
SPECT, activation study, post-traumatic stress disorder, 85P(ab)
stenosis, PET study, 53P(ab)
subacute ischemic stroke, 125I Tc HMPAO super dynamic SPECT, 54P(ab)
123I Tc ECD measurements, continuous arterial blood sampling and, 247P(ab)
123I Tc HMPAO distribution, measurement of cognitive activation, 63P(ab)
125I Tc HMPAO imaging, determination of brain death, 267P(ab)

125I Tc HMPAO SPECT autistic disorder functional deficits, 1156 children with cranioenostosis, 394 narcoleptic REM sleep, 1150
123I Tc HMPAO SPECT measurement of, obsessive-compulsive disorder, 20P(ab)
temporomandibular increase in, cocaine craving, PET study, 21P(ab)
visual stimulation effects, pharmacological stress and, 255P(ab)

Blood flow, coronary, perfused rat heart, 125I Tc nitroretocycle retention, effect of graded hypoxia on, 632

Blood flow, myocardial
after heart transplant, 3P(ab) caffeine and, rest and during pharmacological vasodilation, 2016
delineation, 13N ammonia and 18F deoxyglucose PET, 1543
estimation, 13N ammonia PET, 115P(ab)
18F FDG retention and, acutely stunned porcine myocardium, 637
hypercemic, effects of modified pharmacologic stress approaches, 575 impaired, after heart transplant, 78P(ab)
ischemia, fatty acid uptake in, 4P(ab)
low-flow ischemia, 18F FDG and 13N ammonia uptake comparison, 1633
measurement, 13N ammonia PET, 7P(ab)
13O-water bolus injection, slow infusion, 13O-carbon dioxide slow inhalation, measurement comparison, 78 quantification, 13N ammonia PET and factor analysis of dynamic structures, 2087 quantitative assessment, 13O water and PET, 78P(ab)
resting, measurement by 18F RB PET, 37P(ab) tracer, 125I Tc NOET kinetics, 1069
viability and, acute coronary artery occlusion and, myocardial 125I Tc teboroxime activity in, 1062

Blood flow, pulmonary, measurement, 13O water PET, 371

Blood flow, renal, vasoconstrictor effects, advanced heart failure patients, 55P(ab)

Blood flow, splenic, spleen-blood partition coefficient, determination for water, 13O water and 13C carbon dioxide dynamic PET steady-state methods, 599

Blood-pool imaging
antifibrin activity subtraction, pulmonary emboli detection, 176P(ab)
dep deep venous thrombosis, 125I Tc T2G1s antifibrin scintigraphy, computer processing, 2326 heart sound triggered multigated, assessment of diastolic function, 66P(ab)

2416 The Journal of Nuclear Medicine
lumbar spine, dual-head noncircular orbit acquisition, 236P(ab)
topographical improvement over fast helical scanning x-ray SPECT, 236P(ab)
three-phase imaging, overgrowth in fractured femurs, 234P(ab)
three-phase scintigraphy, reflex sympathetic dystrophy, 274P(ab)
trabecular, electron absorbed fractions and radiouclide S values, revised estimates, 181P(ab)

Bone marrow
ablation, in multiple myeloma, 166Ho DOTMP pharmacokinetics/dosimetry/toxicity, 730
glucose metabolism, response to hematopoietic cytokines, 186Tc FDG PET, 794
metastases, primary breast cancer, detection and follow-up by radioimmuno bone marrow scintigraphy, 1930(1e)
reply, 1930(1e)
new model, current dosimetry review, capabilities and implications, 181P(ab)
radiation dose to, radionuclide therapy, 86P(ab)
red, 2121 skeletal uptake, absorbed dose estimates, thyroid ablation patients, 183P(ab)
scintigraphy, 186Tc-labeled antigranulocyte antibody, 1800
unexpected 201TI uptake, nonsecretory myeloma, 250
Bone scan
age adjustment for, soft tissue to bone ratios, 26P(ab)
CT and MRI, in tumor-induced osteomalacia, 247
high-resolution SPECT
active artherosith of facet joints, 26P(ab)
successful facet joint injection, 26P(ab)
isolated vertebral compression fractures, cancer patients without known spinal metastases, 26P(ab)
Langerhan's cell histiocytosis, diagnosis and staging, 27P(ab)
spinal MRI comparison, assessment of spinal metastasis, 26P(ab)
186Tc MDP
non-Hodgkin's lymphoma, multiple organ metastatic calcification, hypercalcemia after chemotherapy, 820
radiographic findings and, osseous and central nervous system sarcoidosis, 464

Book reviews
A Chronology of Nuclear Medicine, 165
Internal Radiation Dosimetry, 166
Introduction to Clinical Radiation Oncology, 1729
Nuclear Imaging in Drug Discovery and Approval, 714
Nuclear Medicine Annual 1994, 165
Nuclear Medicine Procedure Manual 1995, 1729
Pediatric Nuclear Imaging, 714
Physics and Radiobiology of Nuclear Medicine, 714

Brain
activation, after motor stimulation
Huntington's chorea effects, 75P(ab)
PET versus functional MRI, 75P(ab)
activation studies, sentence ambiguity effects on blood flow, PET, 256P(ab)
altered serotonin and dopamine transporter densities, impulsive violent behavior and, 31P(ab)
baboon, dopamine transporter, 11C d-threo-methylphenidate binding to, PET, 2298
benzodiazepine receptor concentration, 11C flumazenil PET, parameter and index images, 1462
11C C19 hydroxycoronide, demonstration of in vivo binding to mitochondrial complex I, 152P(ab)
11C DTBZ in vivo binding, chronic L-dopa or deprenyl treatments, 153P(ab)
central dopamine transporters, PET quantitation of, 38P(ab)

cerebral arteriovenous malformation, 15O water PET activation studies, delayed data acquisition, 2149
cerebral blood flow sequential measurement, double-injection method, 1271 IMP SPECT, 1339
cerebral glucose utilization, early infancy, 18F FDG PET, simplified quantification methods, 1249
cortical uptake of 18F HMPAO PET, body weight, blood pressure, and age effects, 255P(ab)
dehth, 18F HMPAO survival imaging, 244P(ab)
distinguishing radiation necrosis from tumor recurrence, PET versus SPECT, 159
epilepsy, 18F HMPAO SPECT, ictal and interictal differences from, 684
FDG utilization, thermal injury and modifiers of energy metabolism effect on, 205P(ab)
18F FDG PET, in HIV-1-infected children born to seropositive mothers, 2169
frontal lobe, dopaminergic system in, serotonin reuptake inhibition in depression, 32P(ab)
glucose metabolic rates, improved calculation method using PET, 1668

glucose metabolism, FDG concentration in venous plasma, PET, 82P(ab)
high cortical uptake, 121I signa receptor ligands, 124P(ab)
hyponxia
assessment of dopamine receptors with, 121I IBZM, 240P(ab)
dopamine D2 receptor status, IBZM SPECT assessment of, 97P(ab)
123I IMZ SPECT, benzodiazepine receptors, 235P(ab)

intra-axial tumors, 111F pentetetrotide SPECT and 201TI SPECT and MRI, comparison, 537
intracerebral hematomata, distinguishing neoplastic from non-neoplastic, 11C methionine PET evaluation, 2175
in vivo binding demonstration, 11C dihydroxetanol to mitochondrial complex I, MPP inhibition, 161P(ab)
ischemia, peripheral type benzodiazepine receptor in, 68P(ab)
ischemic infarction, 186Tc ECD SPECT, 240P(ab)

laminar heterotopia, 186Tc HMPAO SPECT, 238
malignant glioma, FDG phosphorylation rate, PET, 61P(ab)

mapping regions with PET scans, 11N(T)
monkey, 11C palmitate, incorporation using PET, 2261
nonoamine oxidase sensitivity, aging and, PET, 127P(ab)
muscarinic receptors, concentrations of SPECT ligand 123I 4-IQNB in blood, 255P(ab)
11O carbon dioxide PET, implicit motor sequence learning, 76P(ab)
perfusion reserve
acacetazolamide loading SPECT assessment of, 243P(ab)
asessment with 123I IMP SPECT, 242(ab)
CO2 and acetazolamide SPECT, internal brain arteriogram, 243(ab)
99mTc HMPAO SPECT with acetazolamide enhancement, 242(ab)
presurgical evaluation, cardiovascular surgery, 242(ab)
PET and MRI images, coregistration method, 1307
primary or recurrent tumors, in vivo protein synthesis rate determination, 11C TVR and PET, 411
regional cerebral functions, 18F FDG PET, normal patterns and age changes, 1141
revised dosimetric model, 85P(ab)
seizure foci, ictal perfusion SPECT comparison with FDG PET, 84P(ab)
sigma subtype receptors, selective SPECT imaging, primates, 144P(ab)
SPECT
FASTSPECT, a new stationary system, 268P(ab)
new radiosynthesis of 123I QNB, 6P(ab)
quantitation, abnormality integral, 170P(ab)
visual cortex evaluation, amygdala, 1170
substrates, N-methyl-4-piperidinol esters as, 58P(ab)
survival/necrosis, predictive value of increased 99mTc HMPAO uptake, acute stage ischemic stroke, 2392(le)
99mTc ECD SPECT
early and delayed, in stroke, 712(le)
in vivo stability evaluation, 166P(ab)
99mTc HMPAO SPECT
after shunt operation, reversible hyperperfusion of cerebral cortex, in hydrocephalus, 470
practical cortical quantitative normalization method, 171P(ab)
three-dimensional intersubject image mapping, elastic image transformation for, 93P(ab)
traumatic injury, 68P(ab)
in PET, 247P(ab)
tumors
amino acid transport, percutaneous radiation therapy effects, 216P(ab)
childhood, 201(le) value over FDG, 222(ab)
glioblastoma cells, ionizing radiation effects, 202P(ab)
grade II astrocytoma, 99mTc HMPAO uptake increase, SPECT, 804
high-dose tamoxifen for, serial PET scans in, 225P(ab)
local relapse detection, 99mTc sestamibi, 196P(ab)
99mTc MIBI, 201P(ab), and CT/MRI comparison, 96P(ab)
radiation necrosis, thallium SPECT and MRI comparison, 95P(ab)
201Tl and, relation between tumor cell activity in astrocytic tumors and proliferating cell nuclear antigen, 2201
201Tl chloride and 99mTc HMPAO SPECT, 274P(ab)
vesicular monoamine transporters
11C DTBZ in, 123P(ab)
11C MIBZ PET, 225P(ab)
Brain agents, 99mTc mixed ligand approach biology, 145P(ab)
radiochemistry, 145P(ab)
Breast
attenuation, defect size measurement and, myocardial SPECT, 40P(ab)
cancer advanced tumor monitoring, 99mTc MIBI scintimammography, 193P(ab)
axillary lymph node involvement, PET, 82P(ab)
axillary lymph node involvement and, detection by 99mTc sestamibi prone scintimammography, 1758
axillary node assessment in, radioimmunodetection, 9P(ab)
bone marrow metastases, detection and follow-up by radioimmune bone marrow scintigraphy, 1930(le)
reply, 1930(le)
c-neu transgenic mice, 99mTc sestamibi and 11C deoxyglucose autoradiography and radioscintigraphy, 1862
detection, 99mTc MIBI, nonpalpable primary malignancies, 194P(ab)
diagnosis and staging with scintimammography and SPECT, 271P(ab)
estrogen receptors and, 18F FES/18F FDG PET and in vitro assay comparison, 1766
estrogen receptor status, PET measured FDG metabolism and, 83P(ab)
FDG distribution and glucose transporter-1 expression, 61P(ab)
FDG intratumoral distribution, inflammatory cells, and, 185
18F FDG-guided surgery, positron-sensitive probe, 1869
18F progestins as potential imaging agents, 39P(ab)
imaging with 99mTc-labeled synthetic peptides, 195P(ab)
mammary lymphoscintigraphy in, 1775
oncogene, imaging with antisense probes, 201P(ab)
PET imaging, Munich experience, 82P(ab)
PET instrumentation for, 69P(ab)
PET radiopharmaceuticals for, 69P(ab)
P-glycoprotein expression and 99mTc sestamibi efflux in, 129P(ab)
presurgical visualization, emission and transmission PET, 1882
primary lymphoma, 68F citrate SPECT detection, 236
quantitation of p-glycoprotein in sections of, 211P(ab)
radioiodinated phospholipid ether analog as imaging agent, 103P(ab)
scintimammography, comparative results, 51P(ab)
sigma receptor radiopharmaceuticals in, 124P(ab)
99mTc MDP scintimammography, 83P(ab), 718
99mTc MIBI mammoscintigraphy, 51P(ab)
99mTc sestamibi mammoscintigraphy, effect of dense breasts, 52P(ab)
99mTc sestamibi mammoscintigraphy in, 52P(ab)
99mTc sestamibi scintimammography, clinical and pathological follow-up, 1784
99mTc sestamibi versus dynamic MRI, 51P(ab)
99mTc tetrofosmin uptake in, 83P(ab)
tumor-bearing mice, chimeric L6 MAbs, conjugation to 111In and 99Y peptide, pharmacokinetics, 829
untreated, PET, FDG uptake differences, 83P(ab)
99Y/111In DOTA peptide chimeric L6, 97P(ab)
lactating, unilateral 131I uptake, 1724(le)
prostate and, tumor imaging, steroid receptor-based radiotracer design, 8S
suspicious lesions, 11In octreotide, comparison with 201Tl, 200P(ab)
tumors, qualitative 18F FDG PET, 189P(ab)
Bromine-76 189HO24, PET evaluation of, dopamine D1 receptor studies, 123P(ab)
enation of, evaluation of dopamine D1 receptors, 6P(ab)
Brown tumors, recurrent parathyroid carcinoma and, 99mTc MIBI uptake in, 511
Bucherer-Strecker, synthesis of 11C ACBC, 149P(ab)
Buprenorphine, chronic cocaine polydrug user treatment, improved regional cerebral blood flow, 99mTc HMPAO SPECT, 1211
Buttocks, soft-tissue trauma, clarification, 709(le)
reply, 709(le)
C
CAD, see Coronary artery disease
Caffeine
diminution of cerebral blood flow after, imaging problems, 245P(ab)
myocardial blood flow and, rest and during pharmacological vasodilatation, 206
Camera-based clearance, 99mTc MAG3, improved measuring method, 1689
Camera systems
BGO scintillation cameras, opposed pair, collimatorless projection imaging of positron emitters, 177P(ab)
ultra-portable cardiac, with radionuclide generator, 176P(ab)
Cancer cells
FDG uptake, increase by hypoxia, 1625
MDA-468, radioiodinated EGF receptor ligands as tumor probes, 71P(ab)
recurrent genetic aberrations, potential targets for nuclear medicine imaging, 22S
Captopril
renal scintigraphy, long-term renal revascularization effects, 44P(ab)
renography
hypertensive patients with reduced renal function, 44P(ab)
individual kidney GFR for parameter of renal function, 44P(ab)
nuclear medicine physician interpretation, 2192
Carbon-11, cocaine binding, subpharmacological versus pharmacological doses, PET, 1289
Carbon-11 ACBC, convenient synthesis, 149P(ab)
Carbon-11 acetate
dynamic PET, aorta time activities, model-based estimation, 186P(ab)
18F FDG and, 123I BMIPP PET compared with, decreased uptake, metabolic alterations in ischemic myocardium, 1974
injection, robotic compounding for clinical PET, 157P(ab)
PET
kidney disease, 1595
myocardial oxidative metabolism, 1595
hypertrophysion, 1974
Carbon-11 di-MP, radiotracer for dopamine transporter, baboons and human brain, 117P(ab)
Carbon-11 beta-CIT, PET, brain monoamine transporters, Parkinson’s disease, 1255
Carbon-11 BMHA, PET, fatty acid metabolism metabolism, 2062
platinum analogue, with 32P chronic phosphate intraperitoneal installations, ovarian cancer, 29
Chernoby induced thyroid carcinoma, politics versus science, 15N(9)
snags in research efforts, 15N(9)
Chest pain emergency center diagnosis, myocardial perfusion imaging, 88P(ab)
low blood flow to caudate nuclei and, 244P(ab)
99mTc sestamibi and tetrofosmin SPECT, prediction of cardiac events, 88P(ab)
Chimera BR96 111In- and 125I-labeled, comparative biodistribution of, 19P(ab)
radioiodination and biotinylation of, 19P(ab)
Chor-38, resorption, ileocolic pouch, quantitative measurement, 54P(ab)
Cholangiocarcinoma, hepatic lobar infarction in, absent uptake in 99mTc DISIDA hepatobiliary scintigraphy, 474
Cholecystitis acute, ultrasound and hepatobiliary scintigraphy in, 218P(ab)
AIDS patients, 99mTc hepatobiliary scintigraphy in, 73P(ab)
Cholecystokinin, pretreatment, gallbladder visualization and, 74P(ab)
Cholecystography endoscopic sphincterotomy for choledocholithiasis, gallbladder function after, 219P(ab)
morphine-augmented, CCK pretreatment effects on gallbladder visualization, 74P(ab)
Cholinergic neuron, 18F FBT PET study, monkey, 59P(ab)
Chromium-51 measurement of red cell mass, 23F(ab)
Chromium-51 EDTA, 99mTc MAG3 and, simultaneous glomerular filtration and tubular excretion rate, renal plasma flow, 1701
Chromosomes, potential targets for nuclear medicine imaging, recurring genetic cancer cell aberrations, 22S
Cine-scatigraphy, aerosol inhalation, mucociliary transport system evaluation, diffuse panbronchiolitis, 1355
Circadian rhythms, morning versus midday differences, baseline cerebral blood flow, 128P(ab)
Cirrhosis, noninvasive diagnosis, hepatobiliary scintigraphy with 99mTc IDA use in, 220P(ab)
Clonipramine, cerebral perfusion and, SPECT, obsessive-compulsive disorder, 2224
Cocaine abuse aging effects on serotonin receptors, 10P(ab)
dopamine transporters in, SPECT imaging of, 31P(ab)
increased mu-opioid receptors in, PET analysis, 20P(ab)
PET study of craving, 43F(ab)
temporolimic increase in cerebral blood flow during craving, PET, 21F(ab)
analogs, PET evaluation, in vivo study of monoamine transporter, 16Z(ab)
11C, binding at subpharmacological versus pharmacological doses, PET, 1289
chronic polydys users, buprenorphine treatment, improved regional cerebral blood flow, 11C- HMPAO SPECT, 1211
dopamine release induced by, transsysteptic modulation of, 11P(ab)
labeled, dopamine transporter occupancy by RTI-55 and, 118P(ab)
neurochemistry of addiction, radiopharmaceuticals and emission computed tomography, 1258P(ab-ed)
receptor sites, 18F FPT synthesis and tissue distribution, PET mapping, 153P(ab)
Colecystectomy, Gardner's syndrome, 99mTc HD PAPD abdominal uptake, 1611
Colistin, imaging model, 99mTc RP128, 114P(ab)
Collimation technique, simple hybrid, without geometric distortion, for emission tomography, 109P(ab)
Collimators collimatorless projection imaging of position emitters, opposed pair of BGO scintillation cameras, 177P(ab)
fanbeam, quality of focusing, 10P(ab)
high-energy pinhole, 131 radionuclide therapy patients, evaluation, 178P(ab)
line source, SPECT system and, transmission CT of head, 328
parallel plate and fanbeam, design and construction techniques, SPRINT and ASP SPECT, 167P(ab)
pinhole, ultra-high resolution SPECT, small animal studies, 2282
201TI myocardial perfusion SPECT, 47P(ab)
Colon cancer metastatic, Phase I radioimmunotherapy trial, 131I CC99, 586
pretargeted tumors, MAB biotinylation through avidin chase, improved targeting of radiolabeled streptavidin, 837
gastric transit and, assessment, 18FGa complexes as radioactive markers, 513
Colon carcinoma comparative biodistribution studies, 111In- and 125I-labeled chimera BR96, 19P(ab)
metastatic, 125I-labeled chimeric 171A, initial clinical evaluation, 2229
molecular radiotherapy of hepatic metastases, 125I IIDL in, 214P(ab)
Colorectal carcinoma anti-CEA MAB tumor uptake, 99mTc BW431/26 SPECT, 679
anti-colorectal carcinoma MAB, fragment 1A3-F(ab), 125I-Cu-labeled, preparation/biodistribution/dosimetry, 850
64Cu versus 125I-coupled MABS, radioimmunotherapy with, 217P(ab)
detection, 125I-coupled MAB 1A3 PET, 1818
immunoangiography, complete versus fragmented 99mTc-labeled anti-CEA MABS, 430
infusional 5-fluorouracil treatment, FDG-PET monitoring of response, 224P(ab)
enter metastases from FDG-PET preoperative evaluation of, 106P(ab)
hepatic arterial perfusion scintigraphy and CT portography, 107P(ab)
targeting with anti-CEA-antibodies, 8P(ab)
occul/recurrent, 18F FDG whole-body PET, 106P(ab), 107P(ab)
preoperative scintigraphy and operative probe scintimetry, 99mTc 68BrV59, 738
radioimmunoPET with MAB1A3 fragments in, 9P(ab)
recurrent, whole-body PET imaging in, 57P(ab)
surgically treated, comparison of 125I-labeled chimeric anti-CEA MAB and original mouse MAB, 420
Compartment syndrome, chronic exertional, legs, 201TI scintigraphy diagnosis, 1618
Compound W, marker for fetal thyroid function, maternal urine, 210P(ab)
Computed tomography (CT) comparison with 18F whole-body PET, lung cancer staging, 196P(ab)
MRI and bone scan, tumor-induced osteomalacia, 247 osteosarcoma, flare phenomenon after complete remission, 1429
PET and, thorax, retrospective image registration, 2333
SPECT and, image registration using external fiduciary band and three-dimensional surface fitting, metastatic thyroid cancer, 100
transmission, head, with SPECT system and line source collimator, 328
Computers crystallography and, structure-aided drug design, 28S
gamma camera system, simultaneous stress 99mTc/resting 99mTc cardioilate acquisition, 170P(ab)
image database, searchable, Basically Bone, 268P(ab)
image processing system, display and quantitative analysis, PET data, 270P(ab)
interactive diagnosis of pulmonary embolism, 271P(ab)
medical decision-making, 270P(ab)
whole-body viewer, onologic 18F FDG PET studies, 165P(ab)
Interfile, interoperability through, 272P(ab)
LARG*net, Internet, 268P(ab)
LYNIS, Mosaic and World-Wide Web server, 267P(ab)
MABDOSE, internal dose calculation program, 182P(ab)
metropolitan area network, ATOM technology, early results, 177P(ab)
Microsoft Windows-based viewing and processing program, DICOM and Interfile format nuclear medicine images, 268P(ab)
multimedia software, radiation accident management training, 267P(ab)
network-based database, quantitative clinical data management, 177P(ab)
uclear data on-line, 272P(ab)
nuclear medicine resident training, multi-institutional, World-Wide Web aid, 270P(ab)
nuclear medicine teaching file case-based, World-Wide Web accessible, 270P(ab)
Internet-based, 269P(ab)
simulation, PTT physiological basis, myocardial viability, 320
software, package for SPECT quantification, 270P(ab)
symbolic interactive modeling package, 271P(ab)
WEB client/server technology, local area networks and, 269P(ab)
Congress, United States, status report, 104th Congress, 24N(11)
Conjugate views, SPECT, correction for truncation, 40P(ab)
Connective tissue disease, esophageal hypomotility in primary and secondary Raynaud's
phenomenon, comparison of esophageal scintigraphy and manometry, 451
Constipation, gastroparesis and, assessment, $^{67}$Ga complexes as radioactive markers, 513
Convolution subtraction, scatter correction technique, high-resolution PET, 121
Copper(I) bis(thiosemiacarbazon), PET, tissue perfusion, species-dependent binding to serum albumin, 1451
Copper-62 DTS, non-nitroimidazole hypoxygen imaging agent, low redox potential, 49P(ab)
Copper-62 HSA-DTS, PET, regional cerebral plasma volume and hematocrit, 239P(ab)
Copper-62 PTSM three-dimensional compartment model and, estimation of regional cerebral blood flow, 128P(ab)
tissue perfusion, animal model studies as predictor of clinical performance, 1456(ed)
Copper-64 comparison, radioimmunotherapy of colorectal tumor-bearing hamsters, 217P(ab)
labeling anti-colorectal carcinoma MAb fragments 1A3-(ab)$_2$, preparation/biodistribution/dosimetry, 850
MAb 1A3 dosimetry determination by PET torso imaging 2363
PET, colorectal carcinoma detection, 1818
Copper-64 octreotide, biodistribution, tumor-bearing animal model, 114P(ab)
Copper-64 TETA octreotide, conjugates, comparison to $^{11}$In DTPA-D-Phe$_1$-octreotide, in vitro and in vivo evaluation, 2315
Coregistration, MRI-PET, striatal dopamine receptors, 252P(ab)
Coronary angioplasty, late result, 201Tl SPECT early myocardial perfusion data and anatomical appearance as predictor, 135P(ab)
Coronary artery disease assessment, intracoronary Doppler flow measurements, $^{99m}$Tc MIBI uptake, 136P(ab)
cardiac SPECT, attenuation correction without transmission measurement, 506
combined rest 201Tl/rest $^{99m}$Tc tetrofosmin SPECT, feasibility and diagnostic accuracy of 90-minute protocol, 932
correlative PET study, relationship of regional myocardial viability and reverse redistribution on planar thallium scintigraphy, 180
detection $^{11}$C acetate, comparison of coronary and metabolic reserves, 140P(ab)
dobutamine $^{99m}$Tc tetrofosmin SPECT, 132P(ab)
detection after heart transplant, $^{13}$N ammonia PET/coronary angiography comparison, 982
detection by dipyridamole, pharmacologic stress testing, modified approaches, effects on hyperemic myocardial blood flow, 575
experimental atherosclerotic lesion localization, $^{99m}$Tc-labeled chimeric Z22D3 antibody Fab, 138P(ab)
$^{123}$I-labeled synthetic peptide fragment, 25P(ab)
first-pass radionuclide ventriculography, $^{99m}$Tc tetrofosmin, motion correction without external source, 1941
$^{123}$I branched fatty acid, identification of ischemic myocardium at rest, unstable angina patients, 134P(ab)
left ventricular dysfunction in, arterial and ventricular elastance and ventricular coupling, role of changes, 131P(ab)
myocardial viability, rest $^{201}$Tl scintigraphy, reverse redistribution, 1968
myocardial viability index, $^{99m}$Tc MIBI redistribution, 1953
normal $^{201}$Tl SPECT with positive exercise ECCs, gender effects, 110P(ab)
occlusion and reperfusion, myocardial $^{99m}$Tc teboroxime activity in, relation to myocardial blood flow and viability, 1062
patients without myocardial infarction, severity of coronary stenosis and abnormal wall motion, decreased $^{125}$I BMIPP, 134P(ab)
severe conventionally fixed thallium defects, reversibility of, thallium scintigraphy, 120P(ab)
severity, $^{99m}$Tc tetrofosmin myocardial uptake at rest, 907
simultaneous function and perfusion imaging, $^{99m}$Tc tetrofosmin myocardial scintigraphy, 100P(ab)
single-vessel, $^{201}$Tl SPECT, implications of normal anatomy variability, 944
SPECT scintigraphy, results of coronary angiography and, 13P(ab)
stable, SPECT perfusion scintigraphy in, 13P(ab)
$^{99m}$Tc-NOET kinetics, myocardial blood flow tracer, 1069
$^{99m}$Tc sestamibi SPECT, attenuation correction, 132P(ab)
$^{99m}$Tc tetrofosmin, tracer biokinetics, quantitative coronary angiography comparison, 133P(ab)
three-vessel, sensitivity for arterial stenosis and, SPECT, 111P(ab)
$^{201}$Tl, reverse redistribution, 1019
$^{201}$Tl cardiac SPECT, simultaneous transmission-emission, myocardial tracer distribution effect, attenuation correction, 921
$^{201}$Tl imaging, dipyridamole and adenosine comparison, 77P(ab)
two-vessel, radionuclide cineangiography, predictive value, 131P(ab)
visible myocardium, enhanced detection by $^{99m}$Tc MIBI after nitrate administration, 1945
women radionuclide cineangiography in, 65P(ab)
$^{82}$Rb PET, 79P(ab)
$^{201}$Tl SPECT and $^{82}$Rb PET, 78P(ab)
Coronary flow reserve, familial hypercholesterolemia patients, 37P(ab)
Coronary stenosis, dogs, myocardial $^{99m}$Tc teboroxime uptake during hyperemia, comparison to $^{201}$Tl and regional blood flow, 476
Corpus callosum, cerebral glucose metabolism and, Lennox-Gastaut syndrome, 260P(ab)
Cortical blindness, after symptomatic hypothermia in, patients, 260P(ab)
cortical hypothermia, dynamic cerebral dysfunction visualized, serial scanning SPECT, 1272
Cost-effectiveness analysis, diagnostic management strategy choice, scaphoid fracture, 45
Craniosynostosis, cerebral blood flow study, $^{99m}$Tc HMPAO SPECT, 394

Cretzfeldt-Jacob disease regional cerebral glucose metabolism in, PET, 239P(ab)
$^{99m}$Tc HMPAO SPECT diagnosis, 616
Crossed cerebellar diaschisis, $^{125}$I IMP SPECT, 399
Cryptococcus neoformans, inhaled capsular-binding monoclonal antibody to, imaging of meningitis, 107P(ab)
Crystallography, computer processing and, structure-aided drug design, 28S
Cytochrome P450, inhibitors of, radioisotopes, biodistribution and PET imaging of, 49P(ab)
Cyclophosphamide, Zn-63 production, proton irradiation of unirradiated copper sulfate solution, 151P(ab)
Cystography nuclear, pediatric populations, 33P(ab)
voiding, bladder/duodenal leak after pancreatic transplant, 54P(ab)
Cytokines, hematopoietic, bone marrow glucose metabolism response to, $^{15}$F PET, 794

D
Database. See also Computers European Nuclear Cardiology Database, a practical guide, 177P(ab)
network-based, quantitative clinical data management, 177P(ab)
Decoupling parameters, gamma camera renography and, estimation of diagnostic yields, logistic regression analysis, 147
Dementia Alzheimer's and microangiopathy comparison, $^{99m}$Tc HMPAO brain SPECT, 108P(ab)
Alzheimer's and Parkinson's severity compared, FDG-PET method, 100P(ab)
Alzheimer type, benzodiazepine receptor, SPECT images of, 236P(ab)
cerebral blood flow, visual stimulation and pharmacological stress effects, 255P(ab)
cholin precursor effects in, $^{15}$O CBF measurements, 237P(ab)
differential diagnosis, follow-up rCBF SPECT scanning in, 108P(ab)
impaired cognitive function, ICBF imaging with $^{99m}$Tc HMPAO, 108P(ab)
neuropsychiatric disorders, hippocampal perfusion assessment, high-resolution SPECT, 1163
SPECT brain imaging, meta-analysis of, 107P(ab)

2-Deoxyglucose retention, glucose-6-phosphate inhibition and glucose transport blockade effects on, 130P(ab)
retention of, glucose transport protein concentration effects, tumor xenografts, 61P(ab)
uptake, tumor cells, glycolytic ATP as determinant of, 39P(ab)
Depression baseline variability and relation to treatment response, FDG PET, 44P(ab)
cerebral perfusion and psychopathology, $^{99m}$Tc HMPAO SPECT value in, 248P(ab)
dipyridamole-induced, ischemic ST changes, 77P(ab)
electroconvulsive therapy for, changes in cerebral blood flow, SPECT measurement of, 248P(ab)
ipsipatient challenge, effects on cerebral blood flow, 247P(ab)
Dermatomyositis

major increased mu opioid receptor binding, PET study, 21P(ab)
sertotonin reuptake inhibition effects on dopaminergic system, 32P(ab)
relapse, cerebral metabolic correlates in, FDG PET, 249P(ab)

Dermatomyositis, intestinal perforation, 99mTc pyrophosphate scintigraphy, 1615
Dextran, transport, 99mTc- and 18F-labeled, in situ rabbit lung, 1436

Diabetes
cardiac FDG studies in, hyperinsulinemic glucose clamp use in, 36P(ab)
cerebral blood flow in, evaluation with 99mTc HMPAO, 240P(ab)
effects on FDG accumulation, pancreatic cancer and skeletal muscle, 61P(ab)
gastric emptying/intragastric meal distribution/ blood glucose concentrations and, relationships, 2220
123I uptake, lung, 35P(ab)
noninsulin-dependent patients, myocardial glucose metabolism in, 18F FDG-PET evaluation, 456

Diagnosis
liver/spleen scintigrams, interpretation improvement by fuzzy logic, 1415
nuclear medicine physicians, interpretation and agreement, captopril renography, 2192
strategy choice, cost-effectiveness analysis, scaphoid fracture, 45

Diagnostic agents, metal-based, molecular modeling for, 269P(ab)

Diomax HMPAO, cerebral SPECT study, transient ischemic attack, 63P(ab)

Diostolic function, assessment, heart sound triggered multigated blood-pool acquisition, 66P(ab)

Digital imaging
dry-film laser printing system, 260P(ab)
event localization, depth-of-interaction information for, 110P(ab)

Diprenorphine, new 123I 7ga-O-iodoallyl, opioid receptor SPECT mapping, 163P(ab)

Dipyrillamine
coronary artery disease detection, pharmacologic stress testing, modified approaches, effects on hyperemic myocardial blood flow, 575
depression induced by, clinical, scintigraphic, angiographic and hemodynamic correlates, 77P(ab)
intravenous, acute effects on pulmonary airflow, during cardiac stress testing, 131P(ab)
myocardial perfusion, blunted response in older adults, 1137(le)
reply, 1137(le)
myocardial perfusion reserve and, effect of aging, 2032
stress myocardial SPECT imaging, image quality of 99mTc tetrofosmin in, 24P(ab)
99mTc tetrofosmin versus 99mTc sestamibi, 2009
stress testing
dynamic exercise and, reverse redistribution, 123I MIBI myocardial SPECT, 2035
myocardial blood flow and caffeine, rest and during pharmacological vasodilation, 2016
99mTc sestamibi SPECT with, myocardial perfusion testing, 76P(ab)
99mTc teboroxime and, myocardial clearance kinetics in coronary artery stenosis, 119(ed)
stenosis severity differentiation, dog, 111
201Tl imaging
detection of coronary artery disease, 77P(ab)
DL-ethylenediamine-cysteine, syn and anti isoformers, synthesis and characterization, 155P(ab)
DNA
antiseen oligonucleotides, preparation and distribution, 113P(ab)
binding domain structure, BP-V-1-E2 protein, binding to DNA target, 225
hybridization, antibody labeling via, 68P(ab)
oligonucleotides, 99mTc labeling, 2306
single strand breaks, repair, 291, mononuclear blood cells, 65P(ab)

Dobutamine
echocardiography, prediction of improvement of left ventricular function, 35P(ab)
exercise comparison, combined function-perfusion imaging, 77P(ab)
99mTc sestamibi SPECT with, myocardial perfusion testing, 76P(ab), 77P(ab)
99mTc tetrofosmin SPECT, coronary artery disease detection, 125P(ab)

Dopamine
cholinergic reserve, age-related loss, vesamicol receptor ligand in, 127P(ab)
11C-labeled transporter ligand, three-injection dynamic PET, design and analysis, 10P(ab)
endogenous, N-methyl-18F-benperidol and, 11P(ab)
18F fluorodopamine, via destannylation reaction, 152P(ab)
123I labeling and biodistribution, rats, 145P(ab)
intrasynaptic, release, imaging by IV cocaine and amphetamine, 10P(ab)
paraganglioma producing, not visualized by 123I MBG scintigraphy, 620
release after amphetamine challenge, schizophrenia, 10P(ab)
cocaine-induced, trans-synaptic modulation of, 11P(ab)
reuptake sites metabolite analysis of 123I IPT, 124P(ab)
brain monoamine transporters, 11C beta-CIT PET, 1255
reuptake transporter imaging, cocaine analog 123I IPT dosimetry, 183P(ab)
striatal cholinergic dysfunction, vesamicol receptor ligand(-)-123I MIB, Parkinson's disease, 162P(ab)
synthesis, from exogenous L-dopa, FDOPA and PET, 241P(ab)

Dopamine receptors
18F fallypride binding at, dose-response curve of amphetamine, 255P(ab)
PET, partial volume correction in, 254P(ab) SPECT, 123I IBZM uptake, basal ganglia lateralized differences, asymmetric Parkinson's disease, 1216
striatal, MRI-PET coregistration for, 252P(ab)

Dopamine D1 receptors
nonbenzazepine ligand for, PET evaluation, 123P(ab)
substituted isoquinoline derivative for, 99mTc ligand A-90204, 6P(ab)

Dopamine D2 receptors
assessment of functional state, agonist development as radiotracers, 152P(ab)
extrastriatal, ligand for, 11C FLP 457 PET, 127S
18F FCP PET studies of, rhesus monkeys, 252P(ab)
functional state assessment, agonist development as radiotracers, 152P(ab)
123I epidipride imaging, 255P(ab)
123I epidipride and IBZM, direct comparison for imaging, 255P(ab)
123I IBF SPECT imaging of, 11P(ab)
123I IBZM SPECT, striatal release after amphetamine challenge, 1182
imaging, schizophrenia, 87P(ab)
imaging dopamine release, IV cocaine and amphetamine, 10P(ab)
123I 2-ISP, 1191
123I epidipride dosimetry, 1316
occupancy of OPC-14597, 13C raclopride PET imaging, 252P(ab)
radiolabeled benzamides and salicylamides, extrastriatal binding effects, 256P(ab)
regional analysis, in Parkinson's disease, SPECT and 123I iodobenzamide, 384
R(-)-FIDA2 imaging agent, in vitro and in vivo binding properties, with 123I or 18F SPECT or PET, 1282

status
123I IBZM SPECT assessment of, 97P(ab)
123I IBZM assessment of, 240P(ab)
striatal and extrastriatal regions, 123I epidipride SPECT studies, 88P(ab)
true equilibrium for measurement, 123I IBZM bolus plus reinjection, SPECT, 252P(ab)

Dopamine D2/D3 receptors, antagonist, FIDA-2, PET or SPECT, 1322

Dopaminergic system, frontal lobe, somatostatin reuptake inhibition effects, major depression, 32P(ab)

Dopamine terminals, PET imaging agents, four 18F-labeled DOPA analogs for, 253P(ab)

Dopamine transporters
after fetal mesencephalic transplant, graft function in Parkinson's disease, 87P(ab)
aging effects
11C d-MP PET, 32P(ab)
123I IFT SPECT imaging of, 32P(ab)
11C cocaine binding, subpharmacological versus pharmacological doses, PET, 1289
11C d-threo-methylphenidate binding, baboon brain, PET, 2298
central, quantitation, PET, 58P(ab)
cocaine analog for use in, PET, 117P(ab)
cocaine-dependent subjects, SPECT imaging of, 31P(ab)
11C WIN 35248 PET imaging of, Parkinson's and progressive supranuclear palsy imaging, 99P(ab)
density
alteration with impulse violence behavior and, 31P(ab)
18F FPI synthesis and imaging for quantitation of, 38P(ab)
123I go-CIT-FE SPECT imaging of, 118P(ab)
123I go-CIT SPECT measures of, disease severity in Parkinson's, 99P(ab)
increase, prehypertensive spontaneously hypertensive rat, 258P(ab)
innervation density, WIN 35428 and GBR 12935 use in, 118P(ab)

marker, 123I beta-CIT simplified multidose preparation, 525
new ligand, 11C d-threo-methylphenidate PET, brain studies, 2162
occupancy by RTI-55, labeled cocaine use in, 118P(ab)
preclinical diagnosis, Parkinson's disease, 98P(ab)

pressynaptic, binding parameter, brain, 123I IPT SPECT, 125P(ab)
quantitative analysis, $^{13}$C CPT PET imaging, 32P(ab)

radiotracer for, baboon and human brain, 117P(ab)

SPECT imaging, Parkinson’s disease after MPTP treatment, 87P(ab)

stratal, 123I IPT SPECT, nonhuman primates, 2290

stratal binding, age-related decline, 123I beta-

CIT SPECT, 1175

Dosimetry

anti-CEA/anti-DTPA immunocomjuagate injection, medullary thyroid carcinoma, 225P(ab)

biodistribution and $^{131}$I IDEX SPECT, for cholinergic muscarinic neuroreceptors, 1332

$^{11}$In polyclonal IgG, normal subjects, 2372

$^{99m}$Tc P280, phase 1 study, 183P(ab)

bladder walls, models and S factors, therapeutic

$^{131}$I MIBG, children, 1530(le)

blood clearance and, MAb, single blood sample for use in, 226P(ab)

calculations, dynamic tumor and organ masses, generalized approach, 1923

clinically useful method, measured effective thickness and derived buildup factor, whole-body images, 182P(ab)

$^{64}$Cu MAb A1A3, determination by PET torso imaging, 2565

$^{14}$C urea breath test, 98P(ab)

dopamine D2/D3 receptor antagonist, FIDA-2, PET or SPECT, 1322

dopamine D2 receptor ligand, 123I epidepride, 1316

effect of dose and specific activity on tissue distribution, rats, 1111 in pentetetoxide scintigraphy, 623

electron absorbed fractions and radionuclide S values, revised estimates, trabecular bone, 181P(ab)

$^{18}$F FDOPA PET studies, reduced uptake, atrophic nerve fibers in, 2060
cardiotoxicity, early assessment by $^{11}$In antiyosin and $^{131}$I MIBG studies, 2044

Drug abuse, opiate dependence, $^{99m}$Tc HMPAO SPECT findings in, 248P(ab)

Drug design, structure-aided, crystallography and computational approaches, 285

Dual-isotope imaging

$^{18}$F ion/$^{18}$FDG PET, simultaneous imaging, whole-body skeletal and soft tissue, 184P(ab)

Schilling test, urine measurement accuracy, multicenter study, 1654

simultaneous, myocardial perfusion study, three-

window technique, 133P(ab)

$^{99m}$Tc and $^{99m}$Tc gamma imaging, design study, 180P(ab)

$^{99m}$Tc MIBI/$^{18}$FDG SPECT, rest myocardial perfusion/metabolism imaging, 2110

Dyspepsia, gastric antral motility in, dynamic antral scintigraphy evaluation, 1579

E

Echocardiography

comparison with $^{99m}$Tc sestamibi myocardial perfusion imaging, arubatine stress testing, 132P(ab)

dobutamine, thallium SPECT comparison, myocardial viability, 120P(ab)

dobutamine stress, PET comparison, myocardial viability, 67P(ab)

MRI and, validation of parameter estimation of cardiac geometry by ECG-gated PET, 1123

Editorials

assessment of the information boodogle resulting from the noninvasive stress tests in cardiology, 1009(ed)

cerebral blood flow quantitation in clinical routine studies: how far have we now come?, 2343(ed)

defining a role for thrombolytic therapy in the management of pulmonary embolism, 369(ed)

diagnosis of scaphoid fractures: the role of nuclear medicine, 48(ed)

functional studies in substance abuse: imaging and beyond, 1299(ed)

how safe for the patient is iodine-131 therapy for differentiated thyroid carcinoma?, 27(ed)

lymphoscintigraphy and the intraoperative gamma probe, 1780(ed)

measuring pulmonary vascular permeability, 1442(ed)

myocardial clearance kinetics of technetium-99m-teboroxime following dipiridamole injection, 119(ed)

myocardial metabolism of radiodinated BMIPP, 1051(ed)

new directions in pharmacologic stress imaging, 276(ed)

pinhole SPECT: ultra-high-resolution imaging for small animal studies, 2287(ed)

radioimmunotherapy of micrometastases: sidestepping the solid-tumor hurdle, 1910(ed)

scattered photons as good counts gone bad: are they reformable or should they be permanently removed from society?, 130(ed)

somatostatin receptor-based imaging in malignant lymphomas, 19(ed)

technologists are not fungible, 1666(ed)

threedimensional display in nuclear medicine: a more useful depiction of reality, or only a superficial rendering?, 703(ed)

tissue characterization in nuclear oncology: its time has come, 207(ed)

tissue perfusion of copper-62 PTSM: relevance of studies in animal models as predictors of clinical radiopharmaceutical performance, 1456(ed)

tumor pretargeting: almost the bottom line, 876(ed)

value of objective assessment of new radiopharmaceuticals, 1086(ed)

Ejection fraction

automatic quantification, myocardial perfusion $^{99m}$Tc sestambit, 2138

gated blood-pool, planar versus reprojected SPECT, 66P(ab)

left ventricular first-pass, 131P(ab)

first-pass radionuclide ventriculography, 101P(ab)

inotropic index assessment, simultaneous radionuclide angiography and oxygen consumption, at rest and during exercise, 138P(ab)

myocardial perfusion $^{82}$Rb PET imaging, 91P(ab)

semi-automated computation, 56P(ab)

Electroenshevelusive therapy

cerebral blood flow changes $^{99m}$Tc HMPAO SPECT measurement of, 248P(ab)

$^{99m}$Tc HMPAO SPECT use in, 244P(ab)

Electrophoresis, cellular uptake of radiolabeled macromolecules, 212P(ab)

Electrophoresis, gel, charge measurement of $^{99m}$Tc complexes, 147P(ab)

Embolism, pulmonary, PIOPED study, National Heart, Lung, and Blood Institute, review, 2380

Emission and transmission measurements, simultaneous, attenuation correction in whole-body PET, 1680

Emphysma, alveolar integrity, $^{99m}$Tc DTPA and $^{99m}$Tc HMPAO radioaerosol inhalation lung scintigraphy, 68

Endocarditis, bacterial, detection with streptavidin and $^{11}$In biotin, rats, 157P(ab)
Endocrine tumor
gastro-entero-pancreatic, bone and somatostatin receptor scintigraphy in, 127P(ab)
rats. 111In-PS28-111In-DTPA tumor uptake comparison, 192P(ab)

Endoscopy
PET/MRI and, 18F FDG, comparison, staging of head and neck squamous-cell carcinomas, 174-175 
variceal sclerosis, effect on esophageal motor function and gastroesophageal reflux, 1363 

Endothelin
derivatives, imaging of atherosclerosis, 102P(ab) after, 123I for imaging ET receptor distribution and occupancy, 163P(ab) 

Endotoxin, removal devices for, short-lived radiopharmaceuticals, 80P(ab) 

Energy-weighted acquisition, Compton scatter reduction, SPECT, receiver operating characteristics analysis, 2352 

Enteropeptidase, protein-losing, scrub typhus patients, 99mTc HSA scintigraphy in, 226P(ab) 

Esosinophilic granuloma, frontal bone, 203T1 versus 99mTc MDP uptake in, 107 

Epibatidine, labeling of nicotine receptors, brain, 253P(ab) 

Epidermal growth factor, receptor ligands, as tumor probes, 71P(ab) 

Epilepsy
11C flumazenil PET, children, 83P(ab) focal, 125I IMZ SPECT imaging in, 72P(ab) frontotemporal, interictal brain SPECT in, 73P(ab) ictal brain perfusion SPECT, comparison with FDG PET, 84P(ab) pediatric, 18F FDG PET imaging techniques with MRI, 262P(ab) 
photosensitive, activation studies, 99mTc HMPAO, children, 84P(ab) 
postictal stage, residual hyperperfusion in epileptogenic foci, SPECT, 73P(ab) seizure focus detection, 99mTc HMPAO SPECT and video-EEG combined, 73P(ab) spontaneous, local blood flow and glucose metabolism in brain, 256P(ab) 99mTc ECD SPECT, children, 84P(ab) 99mTc HMPAO SPECT, ictal and interictal difference images from, 684 temporal and frontal lobe, 99mTc ECD rCBF brain SPECT, 72P(ab) temporal lobe seizure, postictal 99mTc HMPAO SPECT, 73P(ab) 

Erbium-170, enriched erbium oxide, neutron-activated, pancreatic, dosimetric postproduction optimization, 888 

Erectile dysfunction, penile hemodynamics, measurement with nonimaging scintillation probe, 99mTc-labeled red blood cells, 2345 

Erratum, 1723(e) 

Erythrocytes, as 18F FDG integrator, 187P(ab)
Erythrocytosis
diffuse panbronchiolitis treatment, mucociliary transport system evaluation, aerosol inhalation cine-scintigraphy, 1355 
esophageal motility, noninsulin-dependent diabetes, 219P(ab) 
gastric emptying and, noninsulin-dependent diabetes, 218P(ab) 
methocarbamol versus, prokinetic agents for gastroparesis, 63P(ab) 

Esophagus 
hypomotility, primary and secondary Raynaud's phenomenon, comparison of esophageal scintigraphy and manometry, 451 

motility, erythromycin effects, noninsulin-dependent diabetes patients, 219P(ab) 
motor functions, gastroesophageal reflux and, effect of endoscopic variceal sclerotherapy on, 1363 

scintigraphy, systemic sclerosis, 1533 

Ester bond, metabolizable, radioimmunoconjugates, 158P(ab) 

Estrogen receptors
biokinetics of 125I DSEP, tumor-bearing mice, 161P(ab) 
breast cancer and, 18F FES/18F FDG PET and in vitro assay comparison, 1766 
tissues rich in, after tamoxifen treatment, FDG and FES uptake, 39P(ab) 
Exercise, cardiopulmonary tests, normal sedentary subjects, ambulatory monitoring of left ventricular function, 564 
Exercise testing, normal baseline ECG patients, myocardial perfusion imaging necessity in, 110P(ab) 
Expert systems, myocardial SPECT, operatorless processing, 2127 

Extrapulmonary diseases, 2424 

F Fab imaging, 111In antimony, systemic lupus erythematosus, myocardial involvement demonstration, 1432 

Facet fracture, 99mTc anti-CD4, adjuvant arthritis, rats, 2268 

Facet syndrome, diagnosis, planar and high-resolution SPECT bone imaging, 37 

Factor analysis, dynamic structures, blood time-activity curve extraction, 15N ammonia and 18F FDG PET studies, 1714 

13N ammonia PET and, myocardial blood flow quantification, 2087 

Fahr's disease, massive intracerebral calcifications, evaluation of regional cerebral blood flow in, 99mTc HMPAO SPECT, 610 

Familial amyloidotic polyneuropathy, transthyretin-related, cardiac sympathetic denervation in, 1271 MIBG detection, 1040 

Femotomobilization, cardiac SPECT, reconstruction using exact body contour, effect on defect detection, 168P(ab) 

Fats, chemical characteristics of, effects on gastric emptying, 64P(ab) 

Fatty acids 
151I BMIPP decreased uptake, metabolic alterations in ischemic myocardium, PET, comparison with 18F FDG and 13C acetate, 1974 
perfused rat hearts, 1043 
metabolism abnormality detection, PET, patients with cardiomyopathy, 142P(ab) 
11C BMH A SPECT, 2002 
myocardial improved utilization, percutaneous transluminal coronary angioplasty. 203T1 and BMIPP imaging, 1605 
metabolism, evaluation by 125I BMIPP, ga- and gh-oxidation contribution, 137P(ab) 
tracer extraction, perfusion, inotropic state and lactate level effects, 48P(ab) 
uptake, normal and ischemic myocardium, 4P(ab) 
uptake and clearance of 125I-labeled IPPA, low flow ischemia effects, 136P(ab) 

myocardial infarction, defect reversibility analysis, 203T1 and 123I MIHA SPECT, 1561 

FDG imaging, see also Fluorine-18 FDG; Fluorodopa 

Feeding disorders, children, radionuclide studies of upper GI tract, 351 

Fertility, female, carcinogenesis and, assessment after 131I therapy for differentiated thyroid carcinoma, 21 

Fetus, thyroid function, Compound W as marker in maternal urine, 210P(ab) 

Fibromyalgia syndrome, low caudate and thalamic blood flow, shown on 99mTc HMPAO SPECT, 247P(ab) 

Filtered backprojection, reconstruction, depth-dependent blur correction and, 29P(ab) 

First-pass data, Fourier phase analysis, detection of pulmonary sequestration, 244 

Fistulas, postradiation vesicoanastomotic, 111In leucocyte detection, uterine carcinoma, 618 

Flare phenomenon, osteosarcoma, after complete remission, CT and MRI, 1429 

Flow tracer, Rb and Tl mean transit time analysis, regionally altered myocardial perfusion quantification potential, rabbit heart, 138P(ab) 

Fluorine-18 
18F-labeled MeNS652 analog, radiosynthesis and biodistribution, 151P(ab) 
desmethoxy colchicine, radiolabeling with positron emitting radionuclides, 150P(ab) 
distribution, SPECT, 18P(ab) 
FDG PET, regional cerebral functions, normal patterns and age changes, 1141 
FEQNB and PETRB, new peripheral MR ligands, parasympathetic imaging, 137P(ab) 
labeled MLD-28161 and MLD-100151, synthesis and separation of optical isomers, PET ligands for study of SHT2 receptors, 149P(ab) 
labeling of SR 46349B, 5-HT1 receptor antagonist, 149P(ab) 

PET inhibitors of cyclooxygenase, 49P(ab) 
ligands for study of serotonin receptors, 58P(ab) 
nitric oxide synthase inhibitors for, 48P(ab) 
progestosterone labeled with, breast tumor imaging, 39P(ab) 
radiofluorination, fluorosulphonates and fluoroprogestins, 39P(ab) 
synthesis of 18F fluorodopamine, via destannylation reaction, 152P(ab) 
99mTc and, labeled dextran transport, in situ rabbit lung, 1436 
tracers, for the ionophore associated with the NMDA receptor, 150P(ab) 
transferin labeled with, measuring tumor metabolism, 38P(ab) 

Fluorine-18 CEM 219, biodistribution, infection, 206P(ab) 

Fluorine-18 deoxyglucose, 18F ammonia and, PET, myocardial viability delineation, 1543 

Fluorine-18 DOPA, regional striatal transport and decarboxylation activity, PET, Parkinson's disease, 1226 

Fluorine-18 fallypride, binding at dopamine receptors, dose-response curve of amphetamine, 255P(ab)
Fluorine-18 FDG

abdominal activity, level, 106P(ab)
accumulated myocardially, during low flow ischemia, 4P(ab)
11C acetate and, 121I BMIPP PET compared with, decreased uptake, metabolic alterations in ischemic myocardium, 1974 comparison with 201Tl recurrent metastatic differentiated thyroid cancers, 203P(ab)
constrained method, lumped constant during hyperglycemia, 235P(ab)
dementia severity, Alzheimer’s and Parkinson’s compared, 100P(ab)
detection of cervical metastases, head-neck cancer, 221P(ab)
DIS 127 I/SPECT and, with parallel hole and fan beam collimators, 167P(ab)
double injection, cerebral glucose utilization change mapping, constrained weighted-integration method, 187P(ab)
fast back-to-back synthesis, one Siemens/CTI CPCIU, 154P(ab)
18F FES and, PET, comparison with in vitro assays, estrogen receptors in breast cancer, 1766
18F FMISO and, uptake comparison, low-flow ischemia, myocardial viability, 1633
18F FTHA and, PET, left bundle branch block assessment, septal beta-oxidation and glucose utilization, metabolic mismatch, 2056
fusion of PET and MRI studies, pancreatic cancer localization, routine use of anatomically weighted external markers, 174P(ab)
guided surgery, breast cancer, positron-sensitive probe, 1869
high accumulation, in turpentine-induced inflammatory tissue, PET, 1301 improving the yield, use of microwave cavity, 150P(ab)
increased myocardial uptake, after dichloroacetate infusion, rats, 137P(ab)
integrator, erythrocytes as, 187P(ab)
methionine tumor tissue uptake and, PET comparison, 484
myocardial blood flow and, in acutely stunned porcine myocardium, 637
11N ammonia and, PET, blood time-activity curve extraction, factor analysis of dynamic structures, 1714
normal tissues, standardized uptake values, 165P(ab)
PET
bone marrow glucose metabolism, response to hematopoietic cytokines, 794
brain imaging, HIV-1-infected children born to seropositive mothers, 2169
breast cancer and estrogen receptor status, 83P(ab)
clinical assessment of myocardial glucose uptake, nicotinic acid effect, 996
clinical utility, metastastic melanoma detection, 193P(ab)
combined transmission and emission data use, improved myocardial wall detection, 165P(ab)
comparison with 18F FDG SPECT and rest 201Tl SPECT, myocardial viability detection, 176
comparison with MRI, evaluation and follow-up of pelvic lesions, 189P(ab)
comparison with MR spectroscopy and dynamic perfusion MRI, in NFI optic pathway and brainstem tumors, 191P(ab)
detection of occult/recurrent colorectal cancer, 106P(ab)
diagnostic value, primary and metastatic thyroid cancer, 196P(ab)
ey early infancy, cerebral glucose utilization, simplified quantification methods, 1249
6Ga6Ge transmission scan, pulmonary mass lesions, 189P(ab)
glucose metabolism in vivo assessment, hepatocellular carcinoma, 1811
kinetic analysis, comparison with enzymatic activity and histological grading, hepatocellular carcinoma, 188P(ab)
Leber’s hereditary optic neuropathy, 246P(ab)
local recurrent prostatic cancer and scar, 198P(ab)
mediastinal FDG uptake, normal limits and affecting factors, 190P(ab)
metastatic testicular carcinoma, 189P(ab)
monitoring of colorectal cancer response to 5-fluorouracil treatment, 224P(ab)
myocardial, ventricular wall motion and, comparison with reverse redistribution on 24-hour delayed imaging of exercise, 201Tl myocardial SPECT, 86
myocardial glucose metabolism evaluation, noninsulin-dependent diabetes mellitus patients, 456
normal and ischemic myocardium, glucose utilization and plasma insulin, 141P(ab)
oncologic studies, interactive whole-body viewer, 165P(ab)
opinion imaging criteria, malignancy risk estimates, solitary pulmonary nodules, 190P(ab)
opinion scanning protocol, pulmonary malignancy evaluation, 883
Parkinson’s disease, severity assessment, 378
pleomorphic xanthoastrocytoma, 97
prostastic cancer metastases, detection, 189P(ab)
skeletal muscle, viability assessment, 1408
staging for squamous cell carcinoma, head and neck, 221P(ab)
three-dimensional stereotactic surface projections, Alzheimer’s disease diagnosis, 1238
201Ti SPECT and, value in detection of pancreatic cancer, 229
201Tl SPECT comparison, patients with solitary pulmonary nodules, 192P(ab)
tumor-host interaction, potential role, 893
use of maximum likelihood reconstruction, enhanced discrimination, 165P(ab)
PET and MRI, squamous-cell cancer of head and neck, detection of lymph node metastases, 211
PET/MRI/endscopy comparison, staging of head and neck squamous-cell carcinomas, 1747
planar PET, myocardial viability assessment, after recent infarction, 975
SPECT
cardiac and oncologic practice, 273P(ab)
comparison with 18F FDG PET and rest 201Tl SPECT, myocardial viability detection, 176
correlation with 18F FDG PET, 988
image reconstruction, use of geometric point response correction, 167P(ab)
511-keV annihilation photons, 1472
management of head and neck cancer, 221P(ab)
SPECT versus PET comparison of interpretation, 140P(ab)
current technology and clinical experience, 267P(ab)
detection of malignancies, 194P(ab)
standardized uptake values, total body weight and, 201P(ab)
99mTc MIBI and, SPECT, simultaneous dual-isotope acquisition, rest myocardial perfusion/metabolism imaging, 2110
99mTc pertechnetate/131I and, PET, cervical lymph node metastasis of thyroid papillary carcinoma, 1843
uptake emission and transmission PET, presurgical visualization, breast cancer, 1882
glucose metabolism and, 96P(ab)
in normal tissues, standardized values, 165P(ab)
whole-body PET
diagnostic accuracy, oncologic patients, 193P(ab)
lung cancer staging, comparison with CT, 196P(ab)
potential role, unknown origin tumors, 194P(ab)
staging, malignant melanoma, 191P(ab)
Fluorine-18 FDOPA
PET, Parkinson’s disease, 115P(ab)
radiation absorbed dose, reduction by hydration-induced voiding, 98P(ab)
uptake
caudate and putamen, Parkinson’s disease, 246P(ab)
suppression during motor task, 76P(ab)
Fluorine-18 FES, 18F FDG, PET, comparison with in vitro assays, estrogen receptors in breast cancer, 1766
Fluorine-18 FIBG, positron-emitting analog of 125I MIBG, validation as, 644
Fluorine-18 FIFP, synthesis and primate imaging, dopamine transporter density, 38P(ab)
Fluorine-18 fluorophenylalanine, 11C Met comparison, tumor imaging, 72P(ab)
Fluorine-18 FMISO
detection of cerebral hypoxia, in arteriogenous malformation, 53P(ab)
18F FDG and, uptake comparison, low-flow ischemia, myocardial viability, 1633
PET, meningioma, 222P(ab)
Fluorine-18 FPT, cocaine receptor site mapping, potential radioligand, synthesis and tissue distribution, PET, 153P(ab)
Fluorine-18 FTHA, 18F FDG and, PET, left bundle branch block assessment, septal beta-oxidation and glucose utilization, metabolic mismatch, 2056
Fluorine-18 FUG, pharmacokinetics, experimental tumor models, 217P(ab)
Fluorine-18 octreotide, uptake kinetics, PET measurement, tumor-bearing rats, 113P(ab)
Fluorine-18 PFBG, distribution of sympathetic neuronal tracer, canine myocardium, 38P(ab)
Fluorine-18 Phe, PET, blood-brain barrier, aging effect on neutral amino acid transport, 1232
Fluorine-18 Ro419060, synthesis, COMT inhibitor, use in vivo mapping with PET, 153P(ab)
Fluorine-18 setoperone, PET, neurocortical serotonin receptor binding, 128P(ab)
Fluorodeoxyglucose (FDG), See also Fluorine-18 FDG; Positron emission tomography (PET)
accumulation, hypoxia-induced increase, 62P(ab)
cardiac studies, in diabetics, hypersulinemic glucose clamp in, 36P(ab)
cerebral glucose metabolic rates, improved calculation method using PET, 1668
131I-labeled, insulin effects, human myocardium, 38P(ab)
131I PET, optimum scanning protocol, pulmonary malignancy evaluation, 883 intrathoracic distribution
breast cancer, inflammatory cells and, 1854 syngeneic breast cancer, 61P(ab)
PET
11C acetate combined with, renal neoplasms, 55P(ab)
recurrent or residual lung cancer detection, 785
unknown primary malignancy, 56P(ab), 57P(ab)
yohimbine administration, post-traumatic stress disorder, 43P(ab)
regional uptake, normal lung, 4P(ab)
99mTc MIBI/FDG SPECT, evaluation of myocardial ischemia, 35P(ab)
uptake, increase by hypoxia, human cancer cell lines, 1625
uptake of tritiated methionine and, in vitro comparison of cell proliferation kinetics and, squamous-cell carcinoma of head and neck, 252
utilization, thermal injury and modifiers of energy metabolism effects, brain, 205P(ab)
Fluorotropine, synthesis and primate imaging, dopamine transporter density, 38P(ab)
Fluorouracil, 131I-labeled, experimental tumor models, 217P(ab)
5-Fluorouracil, treatment of colorectal cancer, monitoring of response with FDG PET, 224P(ab)
Foot ergometer, device for lymphoscintigraphy, 262P(ab)
Fourier analysis
first-pass data, detection of pulmonary sequestration, 244
gastric contractions, quantitative analysis, liquid versus solid meals, 64P(ab)
radionuclide angiography, diagnosis of cardiomyopathy, 101P(ab)
Fractional uptake, clarification, 711(lec)
reply, 712(lec)
Fractures
femur, overgrowth, three-phase bone imaging, 234P(ab)
sacropoid diagnosis, role of nuclear medicine, 48(ed)
diagnostic management strategy choice, cost-effectiveness analysis, 45
diagnostic role of nuclear medicine, 1725(lec)
tibial, bone loss after, goat, 123P(ab)
vertebral compression, malignancy in, bone scans of cancer patients, 26P(ab)
Fundoplication, gastric, failure of, scintigraphic identification of, 21P(ab)
Furosemide
diuresis, whole-body PET imaging and, aggressive bladder irradiation, 199P(ab)
hindered, expected on lung clearance of 99mTc-DTPA, 73
Fuzzy logic
liver scintigraphy, chronic liver disease diagnosis, 593
liver/spleen scintigrams, interpretation improvement, 1415

Fv fragments
anti-Tac disulfide stabilized, 99mTc labeling methods and tumor detection, comparative studies, 160P(ab)
18F- and 125I-labeled anti-Tac disulfide stabilized, IL-2 receptor positive tumor xenografts, nude mice, 160P(ab)
Fv molecules, single-chain, stable radiolodine conjugation mediation, enhanced tumor specificity, 2276

G
Gallbladder
function, after endoscopic sphincterotomy for choledocholithiasis, 219P(ab)
nonvisualization on hepatobiliary scintigraphy, relation to laparoscopic cholecystectomy, 220P(ab)

Gallium-67 complexes as radioactive markers, constipation and gastroparesis assessment, 513
mediastinal Hodgkin and non-Hodgkin lymphoma, 117P(ab)
scintigraphy
appearance of tuberculosis, 23P(ab)
lung, bone involvement monitoring, 446 radiographically negative tuberculosis in HIV-positive patients, 207P(ab)
salivary gland disorders, 220P(ab)
207Tl and, accumulation in pediatric primitive neuroectodermal tumor, chest wall, 814

Gallium-67 citrate
comparison with 99mTc albumin, lung scanning, HIV-positive patients, 208P(ab)
SPECT, detection of primary breast lymphoma, 236

Gallium-68, PET, myocardial imaging with, 49P(ab)

Gamma camera
event localization, depth-of-interaction information for, 110P(ab)
semiconductor detector arrays, charge transport modeling in, 124P(ab)
single-crystal, first-pass radionuclide angiocardiology, count statistics as limiting factor, 1528(lec)

Gamma probe
intraoperative, lymphoscintigraphy and clinical localized melanoma, 222P(ab)
sentinel node in melanoma patients, 1173P(ab)
leakage measurements, during selective limb perfusion, melanoma patients, 217P(ab)
perioperative radiodetection of endocrine tumors, 202P(ab)
wide-range LSO, intraoperative gamma counting, 109P(ab)

Gardner's syndrome, coloectomy in, 99mTc DTPA abdominal uptake, 1611

Gastroenteropancreatic neuroendocrine tumors, somatostatin receptor imaging, 111In pentetreotide, safety/efficacy/impact on management, 542

Gasric emptying
chemical characteristics of fatty acids, energy density and, 64P(ab)
erthyromycin effects, noninsulin-dependent diabetes, 218P(ab)
imaging posture effects, pediatric, 259P(ab)
inexpensive screening scintigraphic test, evaluation, 93

intragastric meal distribution/blood glucose concentration and, in diabetes mellitus, 2220
lag phase, effect of temporal sampling, 64P(ab)
metoclopramide versus erythromycin as prokinetic agents, comparison, 63P(ab)
milk feedings, infants and children, 259P(ab)
neuromuscularly disabled children, gastrostomy and, 22(ab)

Gastric motility, contractions, quantitative analysis, liquid versus solid meals, 64P(ab)

Gastrinoma, imaging, 111In pentetreotide, 126P(ab)

Gastritis, 13C urea breath test use in, 227P(ab)

Gastroesophageal reflux
esophageal motor functions and, effect of endoscopic varical sclerotherapy on, 1363

measure of regurgitation, children with feeding disorders, 259P(ab)

Gastrointestinal motility, opioid and opioid-like effects, gastroenterocolonic scintigraphy, 65P(ab)

Gastrointestinal tract
absorption/permeability study, 99mTc DTPA not suitable for, 219P(ab)
FDG abdominal activity, level of, 106P(ab)
lower,ileo-rectal anastomosis assessed by 99mTc enema, 220P(ab)
upper, radionuclide studies, children with feeding disorders, 351
Gastropareisia, constipation and, assessment, 67Ga complexes as radioactive markers, 513
Gastroscopy, neuromuscularly disabled children, dumping syndrome in, 22(ab)

Gelatin capsules, 99mTc SC, residence time and disintegration time, 64P(ab)

Gender differences
aging and, sacroiliac scintigraphy, 235P(ab)
normal 201Tl SPECT with positive exercise ECG, CAD, 110P(ab)
pulmonary embolism presentation or response to therapy, 111P(ab)

Generator, radiopharmaceutical, 62Zn/Cu PET, 49P(ab)

Gene therapy
CD, 5-FC in vitro studies, 188P(ab)
HSV thymidine kinase and ganciclovir, hepatoma cells, multiacrier studies, 190P(ab)

Genetic aberrations, recurrent, cancer cells, potential targets for nuclear medicine imaging, 22S

Genotype, to phenotype via chemotype, molecular nuclear medicine, 2S

GFR, see Glomerular filtration rate

Glioblastoma, malignant, intratralesional radiodetection, 213P(ab)
Glioma
high-grade, radiation treatment for, 201Tl uptake after, 96P(ab)
malignant, FDG phosphorylation ratio, brain, PET, 61P(ab)
supratentorial, preoperative, 201Tl brain SPECT imaging in, 96P(ab)

Glomerular filtration rate
dynamic renal images, 99mTc DTPA, 231P(ab)
measurement of hybrid single plasma sample method for, 231P(ab)
renal transplant patients, 231P(ab)
plasma volume product, 99mTc DTPA assessment, 1602
tubular excretion rate and, renal plasma flow and, simultaneous, \(^{99m}Tc\) MAG3 and \(^{201}Tc\) EDTA, 1701

**Glucose**

blood, concentration, gastric
emptying/intestinal meal distribution and, relationships in diabetes mellitus, 2220
cerebral, metabolic rates, improved calculation method using PET, 1668
cerebral utilization, early infancy, \(^{18}F\) FDG PET, simplified quantitation methods, 1249
level, effects on FDG accumulation, pancreatic cancer and skeletal muscle, 619(ab)
metabolism
Alzheimer’s disease diagnosis, \(^{18}F\) FDG PET three-dimensional stereotactic surface projections, 1238
bone marrow, response to hematopoietic cytokines, \(^{18}F\) PET, 794
\(^{18}F\) FDG as parameter, turpentine-induced inflammatory tissue, PET, 1301
fractional uptake value and, 969(ab) in hepatocellular carcinoma, \(^{18}F\) FDG PET in vivo assessment, 1811
ionizing radiation effects, glioblastoma cells, 202(ab)
local blood flow and, spontaneous epilepsy, 256(ab)
overexpression, pancreatic cancer, 211(ab)
Parkinson’s disease severity assessment, \(^{18}F\) FDG and PET, 378
regional cerebral, Creutzfeldt-Jacob disease, PET, 238(ab)
myocardial metabolism
non-insulin-dependent diabetes mellitus patients, \(^{18}F\) FDG PET evaluation, 456
rats, \(^3\)H and \(^{14}C\) autoregulation, 518
myocardial uptake, nicotinic acid effect, clinical assessment by \(^{18}F\) FDG PET, 996
myocardial utilization, \(^{14}C\) deoxyglucose PET quantitation, 2094
transport, skeletal muscle, obese subjects, PET imaging in, 116(ab)
utilization
enhanced, after heart preconditioning, 47(ab)
septal beta oxidation and, left bundle branch block, \(^{14}F\) FTHA and \(^{18}F\) FDG PET assessment, 2056
**Glucose-6-phosphate**, inhibition, glucose transport block and, retention of 2-deoxyglucose, 130(ab)
Glutathione, localization, brain imaging with \(^{99m}Tc\) HMPAO, 147(ab)
P-Glycoprotein
expression, \(^{99m}Tc\) sestamibi efflux and, breast cancer, 129(ab)
quantitation, sections of breast cancer, 211(ab)
Glycosaminoglycans, rapid tumor delivery of radionuclides, neovascular endothelium, 69(ab)
**Government relations**
DOE’s role in isotope production, 30N(6)
institute of medicine NBTF study, 20N(2)
reimbursement issues, 18N(3)
Ward Valley update, 26N(7)
Granulocyte-colony-stimulating factor, skeletal images induced by, 235(ab)
Granulocytes, Ficoll/Hypaque separated, timed hypotonic lysis on, 206(ab)
Graves’ disease
131I therapy, transient hypothyroidism after, 1539
thyroidal and orbital, follow-up 131I in octreotide use in, 203(ab)
Graves’ ophthalmopathy, 131I in pentetretide scintigraphy in, 550
**Growth hormone**, deficiency, improved left ventricular function after replacement, 202(ab)
**Growth hormone-receptor complex**, structure, receptor signaling mechanism and, 145

**HAMA**, see Human anti-mouse antibody

**Head and neck cancer**
cervical metastases to, \(^{11}C\) TYR and \(^{18}F\) FDG PET studies, 221(ab)
management of, FDG SPECT imaging in, 221(ab)
methyl-\(^{11}C\) thymidine and metabolites, measurement in, 880
post surgery/radiation recurrence, comparison of FDG PET and MRI in, 221(ab)
squamous cell, staging with FDG PET, 221(ab)

**H**
aorta time activities, model-based estimation, dynamic PET, 186(ab)
body-contour fanbeam SPECT imaging, 306SD and short scan reconstruction algorithms, phantom evaluation, 174(ab)
congestive failure, progression, assessment of adrenergic neuron function alteration, MiBG, 2069
renal vascular response to vasoconstrictors in, 55(ab)
developing, altered maturation of sympathetic innervation in, 89(ab)
disease
congenital, \(^{99m}Tc\) HMPAO lung clearance in staging pulmonary hypertension, pediatric, 22(ab)
ischemic, percutaneous transluminal coronary angioplasty, improved myocardial fatty acid utilization, 201(ab) and BMIPP imaging, 1605
123I MiBG SPECT, normal myocardial adrenergic neuronal function evaluation, age and gender differences, 969
gamma camera system, simultaneous stress \(^{123}I\)resting \(^{99m}Tc\) cardiacite acquisition, 170(ab)
image
regional wall motion, principal component analysis in, 125(ab)
\(^{99m}Tc\) Q-series complexes with ester functionality, 17(ab)
imaging agent, new \(^{99m}Tc\) Q-series complexes with ester functionality, synthesis and biodistribution, 148(ab)
123I MiBG, enhanced clearance in chronic renal failure, 2037
123I MiBG studies, dynamic and static parameters, 962
intraoperative gamma in counting, wide-range LSO probe for, 109(ab)
isolated, \(^{11}C\) MHED transport distribution capacities and volumes, effect of reuptake 1 blockade on, 139(ab)
labeled thymidine retention, humans and primates, new metabolic pathway, 143(ab)
low rate variability, after myocardial infarction, sympathetic nervous dysfunction detection, 123I MiBG, 956
MiBG studies, critique of methods and interpretation of results, 2133
myocardial PET and SPECT, artificial inhomogeneities, normal subjects, 188
normal human, posteroventral defect, investigation by \(^{13}N\) ammonia and dynamic PET, 391
nuclear scans to diagnose women patients, 28N(6)
parameter estimation of geometry, by ECG-gated PET, validation by MRI and echocardiography, 1123
perioperative vasospm, detection by 123I MiBG, 201(tt) 123I BMIPP myocardial SPECT, 209(ab)
PET, parametric polar map displays, quantitative myocardial mapping of perfusion and metabolism, 153
rat, perfused, \(^{99m}Tc\) nitroimidazole retention, effect of graded hypoxia on, 632
resting cardiacite, stress \(^{201}Tl\) and, simultaneous tomographic imaging, 465(ab)
revascularization, left ventricular function improvement prediction, 123I IPPA SPECT, 1987
severe aortic regurgitation, reduced protein synthesis identification potential, PET, 142(ab)
SPECT
attenuation correction without transmission measurement, 506
123l BMIPP, myocardial viability evaluation, 1022
patient motion correction, selective logigram use, 168(ab)
polar maps, 12(ab)
simultaneous dual-isotope, with projection-dependent spillover correction factor, 166(ab)
single and dual 90SD detector, motion artifact differences, 168(ab)
table attenuation, probe and supine imaging, 1102
three-dimensional, performance characteristics, 174(ab)
three-dimensional displays, left-ventricular epicardial surface, 697
sympathetic denervation, trastuzumab-related FAP, 123I MiBG detection, 1040
\(^{99m}Tc\) teboroxime SPECT, liver-heart artifact, 133
\(^{201}Tl\) SPECT, simultaneous transmission-emission, attenuation correction effect on myocardial tracer distribution, 921
transplantation, see Transplantation after denervation, canine myocardial beta-adrenergic and muscarinic receptor densities, PET, 140
coronary artery disease detection after, \(^{13}N\) ammonia PET/coronary angiography comparison, 982
ultra-parallel cardiac camera, with radionuclide generator, 176(ab)
**Hematomas**, intracerebral, distinguishing neoplastic from non-neoplastic, \(^{11}C\) methionine PET evaluation, 2175
Hemodynamics
intravascular blood volume shifts, scintigraphic recording, 2022
penile, measurement, nonimaging scintillation probe, \(^{99m}Tc\)-labeled red blood cells, 2345
**Hepatic arterial embolization**, hepatocellular carcinoma, \(^{99m}Tc\) HIDA hepatobiliary scans, 1590
Hepatitis, neonatal, differential diagnosis between biliary atresia, hepatic retention index of DISIDA, 742P(ab)

Hepatitis C, chronic liver diseases, effect of interferon therapy on radionuclide imaging, 1587

Hepatobiliary tract, nonvisualization of gallbladder on scintigraphy, relation to laparoscopic cholecystectomy, 220P(ab)

Hepatocellular carcinoma glucose metabolism, 1H FG PET in vivo assessment, 1811

liver function during, 99mTc GSA evaluation of, 219P(ab)

radioimmunodiagnosis and radioimmunotherapy of, 213P(ab)

99mTc hepatobiliary scintigraphy, hepatic arterial embolization in hepatocellular carcinoma, 1590

visualization, 99mTc galactosyl-neoglycoalbumin with 125I Tyr-(A14)-insulin, 1875

Hepatocytes, 111In, liver repopulation by cell transplantation, 227P(ab)

Heterotaxy syndrome, infants, 99mTc sulfur colloid SPEC!, 369

High altitude pulmonary edema, research at high altitudes, 16N(3)

Hippocampus, perfusion assessment, high-resolution SPEC!, neuropsychiatric disorders, 1163

Histocytol, mixture of 131I lipiodol and, hepatic tumors, potential intraarterial therapeutic agent, 163P(ab)

Hodgkin's disease recurrent refractory, 111In 99mTc antiferritin murine polyclonal antibody in, 215P(ab)

staging, whole-body FDG PET, 199P(ab)

Holmium-166 DOTMP, bone marrow ablation, in multiple myeloma, pharmacokinetics/dosimetry/toxicity, 730

Hormesis, fact or fiction?, 13N(12)

HTG, see Thyroglobulin, human

5-HT2 receptors, see Serotonin receptors

Human anti-mouse antibodies fast and cost-effective determination of, 219P(ab)

immunotherapy by, survival in ovarian cancer and, 215P(ab)

overcoming the effects of, 209P(ab)

response after injection of LYM-1 monoclonal antibody, B-lymphocytic malignancies, 215P(ab)

Human immunodeficiency virus, See also Acquired immunodeficiency syndrome infected children, born to seropositive mothers, 1H FDG PET, 2169

intracerebral space occupying lesions, 201Tl brain SPEC!, role in differential diagnosis, 152P(ab)

Hurltule cell tumor, identification, single-injection double-phase 99mTc stent radiolocalization, 778

Hydrocephalus, normal-pressure, after shunt operation, reversible hyperperfusion of cerebral cortex, 99mTc HMFA SPEC!, 470

Hydroxypropl-beta-cycloextrin, radionuclide labeling, usage study, 157P(ab)

Hypercholesterolemia, familial, reduced coronary flow reserve in, 37P(ab)

Hyperglycemia glucose-mediated acidification, effect on enhancement of 99mTc DMS tumor accumulation, 145P(ab)

glucose-mediated acidification effect, tumor accumulation of Tc(V)-DMS, 28P(ab)

lumped constant during, constrained 18F FDG method, 253P(ab)

Hyperkalemia, diabetic, elemental body composition in, 234P(ab)

Hyperparathyroidism ectopic parathyroid adenoma, double-phase 99mTc stent radiolocalization SPEC!, 1840

primary, 54P(ab) Tc stent radiolocalization imaging before reoperation, 218P(ab)

recurrent parathyroid carcinoma and brown tumors, 99mTc MIBI uptake in, 811

Hyperthermia essential, renal dysfunction in, 232P(ab)

portal abdominal blood-pool SPEC!, 218P(ab)

hepatobiliary scintigraphy, 74P(ab)

pulmonary, reverse V/Q perfusion mismatches in, 251P(ab)

pulmonary artery stenosis, ventilation-perfusion mismatch, 1608

reduced renal function with, captoril renography in, 44P(ab)

ovarional captoril renal scintigraphy, 231P(ab)

from renal ischemia, diagnosis with ACE-1 scintigraphy, children, 34P(ab)

spontaneous, increase in dopamine transporters in, 252P(ab)

Hyperthyroidism 131I therapy, pediatric patients, 442

myocardial oxidative metabolism, assessment by 123I acetate PET, 1974

rapid iodine turnover in, 131I therapy effects, 14P(ab)

Hypertrophic osteoarthropathy, growth hormone-secreting pulmonary cancer and, 99mTc HMID bone scintigraphy in, 822

Hypertrophy, left ventricular, enhanced cardiac clearance, 157P(ab) MIBG, chronic renal failure, 2037

Hyponatraemia, symptomatic correction, cortical blindness after, dynamic cerebral dysfunction visualized, serial scanning SPEC!, 1272

Hypothyroidism congenital, 99mTc pertechnetate thyroid scintigraphy in, pediatric, 22P(ab) transient, after 131I therapy, Graves' disease, 1359

Hypoxia detection in tumors, 99mTc nitromidazole use in, 71P(ab)

FDG uptake increase, human cancer cell lines, 1625

glanced, effect on 99mTc nitromidazole retention, perfused rat heart, 632 imaging, 99mTc BMS-194796, 17P(ab)

I

Immune cell subset detection, spot assay, 160P(ab)

Image registration PET movement during, attenuation correction accuracy, 670

rapid and accurate realignment, image edge information use, 657

retroscopic, CT and PET, thorax, 2333

SPECT and CT, by external fiduciary band and three-dimensional surface fitting, metastatic thyroid cancer, 100

Imaging systems multimodality registered, 125P(ab) performance

Cramer-Rao and Barankin Bounds as predictors of, 119P(ab)

maximum likelihood estimation, 119P(ab)

processing language compilers, personal computers, 120P(ab)

Immunoglobulin, radiolabeled scintigraphy, spondyloïditsis diagnosis, 708P(ab)

Immune reactivity, immunoglobulin G, radiiodination effects on, 18P(ab)

Immunoscintigraphy colorectal carcinoma, complete versus fragmented 99mTc-labeled anti-CEA MAbs, 430

four-phase, suspected florid granulocytic inflammatory disease, 23P(ab)

99mTc BW43126 anti-CEA MABS, colorectal tumor uptake, 679

99mTc labeling, three antineoplastic MABS, stability/pharmacokinetics/imaging, 842

three-step pretargeting approach, optimization of, 225P(ab)

Immunotargeting, MAB MOC-31, 111In-labeled, pharmacokinetics and scintigraphy, small-cell lung carcinoma, 2356

India-111 avidin and streptavidin, human breast tumor xenograft, localization, 18P(ab)

chimeric negative-charged-2ZD3 PL-F(ab)2, atherosclerotic plaque detection, 133P(ab)

complex stability, Weiner radius in determination, biodistribution implication, 150P(ab)

energy spectrum fitting in, scatter and attenuation correction for, 60P(ab)

labeled polymer, 125I human serum albumin and, plasma volume determinations, rat, 157P(ab)

planar and SPECT images, scatter subtraction, QEW method, 178P(ab)

planar transmission scans, emission contamination, alignment, 179P(ab)

tumor imaging, dual-window scatter correction inaccuracies, clinical implications, 176P(ab)

18F and, intraperitoneal labeled human IgM, nude mice with peritoneal carcinomatosis of a human cancer, 160P(ab)

18F DOTA and, peptide, conjugation from chimeric L6 MABS, pharmacokinetics, tumor-bearing mice, 829

Indium-111 acetylatedate, radionuclide labeling, study of usage of 2-hydroxpropyl-beta-cycloextrin, 157P(ab)

Indium-111 antimyosin Fab imaging, systemic lupus erythematosus, myocardial involvement demonstration, 1432

131I MIBG, early doxorubicin cardiotoxicity assessment, 204

Indium-111 biotin, streptavidin and, bacterial endocarditis detection, rats, 137P(ab)

The Journal of Nuclear Medicine
Indium-111 capromab pendetide, presurgical staging, prostate cancer, 10(9ab)
Indium-111 CYT-356, SPECT, prostate carcinoma, 11(9ab)
residual or recurrent, 9(9ab)
Indium-111 D-Phe-1-octreotide, somatostatin receptor scintigraphy, central nervous system tumors, blood-brain barrier permeability role, 403
Indium-111 DTPA labeling polypeptides, 104(9ab)
MAB MOC-31, pharmacokinetics and scintigraphy of, small-cell lung carcinoma, 2356
tomatoxen analogue, synthesis, biodistribution, and estrogen receptor scintigraphy, 1619(9ab)
Indium-111 DTPA-Arg., scintigraphy, thymus, 257P(ab)
Indium-111 DTPA-D-Phe-1-octreotide
111mCu TETA octreotide and, in vitro and in vivo evaluation, PET, 2315
intravenous injection, activity concentration in tumor and normal tissue samples, 7
somatostatin receptor demonstration, malignant lymphoma and lymphadenopathy, 13
Indium-111 DTPA-octreotide, uptake, tissues positive for somatostatin receptor, 1139P(ab)
Indium-111 hepatocytes, biodistribution analysis, liver repopulation by cell transplantation, 227P(ab)
Indium-111 ICAM-1, early detection of lung injury, rat, 159P(ab)
Indium-111 IgG
bacterial infection, burned tissues, 256P(ab)
cellular uptake, intraperitoneal infection, 206P(ab)
infection imaging with, comparison with 99mTc (MPEG-PL-DTPA), 205P(ab)
Indium-111 IgM, localization, acute focal infection, 230P(ab)
Indium-111 leukocytes
bone studies and, infected/noninfected differentiation, rapidly progressive neuropathic osteoarthropathy, 1427
detection of posttraumatic vesicocutaneous fistulas, uterine carcinoma, 618
Indium-111 monoclonal antibodies, cardiac imaging, injection, 102P(ab)
Indium-111 octreotide
comparison with 123I MIBG, carcinoids and metastases from, 200P(ab)
follow-up, thyroidal and orbital Graves' disease, 203P(ab)
123I MIBG comparison, neuroendocrine neoplasms, 126P(ab)
medullary thyroid carcinoma, 203P(ab)
versus MIBG scintigraphy, malignant pheochromocytoma diagnosis, 1
SPECT, pituitary activity, 15P(ab)
suspicious breast lesions, comparison with 201Tl, 200P(ab)
Indium-111 oxine, labeled leukocytes, radionuclide targeting study, frozen section micro autoradiography, 499
Indium-111 PEGylated-labeled liposomes, focal infection imaging, 1639
Indium-111 prostate clinical impact, neuroendocrine tumor patients, 127P(ab)
 gastrinoma, CT, MRI, and angiography comparison, 126P(ab)
radiation dosimetry, 182P(ab)
sцинтиграфия
in differentiated thyroid carcinoma, 807
in Graves' ophthalmopathy, 550
malignant lymphomas, staging and follow-up, 195P(ab)
somatostatin receptor imaging, in gastroenteropancreatic neuroendocrine tumors, safety/efficacy/impact on management, 542
somatostatin receptor scintigraphy, Hodgkin- and non-Hodgkin lymphoma, 199P(ab)
SPECT, 111In SPECT and MRI, comparison, intra-axial brain tumors, 537
thyroid cancer, somatostatin receptor scintigraphy for, 14P(ab)
 tissue distribution, effect of dose and specific activity on, rats, 623
Indium-111 platelets
investigation of graft thrombosis, carbonated PFPE prosthesis, 102P(ab)
post-angioplasty sites, 207P(ab)
Indium-111 polyclonal IgG, biodistribution and dosimetry, normal subjects, 2372
Indium-111 white cells, dual-isotope imaging, diagnosis of osteomyelitis, 261P(ab)
Indium-113m DTPA, 99mTc DTPA and, scintigraphy, effects of smoking on bronchial clearance, 1569
Infarction
artifact or, fixed myocardial defects characterization, 99mTc sestamibi SPECT, 952
myocardial sympathetic nervous dysfunction after, low heart rate variability, 121I detection, 956
viability assessment, planar 18F FDG PET, 975
sizing, myocardial 99mTc sestamibi SPECT, multicenter trial feasibility, cardiac phantom evaluation, 1130
Infection
acute bacterial burned tissues, 111In IgG use in, 255P(ab)
soft tissue injuries, detection with 99mTc-labeled chelomoraic peptide, 205P(ab)
detection, white blood cell specific 99mTc imaging agent, development from PF-4, 161P(ab)
distribution of fluoroquinoline antibiotic in, 206P(ab)
experimental, rapid imaging with 99mTc DTPA, 207P(ab)
Ficoll/Hypaque separated granulocytes, timed hypotonic lysis on, 206P(ab)
focal
detection with 99mTc-labeled chelomoraic peptide, primates, 205P(ab), 206P(ab)
111In-labeled monoclonal antibody localization in, 230P(ab)
radiiodinated human recombinant interleukin-1 localization, 229P(ab)
radiolabeled stealth liposomes, 229P(ab)
99mTc-labeled chelomoraic peptide imaging, 230P(ab)
focal imaging, 111In-labeled PEGylated-labeled liposomes, 1639
imaging with 99mTc (MPEG-PL-DTPA), 111In IgG comparison, 205P(ab)
intraperitoneal, cellular uptake of 111In IgG, 206P(ab)
leukocyte membrane labeling and localization, new steryl dye in inflammation sites, 156P(ab)
leukocyte separation techniques, comparison, 261P(ab)
localization, hydradino nicotinamide 99mTc IgG imaging, 235P(ab)
opportunistic, HIV-positive patients, lung scanning comparison, 208P(ab)
thermal injury and modifiers of energy metabolism, effect on FDG utilization, brain, 205P(ab)
Inflammation
99mTc DMSA accumulation, in experimental abscesses, 147P(ab)
turpentine-induced tissue, high accumulation of 111In FDG in, PET, 1301
Inflammatory disease
endothelial activation in, imaging of, 24P(ab)
floid granulocytic, four-phase immunoscintigraphy in, 235P(ab)
Input function, venous blood sampling and, cerebral blood flow measurement, 121T SPECT, 2339
Insulin
effects on FDG accumulation, pancreatic cancer and skeletal muscle, 61P(ab)
effects on 18F-labeled FDG and glucose kinetics, myocardium, 38P(ab)
Intelligence quotient, parietal perfusion deficit prediction by, Alzheimer's disease, 1347
Interferon, therapy, chronic liver diseases from hepatitis C infection, effect on radionuclide imaging, 158P(ab)
Interleukin-1, recombinant, localization of infectious foci, 229P(ab)
Internet. See also Computers accessing nuclear medicine images, 13N(7) how to navigate, 25N(4)
teaching file, nuclear medicine, 1520
Intestines, perforation, 133T pyrophosphate scintigraphy findings, dermatomyositis, 1615
Intracerebral hemorrhage, perilesional and global blood flow in, SPECT study, 52P(ab)
Intraperospective probe
gb-camera, for tumor imaging, 110P(ab)
small area, for tumor imaging, 109P(ab)
In vivo imaging, molecular basis, neuropeptide receptors in health and disease, 1825
Iodine-123
chimeric anti-CEA MAB, comparison with original mouse MAB, surgically treated colorectal carcinoma, 420
endothelin-1, for imaging ET receptor distribution and occupancy, 163P(ab)
new SPECT tracer, serotonin 5HT2 receptors, 164P(ab)
triple-headed SPECT and, activity measurements of in vivo monkey brain, 178P(ab)
uinilateral uptake, lactating breast, 1724(e)
Iodine-123 beta-CIT
dosimetry, 711(e)
simplified multidose preparation, dopamine transporter marker, 525
SPECT, striatal dopamine transporter binding, age-related decline, 1175
Iodine-123 BMIPP
cardiac SPECT, myocardial viability evaluation, 1022
decreased uptake, metabolic alterations in ischemic myocardium, PET, comparison with 18F FDG and 11C acetate, 1974
depressed fatty acid intake, unstable angina, 25P(ab)
evaluation of free fatty acids cardiac metabolism, normal and etomoxir-treated dogs, ga- and gb-oxidation contribution, 137P(ab)
iodine-123 DSEP

123I MIBG/201Tl and, myocardial SPECT, perioperative coronary vasospasm detection, 2050 metabolism.

heart, ischemia and hypoxia effects, 47P(ab)
perfused rat hearts, 1043 severity of coronary stenosis and abnormal wall motion, patients with coronary artery disease without myocardial infarction, 134P(ab)

SPECT after elective coronary angioplasty, stunned myocardium detection, 134P(ab)
vasospastic angina and, diagnosis and follow-up, 201Tl and 99mTc MIBI comparison, 1934

201Tl and, prognostic value of combined imaging, hypertrichotic cardiomyopathy, 133P(ab)
tracer of lipid metabolism, myocardial ischemia, 48P(ab)

Iodine-123 DSEP, biokinetics, investigations in tumor-bearing mice, 161P(ab)

Iodine-123 epidepride
dopamine D2 receptor imaging, 258P(ab)
dopamine D2 receptor ligand, dosimetry, 1316 IBZM direct comparison, dopamine D2 receptors, 258P(ab)
SPECT, dopamine D2 receptors in striatal and extrastriatal regions, 88P(ab)
Iodine-123 fatty acid
identification of ischemic myocardium at rest, patients with unstable, 134P(ab)
impaired utilization, myocardial ischemia, angina, 25P(ab)
retention, myocardial, during low flow ischemia, 4P(ab)
Iodine-123 gb-CIT-FE, SPECT, dopamine transporters, 118P(ab)
Iodine-123 IACFT, radiolabeling and biodistribution, rats, 145P(ab)
Iodine-123 IBF, SPECT
dopamine D2 receptors, 11P(ab)
extrapyramidal disease evaluation, dopamine D2 receptors, 1196

Iodine-123 IBZM
continuous infusion, true equilibrium for measurement of dopamine D2 receptors, 252P(ab)
determination of uptake, iterative reconstruction, 257P(ab)
dopamine D2 receptors, indicator for cerebral hypoxia, 240P(ab)
SPECT, striatal dopamine release after amphetamine challenge, 1182 striatal uptake, basal ganglia lateralized differences, asymmetric Parkinson’s disease, SPECT, 1216
synthesis, labeling, and pharmacokinetics, melanoma, 116P(ab)
Iodine-123 IDAB, scintigraphy, malignant melanoma, 116P(ab)
Iodine-123 IDER, SPECT, for cholERIC muscarinic neuroneceptors, dosimetry and biodistribution, 1332
Iodine-123 IMP
benzodiazepine receptors in Parkinson’s, 241P(ab)
cerebral blood flow
in postprostatectomy dysuria, 246P(ab)
reproducibility and normal values, 239P(ab)
SPECT
cerebral blood flow measurement, calibrated standard input function and venous blood sampling, 2339
cerebral blood flow sequential measurement, double-injection method, 1339
crossed cerebellar diaschisis, analysis, 399
human primary motor cortex, super-early imaging, 2980
rapid calculation of regional cerebral blood flow and distribution volume, 531
iodine-123 IMT, whole-body kinetics, cerebral gliomas, 97P(ab)
iodine-123 IMZ
binding, quantitative analysis, use of arterial sampling and octanol extraction, 167P(ab)
regional binding, correlation with psychotic symptoms, schizophrenia, 20P(ab)
SPECT, focal epilepsy, 72P(ab)
iodine-123 iodobenzamide, SPECT, dopamine D2 receptor regional analysis, in Parkinson’s disease, 384
iodine-123 iodo-betazettazini, study of benzodiazepine receptors, CNS, 6P(ab)
iodine-123 iodazenil, SPECT
benzodiazepine receptor binding and ligand transport, simple quantification, 1201
cerebral infarction evaluation, 2154
measurement reproducibility, benzodiazepine receptors, human brain, 167
iodine-123 ioxly, potential SPECT imaging agent for opiate receptors, 166P(ab)
iodine-123 IPPA
myocardial, SPECT, shorter imaging protocol feasibility, 138P(ab)
SPECT, left ventricular function improvement prediction, after coronary revascularization, 1987
iodine-123 IPT
metabolite analysis of, SPECT, 124P(ab)
SPECT, striatal dopamine transporter, nonhuman primates, 2290
iodine-123 IULR
molecular radiotherapy, hepatic metastases from colon cancer, 214P(ab)
tumor incorporation of, enhancement by 5-fluorouracil and folic acid, 213P(ab)
iodine-123 MIBG
cardiac imaging, dynamic and static parameters, 962 clearance, enhanced cardiac, in chronic renal failure, 2037
comparison with 111In octreotide, carcinoids and metastases from, 200P(ab)
detection of canine myocardial gb-adrenoceptor density, after cardiac denervation, 136P(ab)
experimental study, repetitive ischemia, 90P(ab)
impairment of norepinephrine uptake, ischemic myocardium, 25P(ab)
11In antymyosin and, early doxorubicin cardiotoxicity assessment, 2044
11In octreotide comparison, neuroendocrine neoplasms, 126P(ab)
left ventricular, modulation using renin-angiotensin system, cardiomyopathic Syrian hamsters, 1055
limited sensitivity of, recurrent extra-adrenal pheochromocytoma, 204P(ab)
lung uptake, diabetes and, 35P(ab)
matching of VT with defects in IVT, 134P(ab)
myocardial sympathetic nervous dysfunction detection, after infarction, low heart rate variability, 956
reduced uptake areas, atrophic nerve fibers in, doxorubicin cardiomyopathy, SPECT, 2060
cintigraphy, not visualizing dopamine-producing paraganglioma, 620
SPECT, myocardial adrenergic neuronal function evaluation, age and gender differences, 967
201Tl chloride and, scintigraphy, primary thymic carcinoid tumor, presurgical diagnosis, 2243
201Tl/211T BiMPP and, myocardial SPECT, perioperative coronary vasospasm detection, 2050
transferrin-related FAP detection, cardiac sympathetic denervation, 1040
uptake, myocardial, age and gender effects, 102P(ab)
uptake difference between anterior and inferior left ventricle walls, parasympathetic nerve function in normal volunteers, 134P(ab)
iodine-123 MIHA, 201Tl and, SPECT, defect reversibility analysis, myocardial infarction, 1561
iodine-123 2-IISP, SPECT, dopamine D2 receptors, 1191
iodine-123 Tyr-(A14)-insulin, 99mTc galactosyl-neoglycoalbumin and, hepatocellular carcinoma visualization, 1875
iodine-125 chimeric 171A, metastatic colon cancer, initial clinical evaluation, 2229
human serum albumin, 11In-labeled polymer and, plasma volume determinations, rat, 157P(ab)
retention activity, human tumor xenografts, effect of lysosomal inhibitors, 159P(ab)
iodine-125 BMIPP, 201Tl and, comparison, myocardial hyperperfusion, 1645
iodine-125 IBPN, radiolabeled radical detecting agent with high stability, 79P(ab)
iodine-125 MBG
18F FDG as positron-emitting analog of, validation, 644
uptake, neuroblastoma cells, adrenoceptor ligand effects on, 263P(ab)
uptake and retention, mitochondrial potential, cation transport, 191P(ab)
iodine-125 peptide, biodistribution and localization, experimental atherosclerosis, 25P(ab)
iodine-125 VIP, autoradiography, VIP-R content in human tumors, 1846
iodine-131 amination of iodine avid tissue, after near total thyroidectomy for differentiated thyroid cancer, 203P(ab)
capsules, properties of, 79P(ab)
comparison with 123I. Tc sestamibi, whole-body scans, differentiated thyroid cancer, 200P(ab)
focal SPECT quantification, based on multieenergy window data acquisition, 172P(ab)
lithium effects, metastatic differentiated thyroid cancer, 15P(ab)
optimal dose, remnant ablation in differentiated thyroid cancer, 41P(ab)
skeletal uptake, absorbed dose estimates, thyroid ablation patients, 183P(ab)
therapy differentiated thyroid carcinoma female fertility and carcinogenesis assessment, 21
patient safety, 27(ed)
Graves’ disease, transient hypothyroidism after, 1539
hyperthyroidism, pediatric patients, 442
therapy of autonomous thyroid nodule, patients with or without visible extranodal activity, 217
thyroidal uptake, hyperthyroid patients, 14P(ab)
uptake reappearance, metastatic follicular thyroid carcinoma, 613
Iodine-131 anti-B-1, radioimmunotherapy
non-Hodgkin’s lymphoma, 214P(ab)
refractory B-cell lymphoma, 214P(ab)
relapsed non-Hodgkin’s lymphoma, phase II trial results, 214P(ab)
Iodine-131 beta-CIT, dosimetry, 711(e)
Iodine-131 CCK-4, phase I radioimmunotherapy trial, metastatic colon carcinoma, 586
Iodine-131 iodomethyluridylane, synthesis and tumor imaging, 144P(ab)
Iodine-131 lipiodol, mixture of histocay and, hepatic tumors, potential intra-arterial therapeutic agent, 163P(ab)
Iodine-131 MIBG
correlative imaging, neuroblastoma patients, 22P(ab)
hyperbaric oxygen combined with, therapy for relapsed stage IV neuroblastoma, 42P(ab)
no-carrier-added, evaluation in neuroblastoma, 1088
SPECT and delayed imaging, neuroblastoma patients, 22P(ab)
therapeutic, dosimetric models and 5 factors, bladder wall radiation doses, children, 1530(le)
three-dimensional cellular dosimetry, neuroblastoma, 86P(ab)
Iodine-131 OIH
$^{99m}$Tc EC/$^{99m}$Tc MAG3 and, clinical comparison, in renal disorders, 224
$^{99m}$Tc MAG3 and, single-injection renal clearance methods, with and without urine collection, 603
Iodine-131 sodium iodide, $^{124}$I FDO/$^{99m}$Tc pertechnetate and, PET, cervical lymph node metastasis of thyroid papillary carcinoma, 1843
Iododeoxyuridine, radiolabeled, instantaneous preparation, 144P(ab)
Iododecannitrate, $^{123}$I beta-CIT simplified multidose preparation, dopamine transporter marker, 525
-p-Iodophenyl-N-tetra-butylphosphonium, radiodiocinated radical detecting agent with high stability, 7P(ab)
5-Iodo-2-deoxyxylucose
$^{123}$I-labeled, tumor incorporation, enhancement by 5-fluorouracil and folic acid, 213P(ab)
$^{128}$I-labeled, molecular radiotherapy, hepatic metastases from colon cancer, 214P(ab)
Ischemia
heart disease, $^{99m}$Tc reinjection or rest redistribution, myocardial viability after, multicenter study, 555
hemodynamic carotid, transient attacks, innominate artery stenosis, cerebral blood flow and perfusion reserve capacity in, Doppler ultrasonography and SPECT, 1268
myocardial
detection by $^{99m}$Tc nitromidazole, 1078 silent, during PET, 1034
$^{99m}$Tc nitromidazole ligand SPECT, 1445 perfused rat heart, $^{99m}$Tc nitromidazole retention, effect of graded hypoxia on, 632
stroke, acute stage, increased $^{99m}$Tc HMPAO uptake, predictive value for brain survival/incipience, 2923(e)
Isotopes, residualizing, in radioimmunodetection and therapy, 20P(ab)

K
Kidney
chronic failure, thyroid and parathyroid adenoma in, $^{99m}$Tc sestamibi and $^{131}$I mismatch, 826
disease, $^{11}$C acetate PET, 1595
orders
clinical comparison of $^{99m}$Tc EC/$^{99m}$Tc MAG3/831 OIH, 224
$^{99m}$Tc EC evaluation, extraction ratio determination, 1398
dysfunction, essential hypertension, 232P(ab)
failure
chronic, enhanced $^{131}$I MIBG cardiac clearance, 2037
$^{99m}$Tc MAG3 renal scintigraphy in, 232P(ab)
function
GFR for parameter of, captopril renography, 44P(ab)
prediction of long-term change, 232P(ab)
real-time monitoring after transplant, 54P(ab)
UFP obstruction, SPECT, 233P(ab)
imaging, blood volume and organ attenuation for modeling tracer kinetics, 119P(ab)
ischemia
imaging with $^{99m}$Tc nitromidazole, 45P(ab)
$^{99m}$Tc nitromidazole hypoxic agent for, 45P(ab)
renal agents for detection of, 231P(ab)
localized clear-cell epithelial tumor, diffuse renal retention, $^{99m}$Tc MDP bone scintigraphy, 817
neoplasms, combined $^{11}$C acetate and FDG PET, 55P(ab)
Oberhausen clearance, $^{99m}$Tc MAG3, whole-body geometry and gamma camera ROI-technique, 45P(ab)
plasma flow, simultaneous glomerular filtration and tubular excretion rate, $^{99m}$Tc MAG3 and $^{99m}$Tc EC EDTA, 1701
renal scans for transplant patients, 26N(2)
revascularization, effects on captopril renal scintigraphy, 44P(ab)
scars, after acute pyelonephritis, infants, 33P(ab)
single-injection clearance methods, $^{99m}$Tc MAG3 and $^{131}$I OIH, with and without urine collection, 603
$^{99m}$Tc MAG3 clearance, normal values, 706(le) transplant, see Transplantation tubular reabsorption, $^{99m}$Tc DMSA and $^{99m}$Tc pertechnetate, 1654
takeup, radiolabeled monoclonal antibody fragments, 19P(ab)
Kidney cortex, defects, $^{99m}$Tc DMSA imaging in, 32P(ab)
Kinetic model
evaluation, sensitivity functions and correlation matrices, 208P(ab)
parameter variability, anesthesia depth, $^{123}$I Rb PET, dog, 185P(ab)
Knee, synovitis, $^{153}$Sm PHYF radiation synovectomy, biodistribution data, 51
Knowledge-based reporting, nonverbal graphical interface for, 122P(ab)

L
Labeling
antibody
DNA hybridization, 68P(ab)
preservation of immunoreactivity by radioprotectants, 79P(ab)
direct radiodine, chimeric BR96, 19P(ab)
$^{11}$In and $^{123}$I, chimeric BR96, colon cancer, 19P(ab)
paired, chimeric BR96, colon cancer, 19P(ab)
proteins, organonemtium chelaxes for, 91P(ab)
$^{99m}$Tc, solid-phase technology, 27P(ab)
Laboratory animals, PET scanners, 239P(le)
Lanolin heterotopia, brain perfusion, $^{99m}$Tc HMPAO SPECT, 238
Langerhan’s cell histiocytosis, diagnosis and staging, bone scintigraphy in, 27P(ab)
Language, processing, syntactic and semantic aspects, SPECT, 251P(ab)
Leber’s hereditary optic neuropathy, $^{18}$F FDG PET imaging in, 246P(ab)
Left bundle branch block, septal beta-oxidation and glucose utilization, metabolic mismatch, PET, 2056
Left ventricular
dysfunction
mental stress induced, coronary artery disease, arterial and ventricular elastance and ventriculoarterial coupling, 131P(ab)
resting asynchronous contraction abnormality, phase analysis, spastic angiitis pectoris, 1003
function
ambulatory monitoring, cardiopulmonary exercise tests, normal sedentary subjects, 564
prediction of improvement after revascularization, FDG/Tl SPECT versus echocardiography, 35P(ab)
rest, after growth hormone replacement, 202P(ab)
volumes and mass, gated perfusion tomographs, 12P(ab)
volume measurement, with TMUGA, gradient-echo MRI validation, 131P(ab)
wall thickening, gated SPECT/PET, 8P(ab)
Lennon-Gastaut syndrome, corpus callosumoty effects, cerebral glucose metabolism, 260P(ab)
Leukocytes
$^{11}$In oxine-labeled, radionuclide targeting study, frozen section microautoradiography, 499
new styril dye, membrane labeling and localization, inervation sites, 156P(ab)
radiolabeled, $^{11}$In polyclonal IgG as replacement, biodistribution and dosimetry, normal subjects, 2372
separation techniques, comparison, 261P(ab)
Ligands, See also specific ligand
new neutral water-soluble phosphine, $^{99m}$Tc complexing, reducing $^{99m}$TcO$_4^-$, 146P(ab)
new tetradentate, $^{99m}$Tc dihydroxamidamide, preparartion and characterization, 146P(ab)
potential diagnostic, G protein-coupled receptors and, structure and functional analysis of, 17S
transport, benzodiazepine receptors binding and, simple quantification by $^{123}$I Iomazenil SPECT, 1201
Linopirdine, effects on SPECT rCBF and cognitive function, Alzheimer’s disease, 238P(ab)
Liposomes
radiolabeled stealth, imaging of focal infection, 259P(ab)
detection of prostate cancer, 9P(ab)

direct targeting, pretargeting protocols based on streptavidin-biotin binding,

pharmacokinetic comparison, 867

fibrin-specific GC4, radiolabeled F(AB)2 and FAB fragments, thrombus imaging,

164P(ab)

fragments, kidney uptake of, 19P(ab)

G250, radioimmunotargeting of renal cell carcinoma, 210P(ab)

human colon carcinoma multicell spheroids, comparative targeting, one- and two-step systems, 181P(ab)

human tumor xenografts, effect of lysosomal inhibitors, 121I retention activity, 159P(ab)

125I A33, vascular internalization of, 85P(ab)

LL2 Anti-CD22, imaging and treatment of non-Hodgkin’s lymphoma, 211P(ab)

LYM-1, B-lymphocytic malignancies, 215P(ab)

MOC-31, 111In DTPA-labeled, pharmacokinetics and scintigraphy of, small-cell lung carcinoma, 2356

photoactivation direct labeling, 99mTc, 1913 photo-labeling, using 14C methyl tetrafluoro azido benzoate, 156P(ab)

radiolabeled biotinylated, pid excretion, repeated avidin chase, radioactivity in target tumor, 143P(ab)

186Re-labeled, pharmacokinetics and normal organ dosimetry, ovarian cancer, 754

site-specific dibenzylaline conjugation to, for 99mTc labeling, 147P(ab)

stannous and UV pretreated MAB-170, SDS-CE and size exclusion HPLC, behavior differences, causes, 159P(ab)

99mTc-labeled, binding to human neutrophils, 156P(ab)

99mTc-labeled anti-CEA, complete versus fragmented, immunoscintigraphy in colorectal cancer, 430

three anticancer, 99mTc labeling, stability/pharmacokinetics/imaging, 842

X-ray-labeled HMFG1, anti-chelate body response, ovarian cancer therapy, 746

Monte Carlo simulations attenuation-map determination, fast sequential TCT/ECT, 50P(ab)

high speed calculation, photon transportation, 178P(ab)

radiation dose, metastatic skeletal tumor from 186Re(Sn) HEDP, 336

spectral analysis, scatter correction techniques, comparative assessment, 99mTc SPECT, 1476

temporal resolution effects, SPECT transmission imaging, 50P(ab)

Motion correction cardiac SPECT, 59P(ab)

detection and, 99mTc DMSA tomographic imaging, 33P(ab)

gated cardiac 18F FDG PET, improvement by Fourier analysis, compared with cineangiography, 141P(ab)

by selective ligand, cardiac SPECT, 168P(ab)

three-dimensional, fanbeam SPECT, 18P(ab)

without external point source, first-pass radionuclide videotography, 99mTc tetrofosmin, 1941

prevention, patient, 201Tl SPECT myocardial perfusion imaging, 2001

Myocardial transport system, evaluation, aerosol inhalation cine-scintigraphy, diffuse panbronchiolitis, 1355

Multi-drug resistance breast tumor cells, accumulation of 99mTc tetrofosmin in, 202P(ab)

11C colchicine distribution, neuroblastoma xenografts, colchicine-sensitive and -resistant, 189P(ab)

investigation of, 11C verapamil PET, 123P(ab)

P-glycoprotein-mediated 99mTc-sestamibi transport, effects of extracellular ATP, chloride, cell volume and FKC modulation on, 196P(ab)

99mTc isoindolines targeted to, 27P(ab)

99mTc Q complexes and, 130P(ab)

99mTc sestamibi detection of, 129P(ab)

Multiple myeloma bone lesion detection, 99mTc MIBI scintigraphy, 190P(ab)

bone marrow ablation in, 194Ho DOTMP pharmacokinetics/dosimetry/toxicity, 730

Multiple sclerosis, white matter in, FDG PET, MRI and NMR spectroscopy study of, 241P(ab)

Muscarinic acetylcholine receptors, imaging, molecular probes, 55

Muscarinic receptors, new peripheral ligands FEQNB and FETRB, parasympathetic imaging, 137P(ab)

Muscle perfusion, 15O water PET, 115P(ab)

skeletal electric shock injury, 99mTc DTPA and 99mTc PYP, 235P(ab)

nonthermal electrical injury, 99mTc PYP use in, 122P(ab)

Myeloma, nonssecretory, unexpected 201Tl bone marrow uptake, 250

Myelosuppression, marrow radiosensitiveness and, after multiple cycles of radioantibody therapy, 212P(ab)

Myocardial hyperperfusion, 121I BMIPP and 201Tl, comparison, 1645

Myocardial infarction after thrombolytic therapy, regional myocardial perfusion, glucose utilization, and functional recovery in, 140P(ab)

defect reversibility analysis, 201Tl and 123I MIHA SPECT, 1561

detection, 99mTc antimyosin antibody imaging, 88P(ab)

hypoxic border zone ex vivo delineation, canine infarct model, 99mTc-labeled nitroheterocycle, 137P(ab)

patients with prior, comparison of glucose and oxidative metabolism, PET, 139P(ab)

reverse redistribution on 24-hour delayed imaging of exercise 201Tl myocardial SPECT, comparison with myocardial 18F FDG PET and ventricular wall motion, 86

size, SPECT measurement, effects of scatter correction, cardiac phantom studies, 2080

99mTc gluurate, subcellular distribution, 47P(ab)

Myocardial perfusion imaging after coronary bypass surgery, 13P(ab)

artifacts, caused by liver, 29P(ab)

blunted response to diprydamole, older adults, 1137(Le)

reply, 1137(Le)

cardiac motion, polar map of left ventricular wall, 59P(ab)

cardiac SPECT, three-dimensional displays, left-ventricular epicardial surface, 697

catheterization after, exercise first-pass radionuclide angiography use in referral, 101P(ab)

coronary artery disease in women, 79P(ab)

defect assessment, three-dimensional template-based region-growing technique, 171P(ab)

dipyridamole 201Tl, Kawasaki disease, 13P(ab)

dual-isotope, contamination in, 60P(ab)

emergency center, 88P(ab)

46Ga, tracer distribution and pharmacokinetics, 49P(ab)

gated studies, validation, beating-heart phantom, 177P(ab)

metabolism imaging and, 99mTc MIBI/18F FDG SPECT, simultaneous dual-isotope acquisition, 2110

motion, angle-dependent gamma camera, 59P(ab)

15N ammonia and dynamic PET, postero-lateral defect investigation of normal human heart, 581

necessity in normal baseline ECG patients, stress testing and, 110P(ab)

normal 201Tl SPECT with positive exercise ECG, gender effects, 110P(ab)

organ clearance, heart clearance ratio, 24P(ab)

18O water PET, assessment of regional blood flow, 70P(ab)

PET, silent ischemia during, 1034

PET 13-NH3, ammonia distribution and K1 parametric values in, 37P(ab)

quantitative different body characteristics and, 41P(ab)

exercise first-pass LVEF and, prior myocardial infarction, 100P(ab)

noncircular versus circular orbits of, 46P(ab)

radiopharmaceutical transfer, placental binding and, 154P(ab)

rat hearts, 121I BMIPP metabolism, 1043

125I dipiridamole PET, restenosis assessment after angioplasty, 1553

18F, left ventricular ejection fraction measurement, 91P(ab)

reserve, effect of aging, dipiridamole, 2032

rest and pharmacological stress, assessment of myocardial viability, 66P(ab)

simultaneous dual-isotope stress, three window technique, accuracy, 133P(ab)

simultaneous transmission-emission nonuniform attenuation-correction, 46P(ab)

SPECT, 12P(ab)

SPECT emission-based attenuation correction technique for, 18P(ab)

normal distributions, correlative evaluation method, 132P(ab)

operatorless processing, 2127

scatter and attenuation compensation, four energy window acquisition, 136P(ab)

technical maturation, art becoming science, 905

stress 201Tl, diagnostic accuracy in left ventricular hypertrophy, 110P(ab)

99mTc MIBI, viable myocardium identification, 1037

99Tc NOET, comparison with 201Tl and coronary angiography, 936

99mTc Q12, kinetics, effects of no flow and reperfusion, 2103

99mTc sestamibi comparison with echocardiography, with arbutamine stress testing, 132P(ab)

dobutamine, gb-receptor blockade effects on, 77P(ab)

dobutamine or dipiridamole addition, 76P(ab)
preconditioning of, enhanced glucose usage after, 47P(ab)
quantitative mapping, perfusion and metabolism, parametric polar map displays, cardiac PET, 153
Rb extraction fraction determination, humans, 139P(ab)
regionally altered perfusion, quantification potential, Rb and Ti mean transit time analysis, rabbit heart, 138P(ab)
regional viability, relationship with reverse redistribution on planar thallium scintigraphy, coregistered PET study, 180 reversible dysfunctional, near-normal perfusion in, PET, 67P(ab)
scintigraphy, 20Tl and 99mTc sestamibi, VEX test, effect on abdominal background activity, 914
septal data, PET, dual spillover problem, 7P(ab)
silent ischemia, during PET, 1034
sympathetic nervous dysfunction detection, after infarction, low heart rate variability, 123J
MBG, 956
95mTc N-NOET subcellular distribution, rat, 2075
99mTc teboroxime activity, in acute coronary artery occlusion, relation to myocardial blood flow and viability, 1062
99mTc teboroxime uptake during hyperemia, in dogs with coronary stenosis, comparison to 20Tl and regional blood flow, 476
99mTc tetrofosmin uptake at rest, relation to coronary artery stenosis severity, 907
tissue viability definition, PET, automated analysis, quantitative criteria evaluation, 140P(ab)
viability after revascularization, FDG and 20Tl SPECT for, 36P(ab)
after 20Tl reinnervation or rest-redistribution, multicenter study, 55S
chronic coronary artery disease, restig 20Tl scintigraphy, reverse redistribution, 1968
comparison of 18F FDG SPECT/13N FDG PET/rest 20Tl SPECT, 176
delineation, 13N ammonia and 18F deoxyglucose PET, 1543
dobutamine echocardiography and thallium SPECT, 120P(ab)
dobutamine stress echocardiography and PET comparison, 67P(ab)
enhanced detection, 99mTc MIBI after nitrate administration, chronic coronary artery disease, 1945
evaluation, cardiac 123I MIBP SPECT, 1022
18F FDG PET cost-effectiveness, 67P(ab)
gated 99mTc sestamibi correlates of, 56P(ab)
glucose loading 20Tl SPECT detection of, 121P(ab)
hibernating, detection by 99mTc sestamibi and nitrate infusion, postrevascularization recovery prediction, 1994
identification, 99mTc MIBI imaging, 1037
index, chronic coronary artery disease, 99mTc MIBI redistribution, 1953
low-flow ischemia, 18F FDG and 13N FMISO uptake comparison, 1633
myocardial perfusion at rest and pharmacologic stress, 66P(ab)
physiological basis of PTI, computer simulation, 320
38P kinetics in, ischemic heart disease, 67P(ab)
rest/redistribution/reinjection protocol for, 121P(ab)
Myositis ossificans

spontaneous improvement after infarction, $^{99m}$Tc-tetrofosmin and $^{201}$TI SPECT

rejection, coronary artery disease, 1961

$^{99m}$Tc-tetrofosmin identification of, 121P(ab)

viable segments, FDG SPECT imaging of, PET comparison, 3P(ab)

wall motion, automated computer analysis, correlation with echocardiography, 30P(ab)

wall thickening, quantitative gated SPECT, 5SP(ab)

wall uptake, artificial decreased, new window function for, 30P(ab)

Myositis ossificans, juxta-articular ossification and, $^{201}$TI accumulation, 2239

N

Narcolepsy, REM sleep, cerebral blood flow during, $^{99m}$Tc-HMPAO SPECT, 1150

Neonates, diuretic $^{99m}$Tc MAG3 renography, utility, 2214

Nephrectomy, short-term change in renal function, prediction of long-term change, 232P(ab)

Neural networks

artificial diagnosis of acute pulmonary embolism, clinical findings and, 112P(ab)

V/Q scanning and, 112P(ab)

model parameter estimation, 81P(ab)

Neural toxins, characterization of sigma receptors, radiodinated benazanides, 144P(ab)

Neuroactiviation studies, $^{15}$O, water and butanol use in, PET, 81P(ab)

Neuroblastoma
correlate imaging in, $^{111}$mIBG scanning role in, 22P(ab)

$^{131}$I MIBG cellular dosimetry, 86P(ab)

no-carrier-added $^{131}$I MIBG, evaluation, 1088

relapsed stage IV, therapy with combined $^{131}$I MIBG and hyperbaric oxygen, 42P(ab)

SPECT and delayed imaging, $^{123}$I MIBG, 22P(ab)

targeting, phenylpipеразинеs as radiopharmaceuticals, 191P(ab)

uptake of $^{123}$I MIBG, adrenocortical ligand effects on, 263P(ab)

Neuroendocrine tumors

$^{111}$In DTPA-D-Phe-1-octreotide intravenous injection, activity concentration in tissue samples, 7

$^{111}$In pentetreotide imaging effects, 127P(ab)

Neurofibrinostosis, type I, optic pathway and brainstem tumors, $^{18}$F FDG PET/MRI, 191P(ab)

Neurons, adrenergic function alteration, progression of congestive heart failure, MIBG assessment, 2069

Neuropathic osteoarthropathy, rapidly progressive, infected/noninfected differentiation, bone,$^{111}$In leukocyte study, 1427

Neuropeptides, receptors in, health and disease, molecular basis for in vivo imaging, 1825

Nicotine receptors, labeling with epibatidine, brain, 253(ab)

Nitrate

$^{99m}$Tc MIBI and, enhanced viable myocardium detection, chronic coronary artery disease, 1945

$^{99m}$Tc sestamibi and, perfusion imaging, viable hibernating myocardium detection, postvascularization recovery prediction, 1994

Nitric oxide

biological fate of inhaled $^{15}$N, comparison to $^{15}$N nitrogen, PET measurement, 153P(ab)

carriers, S-nitroso derivatives as, 48(ab)

Potentiation of serum, inhibitors of, PET, 48P(ab)

Nitrogen-13 ammonia

$^{18}$F deoxyglucose and, PET, myocardial viability delineation, 1543

$^{18}$F FDG and, PET, blood-time-activity curve extraction, factor analysis of dynamic structures, 1714

PET

after heart transplant, coronary artery disease detection, coronary angiography comparison, 982

factor analysis of dynamic structures and, myocardial blood flow quantification, 20P(ab)

measurement of myocardial blood flow, 7P(ab)

myocardial blood flow estimation with, 115P(ab)

myocardial blood flow measurements, reproducibility, 142P(ab)

with partial volume effect correction, myocardial blood flow quantification, 175P(ab)

postero lateral defect investigation of normal human heart, 581

rest and stress, dilated cardiomyopathy, 3P(ab)

regional distribution, PET characterization of, 5P(ab)

Nitrogen-13 nitric oxide, inhaled, biological fate, comparison to $^{15}$N nitrogen, PET measurement, 153P(ab)

Nitroimidazole

BMS-181321 and $^{99m}$Tc myocardial and hepatic uptake after regional ischemia, 138P(ab)

$^{99m}$Tc-labeled, hypoxic infarct border zone delineation, in canine infarct model ex vivo, 137P(ab)

Nobel Prize, winners, prediction of future research usage, 24N(10)

Noise, properties, three-dimensional PET images, 105P(ab)

Nuclear medicine

cardiovascular, technical maturation, art becoming science, 905

changes in physician’s practices, 30N(9)

changing practice, nuclear physician at work, 30N(9)

chronology (book review), 165

data on-line, 272P(ab)

diagnostic role, scaphoid fractures, 1725(le)

European Nuclear Cardiology Database, a practical guide, 177P(ab)

evaluation of discipline, 26N(10)

$^{15}$I radionuclide therapy patients, high-energy pinhole collimator evaluation, 178P(ab)

molecular, genotype to phenotype via chemotype, 2S

new digital radiomager, film autodiagrapy comparison, radionuclide imaging, 180P(ab)

oncology, tissue characterization, 207(ed)

potential imaging targets, recurring genetic aberrations in cancer cells, 22S

teaching

case-based file, World-Wide Web accessible, 270P(ab)

Internet-based file, 269P(ab)

residents, multi-institutional training, World-Wide Web aid, 270P(ab)

teaching file, Internet, 1520

three-dimensional display, depiction of reality or superficial rendering, 702(ed)

Nuclear Medicine Annual 1994, (book review), 165

Nuclear Regulatory Commission, radiopharmacy and quality management rules, 14N(3)

O

Obsessive-compulsive disorder

drug therapy and cerebral perfusion, SPECT, 2234

pathological cerebral perfusion patterns in, $^{99m}$Tc HMPAO SPECT, 248P(ab)

regional cerebral blood flow in, $^{99m}$Tc HMPAO SPECT measurement of, 20P(ab)

Obstructive airway disease, perfusion and ventilation scans, single-bread washin $^{133}$Xe utility, 64

Oligonucleotides, DNA, $^{99m}$Tc labeling, 2306

Oncology

atlas, FDG PET, 269P(ab)

cancer screening, non-attenuation-corrected whole-body PET, 201P(ab)

indeterminate solitary pulmonary nodules, FDG PET, 94P(ab)

one-year experience, whole-body PET, 19P(ab)

three-step pretargeting approach, optimization of, 225P(ab)

Oncoscintigraphy, $^{99m}$Tc MIBI, differentiated thyroid cancer, 204P(ab)

Open wounds, skeletal muscle viability assessment, $^{18}$F PET, 1408

Opioid receptors

in cocaine abuse, PET analysis, 20P(ab)

potential SPECT imaging agent for, $^{123}$I oxy, 165P(ab)

unmedicated major depression, PET analysis, 21P(ab)

Organometalllics, rhenium complexes, labeling of proteins, 91P(ab)

Ossification, juxta-articular, myositis ossificans and, $^{201}$TI accumulation, 2239

Osteogenic sarcoma, myositis ossificans and juxta-articular ossification, $^{201}$TI accumulation in, 2239

Osteomalacia, tumor-induced, bone scan, CT and MRI, 247

Osteopathitis

carcinoid syndrome, chronic, $^{99m}$Tc-labeled leukocyte imaging, 24P(ab)

$^{111}$In-labeled white cells, 4-phase $^{99m}$Tc MDP bone scan and, 261P(ab)

Osteosarcoma

cancer chemotherapy effects, $^{201}$Ti chloride effects, 129P(ab)

flare phenomenon, after complete remission, CT and MRI, 1429

Ovarian cancer

$^{11}$C methionine PET, metabolic imaging, 2196

immunoscintigraphy, monoclonal antibody to CA125, 210P(ab)

$^{32}$P chronic phosphate interperitoneal installations with platinum analogue chemotherapy, 29

recurrent, $^{18}$F FDG PET, 106P(ab)

$^{188}$Re-labeled MAb, pharmacokinetics and normal organ dosimetry, 754

$^{99m}$Tc-labeled HMFG1 MAbS for, anti-chelelate body response, 746

Oxygen-15 butanol

$^{18}$O water and, PET activation studies, signal-to-noise improvement, 307

2436
PET, neuroactivation studies, 81P(ab)

**Oxygen-15 carbon dioxide**

15O water and, dynamic PET steady-state methods, determination of splanchnic blood partition coefficient for water, 599
PET, brain, implicit motor sequence learning, 76P(ab)
slow inhalation15O water bolus injection/slow infusion, comparison, MBF measurement, 78

**Oxygen-15 carbon monoxide**
gated blood oxygen scan, 141P(ab)
versus 15O water, cerebrocerecal responses to vibrotactile stimulation, 75P(ab)

**Oxygen-15 water**
bolus administration, radiation dosimetry for, blood flow PET, 651
bolus injection/slow infusion15O carbon dioxide slow inhalation, comparison, MBF flow measurement, 78
13O butanol and, PET activation studies, signal-to-noise improvement, 307
15O carbon dioxide and, dynamic PET steady-state methods, determination of splanchnic blood partition coefficient for water, 599
PET activation studies, delayed data acquisition, cerebral arteriovenous malformation, 2149
evaluation imaging, tumor perfusion in response to IL-1, 187P(ab)
investigation of visual- and memory-search, 251P(ab)
new three-dimensional, dose optimization for rCBF, 105P(ab)
17O and, noninvasive activation studies, 82P(ab)
regional pulmonary blood flow measurement, 371
sequential, acetazolamide visualization of drug reaction, 242P(ab)

**Oxygen radicals**, IPBN, radioiodinated radical detecting agent with high stability, 7P(ab)

**P**

PACS, metropolitan area computer network, ATM technology, early results, 177P(ab)
Paget's disease
ankylosing spondylitis/rheumatoid arthritis and, palliative 125Sn EDTMP, 1417
bone, 99mTc oxonide pinhole bone scintigraphy, 1421

**Pain**
low back, SPECT bone imaging, clinical efficacy, 1707
palliation, 117Sn DTPA, osseous metastases, pilot study, 725

**Panbrochialitis**, diffuse, mucociliary transport system evaluation, aerosol inhalation cinescintigraphy, 1355

**Pancreas cancer**
versus chronic pancreatitis, FDG PET, CT, and ERCP, 223P(ab)
detection, 18F FDG PET and 201Tl SPECT, 229
evaluation, 201Tl SPECT and 99mTc phytate subtraction liver imaging, 762
localization, fusion of FDG PET and MRI, anatomically weighted external markers, 174P(ab)
overexpression of GLUT-1 glucose transporter in, 211P(ab)
suspected, 11C ACBC and 18F FDG PET, complimentary roles, 193P(ab)
disease, 11C and FDG combined PET, 227P(ab)
endo- and exocrine tumors, somatostatin receptor scintigraphy in, 125P(ab)
malignant or benign tumors, differentiation, FDG PET, 224P(ab)
preoperative assessment of masses, differentiation, FDG PET, 224P(ab) transplant, see Transplantation

**Pancreatitis, dorsum of**

**Parathyroid adenoma**
99mTc SPECT, 228P(ab), 229P(ab)
rapid washout of 99mTc MIBI, 1928P(ab)
reply, 1928L(ab)
Tc MIBI, rapid washout, 241
ectopic adenoma, localization by double-phase 99mTc sestamibi SPECT, 1840
enlarged glands, scintigraphic pitfalls, 467
lesion localization, 99mTc sestamibi scintigraphy, 202P(ab)
recurrent carcinoma, brown tumors and, 99mTc MIBI uptake in, 811
thyroid and, adenoma, in chronic renal failure, 99mTc sestamibi and 201Tl mismatch, 826

**Parathyroidectomy**, after 99mTc sestamibi localization, three-dimensional SPECT, 228P(ab)

**Parathyroid hormone-related peptides**, synovial fluid, osteoarthritis and rheumatoid arthritis patients, 209P(ab)

**Parkinson's disease**
asymmetric, 123I IBZM uptake, basal ganglia lateralized differences, SPECT, 1216
benzodiazepine receptors in, 125I IMP SPECT measurement of, 241P(ab)
brain monoamine transporters, 11C beta-CIT PET, 1255
d2 dopamine receptor analysis, SPECT and 123I iodobenzamide, 384
dopaminergic degeneration, 123I gb-CIT SPECT discrimination between early and late, 99P(ab)
18F DOPA, regional striatal transport and decarboxylase activity, PET, 1226
FDOPA and 3OMFD PET studies, striatal DOPA decarboxylase activity, clinical significance, 186P(ab)
FDOPA PET, with inhibitor of catechol-O-methyltransferase, 128P(ab)
18F FDOPA studies PET, 115P(ab)
uptake, caudate and putamen, 240P(ab)
MPTP treatment, dopamine transporter sites, SPECT imaging, 87P(ab)
nuclear graft viability in 11C CFT PET, 86P(ab)
detection of dopamine transporter, 87P(ab)
preclinical diagnosis, 11C WIN 35248 PET imaging of dopamine transporter, 98P(ab)
progressive supranuclear palsy and, 11C WIN 35248 PET imaging of dopamine transporter, 99P(ab)
rodent model, striatal cholinergic dysfunction, vesamicol receptor ligand(),125I MIBT, 162P(ab)

severity, 123I gb-CIT SPECT measures of, 99P(ab)
severity assessment, 18F FDG and PET, 378

**Partial volume effect**
dopamine transporter, PET, 254P(ab)
pulmonary mass lesions, 18F FDG PET, 66Ga/68Ge transmission scan, 189P(ab)

**Pediatric patients**
cystic fibrosis, renal failure assessment, 189P(ab)
attention deficit hyperactivity disorder, 888P(ab)
HMPAO brain SPECT, 246P(ab)
brain tumors, 210Tl value over FDG, 222P(ab)
genital heart disease, 99mTc HMPAO lung clearance in staging pulmonary hypertension, 22P(ab)
genital hypothyroidism, 59mTc pertechnetate thyroid scintigraphy in, 22P(ab)
craniosynostosis, cerebral blood flow study, 99mTc HMPAO SPECT, 394
cyclic cystography, diagnostic yield in, 33P(ab)
detection and correction of motion, 99mTc DMSA tomographic imaging, 33P(ab)
epilepsy
11C flumazenil PET, 83P(ab)
18F FDG PET imaging techniques with MRI, 262P(ab)
ictal perfusion SPECT and FDG PET, 84P(ab)
photosensitive, activation studies, 99mTc HMPAO SPECT, 84P(ab)
99Tc ECD SPECT, 84P(ab)
failed gastric fundoplication, scintigraphic identification of, 214P(ab)
feeding disorders, radionuclide studies of upper GI tract, 351
gastric emptying
imaging posture effects, 259P(ab)
milk feedings, infants and children, 259P(ab)
gastroesophageal reflux index for, 259P(ab)
hyperthyroidism, 127I therapy, 442
metabolic disease with hyperammonemia, brain PET, 260P(ab)
neonatal hepatitis and biliary atresia, differential diagnosis, 74P(ab)
neuromuscularly disabled, dumping syndrome in, 22P(ab)
renovascular hypertension, diagnosis with ACE-1 scintigraphy, 34P(ab)
99mTc MAG3 clearance, 258P(ab)
thyroid cancer, radioiodine treatment of, Chernobyl, 42P(ab)
urinary tract obstruction, 99mTc MAG3 diuretic renogram in, 33P(ab)
vesicoureteral reflux, renal scintigraphy with DMSA, long-term effects, 259P(ab)

**Pelvis**
lesions, evaluation and follow-up, MRI/18F FDG PET comparison, 189P(ab)

**Penis**
cavernosal blood volume and blood flow, 99mTc RBC washin time-activity curves, 55P(ab)
hemodynamics, measurement, nonimaging scintillation probe, 99mTc-labeled red blood cells, 2345
99mTc pertechnetate and 99mTc RBCs scintigraphy, priapism in sickle cell disease, 1404

**Penetredoiside**, successful therapy, evaluation of somatostatin receptor density and, 42P(ab)

**Peptides**
parathyroid hormone-related, synovial fluid, osteoarthritis and rheumatoid arthritis patients, 209P(ab)
The Journal of Nuclear Medicine

2438

Perfusable tissue index

radiolabeled, imaging of pulmonary embolism, 104(P(ab)
radiopharmaceutical research, Diatech, Inc., 253N(11)
synthetic P200, 99mTc-labeled, deep venous thrombosis detection, 1384
99mTc-labeled synthetic, breast cancer imaging, 195P(ab)
vasoactive intestinal receptors, in vitro identification in human tumors, imaging implications, 1846
Perfusable tissue index, physiological basis, myocardial viability, computer simulation, 320
Perfusion zones, specific coronary arteries and, three-dimensional mapping, 99mTc septambri SPECT, 2120
Peripheral vascular disease, arterial and venricular elastance and ventricular arterial coupling, coronary artery disease, 131P(ab)
Perctechnegas, transition to technegas, 267
Phantom, cardiac, myocardial 99mTc septambri SPECT for infarct sizing, multicenter trial evaluation, 1130
Pharmacokinetics
11C cocaine binding, subpharmacological versus pharmacological doses, PET, 1289
chimeric human-mouse IgG antibodies, structural factors determining Ig half-life, 161P(ab)
direct antibody targeting, pretargeting protocols based on streptavidin-biotin binding, comparison, 867
normal organ dosimetry and, 199-Re-labeled MAb, ovarian cancer, 754
Pharmacologic stress imaging
adenosine, effect of N-0661 adenosine A1 receptor antagonist, 270
new directions, 276(ed)
Phase analysis, resting asynchrony of left ventricular contraction abnormality, spasitic angina pectoris, 1003
Phenotype, genotype to, via chemotype, molecular nuclear medicine, 2S
Pheochromocytoma
malignant, 111In octreotide versus MIBG scintigraphy, 1
PET epinephrine studies of, 229P(ab)
xenografted PC12 cell line, targeting, intratumor distribution and uptake assessment with MIBG versus MIBG imaging and, 859
Phosphines, oxides, 99mTc chelates, novel amines and carboxylates, 146P(ab)
Phosphodiester, single-stranded, 99mTc-labeled, 103P(ab)
Phosphorus-32 chronic phosphate, for ovarian cancer, low-dose intraperitoneal treatment with platinum analog chemotherapy, 29
Photoactivation, MAb direct labeling, 99mTc, 1913
Photolabeling, MAbs, using 14C methyl tetrafluoro azido benzene, 156P(ab)
Photons, annihilation, 18F FDG SPECT images, 1472
Pituitary
denervation, somatostatin receptor density in, 205P(ab)
111In octreotide activity in, quantitative evaluation, 15P(ab)
Placenta, binding, myocardial perfusion imaging radiopharmaceutical transfer, 154P(ab)
Planar imaging, emission contaminated transmission scans, alignment, 179P(ab)
Plasma
123I gb-CIT-FP and gb-CIT-FE and 11C gb-CIT-FP and gb-CIT-FE metabolism, 258P(ab), volume product, 99mTc DTGA assessment, for glomerular filtration rate calculation, 1602
Plasmacytoma, intracranial, 99mTc HMPAO uptake, carotid balloon test occlusion, 800
Platelet factor-4, white blood cell specific 99mTc imaging agent development from, infection detection, 161P(ab)
Platinum-155m, modeling analysis, adjuvant radioimmunotherapy, targeting blood-borne tumor cells, 315
Plomorphic santoastromycaya, 18F FDG PET study, 97
Polar maps
parametric displays, cardiac PET, quantitative myocardial mapping of perfusion and metabolism, 153
SPECT myocardial perfusion images, new evaluation program, software validation and quality assurance, 169P(ab)
Polymers, implantable biodegradable devices, controlled radiochemical release, 164P(ab)
Polypeptides, DTGA for labeling of, reassessment of, 104P(ab)
Portal vein occlusion, hepatic lobar infarction, in cholangiocarcinoma, 99mTc DISIDA hepatobiliary scintigraphy, 474
Positron emission tomography (PET)
abdominal, two-dimensional and three-dimensional comparison, 79P(ab)
activation studies, O2 water or O2 butanol, 59P(ab), signal-to-noise improvement, 307
adverse reactions, retrospective and prospective studies, 157P(ab)
avenule photodiode readout, fast scintillation crystals, 70P(ab)
baboon brain, 11C d-threo-methylphenidate binding to dopamine transporter, 2298
BGO block detector elements, electron contribution to energy escape in, 175P(ab)
brain
foci intensity and location of activation areas, 93P(ab)
implicit motor sequence learning, 76P(ab)
monoamine oxidase sensitivity, 127P(ab)
pediatric metabolic disease with hyperammonemia, 260P(ab)
quantitation of central dopamine transporters, 58P(ab)
11C ACBC and 18F FDG, complimentary roles, suspected pancreatic cancer, 193P(ab)
11C acetate
kidney disease, 1595
myocardial oxidative metabolism, 24P(ab)
hyperthyroidism, 194
C and FDGA combined, pancreatic disease, 227P(ab)
99mTc-DTPA-DTGA
11C beta-CIT, brain monoamine transporters, Parkinson's disease, 1255
11C BMHA, fatty acid metabolism metabolism, 2062
11C BMHDA, as myocardial fatty acid metabolism marker, 142P(ab)
11C carazolol, gb-adrenergic receptor assessment, 142P(ab)
11C CFT
dopamine transporter sites, 32P(ab)
neural graft viability, chronic parkinsonism, 86P(ab)
11C cocaine binding, subpharmacological versus pharmacological doses, 1289
11C DTBZ, assessment of vesicular monoamine transporter, 118P(ab)
11C d-threo-methylphenidate, new dopamine transporter ligand, brain studies, 2162
11C F1B 457, radiogand for extravascular dopamine D2 receptors, 1275
11C flumazenil, parameter and index images, benzodiazepine receptor concentration in brain, 1462
11C FMZ, metabolite-corrected arterial plasma input function, simplified estimation, 175P(ab)
11C LCM, protein synthesis in muscle, 230P(ab)
11C methionine
intracerebral hematoma evaluation, distinguishing neoplastic from non-neoplastic, 2175
malignant melanoma, 1806
metabolic imaging, ovarian tumors, 2196
11C MTBZ, brain vesicular monoamine transporter, 2252
11C palmitate, incorporation in monkey brain, 2261
11C raclopride dopamine D2 receptor occupancy of OPC-14597, 252P(ab)
reconstruction parameter effects on D2 receptors, 262P(ab)
11C TYR and, in vivo protein synthesis rate determination, in primary or recurrent brain tumors, 411
11C WIN 35248, dopamine transporter, Parkinson's and supranuclear palsy, 140
camera design
breast cancer and axillary node involvement, 69P(ab)
ECAT ART, rotating detectors, 70P(ab)
canine beta-adrenergic and muscarinic receptor densities, myocardium, after denervation, 140
cardiac, parametric map display, quantitative myocardial mapping of perfusion and metabolism, 153
carcinoid artery stenosis, 53P(ab)
CD gene therapy, 5-FC in vitro studies, 188P(ab)
cerebral blood flow
anticipatory anxiety, irritable bowel syndrome, 246P(ab)
morning versus midday differences, 128P(ab)
cerebral glucose metabolic rates, improved calculation method, 1668
clinical attenuation scans, thorax model database, construction, 185P(ab)
59Co
ischemic stroke, 239P(ab)
traumatic brain injury, 247P(ab)
cocaine abuse, increased mu-opioid receptors in, 20P(ab)
cocaine-induced dopamine release, trans-synaptic modulation of, 11P(ab)
cognitive activation studies, principle component analysis in, 81(ab)
coincidence imaging, preliminary investigation, dual-headed SPECT system, 175P(ab)
comparison of 18F FDG and methionine uptake, 484
comparison of glucose and oxidative metabolism, in moderately hyperperfused myocardium, 139P(ab)
copper(II) bis(thiosomcarbazone), tissue perfusion, species-dependent binding to serum albumin, 1451
correction of data for partial volume effects, 233

correlative study, relationship of regional myocardial viability and reverse redistribution on planar thallium scintigraphy, 180
CT and, thorax, retrospective image registration, 233
62Cu HSA, regional cerebral plasma volume and hematocrit, 239P(ab)
62Cu PSAM, animal model studies as predictor of clinical performance, 1456(ed)
62Cu-labeled MAb IAA, colorectal carcinoma detection, 1818
62Cu TETA octreotide and 11In DTPA-D-Phe-1-octreotide, comparison, in vitro and in vivo evaluation, 2315
data fitting, multiple brain regions, parameter estimate stability increases, 187P(ab)
definition of cardiac tissue viability, automated analysis, quantitative criteria evaluation, 1407P(ab)
detection of abnormalities, in fatty acid metabolism, patients with cardiomyopathy, 142P(ab)
dopamine nerve terminals, four 18F-labeled DOPA analogs for, 253P(ab)

dopamine transporter alterations of synaptic dopamine, 253P(ab)
cocaine analog for use in, 117P(ab)
radiotracer for baboon and human brain, 117P(ab)
D2 receptors, rhesus monkeys, 252P(ab)
dynamic improving ROI quantitation, principal component analysis and sinogram restoration, 185P(ab)
11N ammonia and, posterolesional defect investigation of normal human heart, 581
small cardiac chambers relative to resolution, factor analysis, blood TAC extraction, 185P(ab)
ECG-gated, parameter estimation of cardiac geometry, validation by MRI and echocardiography, 1123
emission and transmission, primary breast cancer, presurgical visualization, 1882
endotoxin removal devices, short-lived radiopharmaceuticals, 80P(ab)
epinephrine study, photochromocytoma, 229P(ab)
estimation of tracer activity, correction of, 115P(ab)
evaluation of 11C WAY 106355, serotonin 5-HT1A receptor antagonist, 162P(ab)
evaluation of radiolabeled phenyl-tropane analogs, in vivo study of monoamine transporter, 162P(ab)
18F in concurrent 181T therapy patients, 197P(ab)
inhibition of cyclooxygenase, 49P(ab)
use of maximum likelihood reconstruction, enhanced discrimination, 165P(ab)
FDG abnormal olfaction and cerebral glucose metabolism, schizophrenia, 247P(ab)
accumulation, pancreatic cancer and skeletal metastases, 613(ab)
assay of cerebral glucose metabolism, 82P(ab)
breast tumors, 82P(ab)
auxiliary lymph node involvement, 82P(ab)
cerebral metabolic correlates in depressive relapse, 249P(ab)

cocaine craving, 43P(ab)
combined 13C acetate, renal neoplasms, 55P(ab)
comparison with icatal perfusion SPECT, epilepsy, 84P(ab)
depression, 44P(ab)
detection of ovarian cancer, 106P(ab), 107P(ab)
extrathoracic metastases, lung cancer, 4P(ab)
detected, independent solitary pulmonary nodules, 94P(ab)
lung cancer, systemic distortion in, 5P(ab)
neoplasms, 94P(ab)
management of malignant tumors, 57P(ab)
metabolic abnormalities in Alzheimer's, 237P(ab)
metabolism, estrogen receptor status and, breast cancer, 83P(ab)
nonsmall, regional carcinoma, 57P(ab)
cost effectiveness, 95P(ab)
occult/recurrent colorectal cancer, 106P(ab)
oncology atlas, 269P(ab)
3P(ab) comparison with, myocardial viability assessment, 67P(ab)
phosphorylation rate, malignant glioma, 61P(ab)
preoperative evaluation of colorectal cancer metabolic to liver, 106P(ab)
pulmonary sarcoidosis, 250P(ab)
recovery of gray matter activity, resolution effects, 114P(ab)
recurrent musculoskeletal sarcoma, 234P(ab)
recurrent or residual lung cancer detection, 788
solitary pulmonary nodules
determination of tumor size, 95P(ab)
estimating risk in, 94P(ab)
SPECT comparison, viable myocardial segments, 3P(ab)
staging and therapy-control of malignant lymphoma, 224P(ab)
staging lung cancer by, 95P(ab)
staging regional lymph nodes, cutaneous malignant melanoma, 116P(ab)
unknown primary malignancy, 56P(ab), 57P(ab)
untreated breast and lung cancer, 83P(ab)
while matter, multiple sclerosis, 241P(ab)
whole-body, metastatic melanoma, comparison to, 116P(ab)
FDOPA, Parkinson's disease, with inhibitor of catechole-O-methyltransferase, 128P(ab)
18F and 13C microparticles, absolute quantification, 69P(ab)
18F DOPA, Parkinson's disease, striatal transport and decarboxylase activity, Parkinson's disease, 1226
18F FBT, cholinergic terminals in monkeys, 59P(ab)
18F FDG brain imaging, HIV-1-infected children born to seropositive mothers, 2169
clinical assessment of myocardial glucose uptake, nicotinic acid effect, 996
combined transmission and emission data use, improved myocardial wall detection, 165P(ab)
comparison with MRI, evaluation and follow-up of pelvic lesions, 189P(ab)
correlation with 18F FDG SPECT, 988
cost-effectiveness, assessment of myocardial viability, 67P(ab)
detection of bone metastases, hormone-resistant prostate cancer, 198P(ab)

early infancy, cerebral glucose utilization, simplified quantification methods, 1249
versus 18F SPECT, detection of malignancies, 194P(ab)
glucose metabolism in vivo assessment, hepatocellular carcinoma, 1811
high accumulation, turpentine-induced inflammatory tissue, 1301
improving yield, use of microwave cavity, 150P(ab)

liver metastases from colorectal cancer, 216P(ab)
lung cancer, patient survival prediction, regional pulmonary lymph node hypermetabolism data, 192P(ab)
mediastinal FDG uptake, normal limits and affecting factors, 190P(ab)
MRJ and, detection of lymph node metastases, squamous-cell cancer of head and neck, 211
MR spectroscopy, dynamic perfusion MRI and, in NFI optic pathway and brainstem tumors, 191P(ab)
myocardial glucose metabolism evaluation, noninsulin-dependent diabetes mellitus patients, 456
optimum imaging criteria, malignancy risk estimates, solitary pulmonary nodules, 190P(ab)
optimum scanning protocol, pulmonary malignancy evaluation, 883
pancreatic cancer versus chronic pancreatitis, 223P(ab)
pediatric epilepsy, 262P(ab)
prostate cancer metastases detection, 189P(ab)
regional cerebral functions, normal patterns and age changes, 1141
skeletal muscle, viability assessment, 1408
three-dimensional stereotactic surface projections, Alzheimer's disease diagnosis, 1238

3P(ab) SPECT and comparison, patients with solitary pulmonary nodules, 192P(ab)
value in detection of pancreatic cancer, 229

malignant tumor-host interaction, potential role, 893
whole-body, diagnostic accuracy, oncologic patients, 193P(ab)
18F FDG and, Parkinson's disease, severity assessment, 378
18F FDG and 99mTc sestamibi, recurrent malignant lymphomas, 216P(ab)

18F/3P(ab) Tc pertechnetate/111T sodium iodide, cervical lymph node metastasis of thyroid papillary carcinoma, 1843
18F FDOPA estimation of dopamine synthesis with, 241P(ab)
Parkinson's disease, 115P(ab)
18F FES/18F FDG, comparison with in vitro assays, estrogen receptors in breast cancer, 1766
18F FBG, validation as positron-emitting analog of 111T MBG, 644
18F FMISO, meningioma, 222P(ab)
18F iodine/18F FDG, simultaneous imaging, whole-body skeletal and soft tissue, 184P(ab)
18F, bone marrow glucose metabolism, response to hematopoietic cytokines, 794
fluorocarazolol, gb-adrenoeceptor, 59P(ab)
18F octreotide uptake kinetics, tumor-bearing rats, 113P(ab)
18F Phe, blood-brain barrier, aging effect on neutral amino acid transport, 1232

Subject Index • 1995
2439
Positron emission tomography (PET)

18F setoperone
human pituitary 5-HT2 receptors, 15P(ab)
necrotocellular serotonin receptor binding,
128P(ab)

18F SPECT and, comparison of interpretation,
140P(ab)

18F study, pleomorphic xanthoastrocytoma, 97
FDOPA and 30MD imaging, stratal DOPA
decarboxylase activity, clinical significance,
186P(ab)

functional MRI versus, cerebral activation after
motor stimulation, 75P(ab)
gated, left ventricular wall thickening from,
8P(ab)
gated cardiac 18F FDG, comparison of Fourier
analysis and cineventriculography,
141P(ab)
glucose transport, skeletal muscle, 116P(ab)
graft viability, neural degeneration and, 87P(ab)
head and neck cancer, post-surgery/radiation
recurrence, 221P(ab)

head-tome-v-dual camera, performance
evaluation, 70P(ab)

heart, function, autonomic nervous system
modulation of, 37P(ab)

high-resolution cerebral metabolism and blood flow in cats,
application of clinical camera to experimental studies, 484

scatter component assessment, nonstationary
convolution subtraction correction, 121

historical archive, 24N(1)

Huntington’s chorea, recruitment of additional
cortical sites in motor task, 75P(ab)

hybrid collimator technique, without geometric
distortion, 109P(ab)

BMIPP, decreased uptake, metabolic
alterations in ischemic myocardium, comparison with 18F FDG and 13C
acetate, 1974

idiopathic dilated cardiomyopathy, wall motion
reversibility in, 36P(ab)

image reconstruction, accelerated conjugate
gradient preconditioners, 184P(ab)

imaging thrombotic disease, radiolabeled anti-
tissue factor antibody, 149P(ab)

increased opioid receptor binding, major
depression, 217P(ab)

left bundle branch block assessment, septal beta-
oxidation and glucose utilization,
metabolic mismatch, 2056

liver regeneration, site-specific protein synthesis,
628

MAO B mapping, 1C L-depenyl and 13C
deprenyl-D2 comparison, radiotracer
trapping by deuterium substitution,
selective reduction, 1255

methyl-1C thymidine, in head and neck tumors,
880

modeling, cardiac, dual spillover problem,
17P(ab)

motor activation study, 18F FDOPA uptake in,
76P(ab)

movement during, attenuation correction
accuracy despite, 670

MRI and, brain images, coregistration method,
1307

MRI coregistration, striatal dopamine receptors,
252P(ab)

MRI/CT, association of, 18P(ab)

MRI guided reconstruction, defective
anatomical a priori information, 94P(ab)

multitracer studies, hepatoma cells, during HSV
thymidine kinase and ganciclovir gene
therapy, 190P(ab)

myocardial blood flow and 18F FDG retention,
in acutely stunned porcine myocardium, 637

myocardial oxygen consumption, identification of
viable myocardium, 68P(ab)

myocardial perfusion, glucose utilization, acute
myocardial infarction after thrombolytic
therapy, 140P(ab)

N ammonia
after heart transplant, coronary artery disease
detection, coronary angiography
comparison, 982

factor analysis of dynamic structures and,
myocardial blood flow quantification,
2087

with partial volume effect correction,
myocardial blood flow, 175P(ab)

rest and stress, dilated cardiomyopathy,
3P(ab)

takeup, lung, 5P(ab)

N ammonia and 18F deoxyglucose, myocardial
viability delineation, 1543

N ammonia/FDG, resting myocardial ischemia,
79P(ab)

N and 18F FDG, dobutamine stress
comparison, myocardial viability, 67P(ab)

NH4, myocardial perfusion imaging, ammonia
distribution and K1 parametric values in,
37P(ab)

non-Hodgkin’s lymphoma, malignancy grade
prediction, 1790

O-labeled carbon monoxide, gated blood-pool
scan, 141P(ab)

oncologic 13N FDG studies, interactive whole-
body viewer, 165P(ab)

O water, activation studies, delayed data
acquisition, cerebral arteriovenous
malformation, 2149

O water
and butanol, neuroactivation studies, 81P(ab)
dementia patients, cholin precursor effects,
237P(ab)

evaluation imaging, tumor perfusion in
response to L-1, 187P(ab)

investigation of visual- and memory-search,
251P(ab)

regional myocardial blood flow, 78P(ab)

regional perfusion in peripheral muscle,
115P(ab)

regional pulmonary blood flow measurement,
371

sentence ambiguity effects on blood flow,
brain, 256P(ab)

O water and 12C carbon dioxide, determination of spleen-blood
partition coefficient for water, 599

O water bolus injection/slow infusion/13C
carbon dioxide slow inhalation
comparison, MBF measurement, 78
peripheral benzodiazepine binding sites,
microgliosis, Alzheimer’s disease, 2207

planar 18F FDG, myocardial viability
assessment, after recent infarction, 975

potential nitric oxide synthase tracer for,
development of, 45P(ab)

qualitative 18F FDG, breast tumors, 189P(ab)
radiation exposure to personnel, techniques for
lowering, 260P(ab), 261P(ab)

radioimmuno-, colorectal cancer patients, 9P(ab)
radiopharmaceuticals
in-house human use, validation and approval
program, 157P(ab)

prototype geometries for breast cancer,
69P(ab)

rapid and accurate realignment, image edge
information use, 657

R coronary artery disease in women, 78P(ab),
79P(ab)

kinetic parameter variability, anesthetia depth,
dog, 185P(ab)

myocardial perfusion imaging, first-pass
cardiac output determination during,
141P(ab)

prediction of cardiac events, after vascular
surgery, 79P(ab)

resting myocardial blood flow measurement,
37P(ab)

variability and reproducibility of kinetic
parameters, anesthetized canine
myocardium, 287

Rb dipyridamole, serial myocardial perfusion
imaging, restenosis assessment after
angioplasty, 1553

cerebral glucose metabolism, 187P(ab)

Cerebral glucose metabolism, 187P(ab)

rCBF measurements, task-specific
neurophysiological changes, aging,
21P(ab)

reduced protein synthesis identification
potential, severe aortic regurgitation,
142P(ab)

regional cerebral glucose metabolism,
Cruetzfeld-Jacob disease, 238P(ab)

regulation, 34N(9)

resting myocardial blood flow, reversible
dysfunctional myocardium, 67P(ab)

scanner, coincidence capability, 70P(ab)

scanners, for small animals, 231(1c)

script-driven imagery and, post-traumatic stress
disorder, 42P(ab)

serial scans, brain cancer patients receiving high-
dose tamoxifen, 225P(ab)

sigma receptor ligands, synthesis and evaluation,
151P(ab)

silent myocardial ischemia during, 1034

skeletal fluoride kinetics, nutritional
osteoporosis, 122P(ab)

SPECT and
myocardial, artificial inhomogeneities in
normal values, 188

sinograms, calculation of three-dimensional
spatial coordinates, 179P(ab)

SPECT or
FIDA-2 and, dopamine D2/D3 receptor
antagonist, 1322

with 123I or 18F, R(-)-FIDA2 imaging agent, in
vitro and in vivo binding properties, 1282

SPECT versus, brain, distinguishing radiation
necrosis from tumor recurrence, 159

standard uptake values, standard or silly, 1836
two-dimensional
activity outside the field of view, influence,
164P(ab)

brain receptor imaging, 81P(ab)

image reconstruction, improvement strategies,
93P(ab)

noise properties, 105P(ab)

normalization with translating line pseudo-
plane source, 92P(ab)

O and, noninvasive activation studies,
82P(ab)

O water, dose optimization for rCBF,
105P(ab)

performance characteristics, cardiac imaging,
174P(ab)

correction, out-of-field activity effects,
105P(ab)
scatter correction using two-dimensional fitted Gaussian functions, 105P(ab)
three-injection dynamic, 11C-labeled dopamine transporter ligand, design and analysis, 1680
monkey, 1680P(ab)
201Tl SPECT and, sequential use, viable myocardium identification, superiority over single tests, 143P(ab)
torsio, 11Cu-labeled MAB 1A3 dosimetry determination, 2363
variance and covariance image maps, rapid direct computation, implementation and validation, 176P(ab)
visual cortex, deactivation of, vestibular nystagmus and, 76P(ab)
whole-body attenuation correction, simultaneous emission and transmission measurements, 1680 bone metastasis in lung cancer, 200P(ab) continuous axial sampling in, 93P(ab) elevated tumor markers and suspected recurrent cancer, 57P(ab)
furosemide diuresis and aggressive bladder irrigation with, 199P(ab)
non-attenuation-corrected, cancer screening with, 201P(ab)
one-year experience in oncology, 199P(ab) recurrent colorectal cancer, 57P(ab) staging of Hodgkin's disease, 199P(ab)
whole-body 18F FDG potential role, unknown origin tumors, 194P(ab) staging, malignant melanoma, 191P(ab) whole-body segmented, attenuation correction, 104P(ab), 105P(ab)
yohimbine administration, post-traumatic stress disorder, 43P(ab)
62Zn-65Cu, radiopharmaceutical generator, 49P(ab)
67Zn production, proton irradiation of unenriched copper sulfate solution, 151P(ab)
Posterolateral defect, normal human heart, investigation by 11N ammonia and dynamic PET, 58I
Post-traumatic stress disorder, regional cerebral blood flow SPECT, 85P(ab)
Potassium-38, kinetics, ischemic heart disease, assessment of myocardial viability, 67P(ab)
Pretargeting, tumors, 876(ed)
Priapism, sickle-cell disease, 99mTc pertechnetate and 99mTc RBCs penile scintigraphy, 1404
Primary motor cortex, 123I IMP SPECT, super-early imaging, 2180
Probes
intraoperative gamma, lymphoscintigraphy, 1780(ed)
positron-sensitive, 18F FDG-guided breast cancer surgery, 1869
Progestrone, 11F-labeled, breast tumor imaging, 39P(ab)
Prospective Investigation of Pulmonary Embolism Diagnosis, National Heart, Lung, and Blood Institute sponsored, ventilation-perfusion lung scan interpretation criteria, comprehensive results analysis, 2380
Prostate
cancer
athymic mice with PC-3 tumors of, radiotherapy with 185Re RC160, 42P(ab)

11In capromab pendetide for presurgical staging, 10P(ab)
11In in CFT-356 SPECT in, 9P(ab) lumbar spine and pelvic metastases, bone scintigraphy and MRI, 236P(ab) outcome prediction, bone scintigraphy, 196P(ab) perineural invasion, PSA test, 208P(ab) quantitation of serial bone scintigram changes, 180P(ab) residual or recurrent, 11In in CFT-356 SPECT in, 9P(ab) scar and, 18F FDG PET for differentiation, 198P(ab) somatostatin analog for imaging of, 92P(ab) treatment with 99mTc KC4, 213P(ab) cancer metastases, detection, 18F FDG PET, 189P(ab)
Prostate-specific antigen test, perineural invasion, 208P(ab) variation in levels of, nonprostatic malignancy patients, 209P(ab)
Protein
BPV-1 E2, DNA-binding domain structure, binding to DNA target, 25S glucose transport, tumor xenographs, 2 deoxyglucose retention and, 61P(ab) G protein-coupled receptors, potential diagnostic ligands and, structure and functional analysis of, 17S nonspecific labeling, 99mTc transchelation agents, quantitative study, 159P(ab) site-specific synthesis, 13C methionine PET determination, in liver regeneration, 628 synthesis, PET tracers for assessing liver metabolism, 152P(ab) in vivo synthesis rate determination, primary or recurrent brain tumors, 11C TYR and PET, 411
PSA, see Prostate-specific antigen PTA, see Angioplasty, percutaneous transluminal
Pulmonary embolism
abnormal washout clearance patterns, 99mTc pertechnetepega
determination, 176P(ab)
lung scan, PIOPED scintigraphy criteria, 99mTc MAA and 99mTc DTPA, 1573 diagnosis, five years after PIOPED, 273P(ab) extensive obstructive airway disease, perfusion and ventilation scans, single-breath washin 133Xe utility, 64 high post-clinical surgical suspicion, angiography in patients with low probability VPS, 186P(ab) imaging sequence of labeled disintegrins on, 104P(ab) 99mTc PT48 synthetic peptide use in, 34P(ab) management, thrombolytic therapy, role definition, 369(ed) presentation or response to therapy, gender differences, 111P(ab) thrombolytic therapy, lung scan evaluation, 364 V/Q scanning diagnostic accuracy, source of patient referral and, 112P(ab)
interpretation, prior cardiopulmonary disease and, 112P(ab)
very low probability scan pattern, 113P(ab)
Pulmonary hypertension, reverse V/Q perfusion mismatches in, 251P(ab)
Pulmonary ventilation imaging, 99mTc DTPA, prostaglandin and cytokine release stimulated by, 250P(ab)
Q
Quality control, sodium iodide well counter for, 99Sr chloride wipe tests, 126P(ab)
Quantitation
conjugate view activity, source thickness correction factor, 120P(ab)
maximum likelihood performance, imaging systems, 119P(ab)
region of interest activity estimation, with resolution recovery, 119P(ab)
R
Radiation
dosimetry, 105P(ab)
exposure, human trachea, from 133Xe, 1458 necrosis, distinction from tumor recurrence, brain, PET versus SPECT, 159 risk, and nuclear medicine, 24N(12)
Radiation Effects Research Foundation, function. DOE certification, 36N(9)
Radiation safety, NIH, accident, 36N(9)
Radiation therapy
accident management training, multimedia software, 267P(ab)
brain tumors, necrosis from, thalamus brain SPECT and MRI comparison, 95P(ab) damage, DNA single stranded breaks, repair, 121, mononuclear blood cells, 85P(ab) effects on amino acid transport, brain tumors, 216P(ab) pelvic or nonprostatic malignancies, level of PSA in, 209P(ab) somatostatin receptor-mediated, cancer, 114P(ab)
Radioaerosol, central and peripheral distribution, normal and deep breathing, 34P(ab)
Radioantibody therapy, multiple cycles, myelotoxicity and marrow radiosensitivity after, 212P(ab)
Radiochemical purity, dependence on specific activity, 99mTc HMPAO, 706(ed)
Radiochemistry, LYM-1 monoclonal antibody, HAMA response after, B-lymphocytic malignancies, 215P(ab)
Radiochemotherapy, bleomycin and, 1531(ed)
Radioimmunosass
human anti-mouse antibodies fast and cost-effective determination of, 210P(ab) overcoming the effects of, 209P(ab) protein-A IgG binding domain cloned with ScFv, development of novel immunosass, 209P(ab) thyroid binding globulin, correction of triiodothyronine uptake distortion, 209P(ab)
Radioimmunodetection
axillary node assessment, breast cancer, 9P(ab) recurrent medullary thyroid cancer, bispecific antibody and 111In bivalent hapten for, 211P(ab) 99mTc detector at nanocurie level, potential tool for preclinical pharmacology applications, 154P(ab) therapy, residualizing isotopes in, 20P(ab)
Radioimmunotherapy

Radioimmunotherapy
adjuvant, targeting blood-borne tumor cells, 192Wm@ modeling analysis, 315
antibody protein dose, effect on dosimetry and diagnostic accuracy of CEA-expressing tumors, 226P(ab)
antibody streptavidin pretargeting, performance of, 225P(ab)
antibody CEA/anti-DTPA immunocomplex, medullary thyroid cancer patients, 225P(ab)
B-lymphocytic malignancies, IgG responses to macromolecular agents, 92P(ab)
66Cu and 68Ga monocolonal antibody, colon cancer, GW39 hamster model, 92P(ab)
66Cu-versus 68Ga-labeled MAb, colorectal tumor-bearing hamsters, 217P(ab)
dosimetry, three-dimensional activity map, SPECT, 1885
HAMA induction, survival in ovarian cancer and, 215P(ab)
high tyrosine fraction, impact in complementarity determining regions, 18P(ab)
human colon carcinoma multicell spheroids, comparative targeting, one- and two-step immunocomplex systems, 181P(ab)
131I anti-B-1
non-Hodgkin's lymphoma, 214P(ab)
refractory B-cell lymphoma, 214P(ab)
relapsed non-Hodgkin's lymphoma, phase II trial results, 214P(ab)
tracer dosimetry studies in, 226P(ab)
131I G250, metastatic renal cell carcinoma, 213P(ab)
125I-labeled chimeric 171A, metastatic colon cancer, initial clinical evaluation, 2229
imaging and dosimetry study, medullary thyroid cancer, 41P(ab)
intralesional, malignant glioma, 213P(ab)
micrometastases, solid-tumor hurdle, 1910(ed)
phase I trial, 111I CC49, metastatic colon carcinoma, 586
preservation of antibody immunoreactivity, 79P(ab)
radioimmunoassay and, hepatocellular carcinoma, 213P(ab)
targeted beta-emitting radionuclides, tumor size and curability relationship, 1902
tumors and organ masses, dose calculations, generalized approach, 1923
various cytokine effects, tumor-bearing mice, 216P(ab)
66Ga-111In DOTA peptide chimeric L6, breast cancer, 97P(ab)

Radioiodine
stable conjugation, mediation of single-chain Fv molecule tumor specificity enhancement, 227P
synthesis and biodistribution, two acridine derivatives, 6P(ab)
tumoricidal cytokine enhancement of uptake, thyroid cancer cells, 204P(ab)

Radioiodine therapy
thyroid cancer, pulmonary metastases in, alveolar-capillary membrane integrity, 99mTc DTPA clearance as dosage index, 783
uptake reappearance, metastatic follicular thyroid carcinoma, 613

Radioiodides, 18Flabeled benperidol derivatives, in vitro metabolism, isolated rat hepatocytes, 153P(ab)

Radioisotopes
beta-emitting, targeted therapy, tumor size and curability relationship, 1902
delivery improvement, direct antibody targeting, pretargeting protocols based on streptavidin-biotin binding, 867
equilibrium angiography, edge detection algorithm, 1014
18F FDG PET, tumor-host interaction, potential role, 893
first-pass angiography, single-crystal gamma camera, recent statistics as limiting factor, 1528P(ab)
imaging clinically useful dosimetry method, use of measured effective thickness and derived build-up factor, 182P(ab)
complicated renal transplant, evaluation of, 272P(ab)
electroporation in, 212P(ab)
imaging, comparison of new digital radioimager and film autoradiography, 180P(ab)
reduction of radiation dose, bone marrow, 86P(ab)
interferon therapy and, chronic liver diseases from hepatitis C infection, 1587
internal, in vivo radioprotection against biological effects, AET, 259
molecular probes, mACHr imaging, SS
targeting study, frozen section microautoradiography, 111In onix-labeled leukocytes, 499
66Ga MDP bone scan and radiography findings, oncocytic and central nervous system sarcoidosis, 464
thrombolytic therapy, pulmonary embolism, lung scan evaluation, 364
upper GI tract studies, children with feeding disorders, 351

Radioisotopes, See also specific substance approval process, day in the life, 15N(10)
controlled radiochemical release, implantable biodegradable polymer devices, 164P(ab)
expenses of, cost-containment measures, 260P(ab)
new, objective assessment, 1086(ed)
no-carrier-added 111In MBG, evaluation in neuroblastoma, 1088
PBBS IPK, lesioned brain area detection, 143P(ab)
PET, in-house human use, validation and approval program, 157P(ab)
phenylpropazines, neuroblastoma targeting, 191P(ab)
problems with the industry, 17N(1)
reconstitution and fractionation of Cardiolite kit, cost saving, 80P(ab)
renewing the market, 34N(5)
Stannous chloride treatment, biological effect on a plasmid DNA, 148P(ab)
strategies for industry's survival, 30N(2)
Radioprotection, by AET, against biological effects of internal radionuclides, 259

Radiotargeting, antibody-dependent approach, intercalator and, 212P(ab)

Radiotherapy, 111In leukocytes, postradiation veno-occlusive fistulas, uterine carcinoma, 618

Radiotracer
kines, 99mTc Q12, effects of no flow and reperfusion, 2103
standard uptake values, PET, standard or sily, 1836
steroid receptor-based, design, breast and prostate tumor imaging, 8S

Rapid-eye-movement sleep, narcoleptics, cerebral blood flow during, 99mTc HMPAO SPECT, 1150

Raynaud's phenomenon, primary and secondary, esophageal hypomotility, comparison of esophageal scintigraphy and manometry, 451

Receiver operating characteristics analysis, energy-weighted acquisition, Compton scatter reduction, SPECT, 2352

Receptor imaging
endocytosis, evaluation of 67Ga folate deferoxamine conjugate, 68P(ab)
substance P, human primary neoplasms, 71P(ab)
vaccinatory internal peptide, human tumors, 71P(ab)

Receptors
adrenergic ligand, compartmental modeling, 11C carazolol pharmacokinetics analysis, 186P(ab)
11C FMZ PET, metabolite-corrected arterial plasma input function, simplified estimation, 175P(ab)
determination of binding potentials, unsuitability of pseudoequilibrium methods, 179P(ab)
D2 sites, PET mapping, tissue distribution and primate imaging, 151P(ab)
G protein-coupled, potential diagnostic ligands and, structure and functional analysis of, 17S
neuropeptide, in health and disease, molecular basis for in vivo imaging, 1825
NMDA, ionophore associated with, toward a positron radiotracer for, 150P(ab)
18F Re somatostatin analog RC166, scintigraphic behavior and therapy dose estimates, 183P(ab)

Reconstruction
algorithm image reconstruction, 18F FDG SPECT, 167P(ab)
iterative, using a massively parallel computer, 180P(ab)
filtered backprojection, depth-dependent blur correction and, 29P(ab)
implementation of recursive two-dimensional maximum likelihood estimator, scintillation cameras, 172P(ab)
iterative, uptake of 111In HRZM, 257P(ab)
parameters, effect on D2 receptors using 11C raclopride, 262P(ab)
SPECT, hybrid-grid parameterization method, 172P(ab)
three-dimensional whole-body PET, improvement strategies, 93P(ab)

Reflex sympathetic dystrophy, confirmation of diagnosis, three-phase bone scintigraphy, 274P(ab)

Region of interest, activity estimation, with resolution recovery, 119P(ab)
quantitation, improvement, dynamic PET studies, principal component analysis and sinogram restoration, 185P(ab)

Renal artery stenosis
renovascular hypertension and, captopril renal scintigraphy, 231P(ab)
99mTc MAG3 renogram in, 234P(ab)

Renal cell carcinoma
11C acetate PET, 1595
metastatic, radioimmunotherapy with 131I G250, 213P(ab)
radioimmunotargeting of, 131I-labeled chimeric G250 monoclonal antibody, 210P(ab)
Scintimammography

preoperative, operative probe scintimetry, $^{99m}$Tc 88BV59, colorectal carcinoma, 738
pulmonary aerosol, lung clearance of $^{99m}$Tc DTPA, effect of inhaled furosamide, 73
radioimmune bone marrow, bone marrow metastases from primary breast cancer, detection and follow-up, 1930(le)
replay, 1930(le)
radiolabeled IgG, spondylodiscitis diagnosis, 708(le)
renal, captopril, long-term renal analysis of kidney function, 44P(ab)
sacroiliac, age and gender effects, 235P(ab)
serial bone scintigrams, quantitation of changes, carcinoma of the prostate, 180P(ab)
skeletal, $^{99m}$Tc HDP, abdominal uptake, after colectomy in Gardner’s syndrome, 1611
somatostatin receptor

differentiation of benign dermatopathic lymphadenopathy and malignant lymphoma, cutaneous T-cell lymphomas, 197P(ab)
neuroendocrine tumors, 188P(ab)
somatostatin receptor

$^{111}$In DTPA-D-Phe-l-octreotide, central nervous system tumors, blood-brain barrier permeability role, 403
synthesis, biodistribution, and estrogen receptor, $^{111}$In DTPA tamoxifen analogue, 161P(ab)
$^{99m}$Tc DISIDA hepatobiliary, hepatic lobal infarction, absent uptake, cholangiocarcinoma, 474
$^{99m}$Tc DTPA and $^{111}$In DTPA, effects of smoking on bronchial clearance, 1569
$^{99m}$Tc DTPA and $^{99m}$Tc HMPAO radioaerosol lung, alveolar integrity in pulmonary embolism, 58
$^{99m}$Tc MAA, after endovascular stenting of pulmonary artery stenosis, 2006
$^{99m}$Tc MAG3, clearance measurement improvement, camera-based method, 1689
$^{99m}$Tc MDP bone, localized clear-cell renal epithelial tumor, diffuse renal retention on, 817
$^{99m}$Tc methylene diphosphonate, enhanced bone metabolism induction by acupuncture, 2246
$^{99m}$Tc MIBI rapid washout, large parathyroid adenoma, 241
uptake in recurrent parathyroid carcinoma and brown tumors, 811
$^{99m}$Tc pyrophosphate, intestinal perforation, dermatomyositis, 1615
$^{99m}$Tc RBC in liver metastasis, 709(le)
replay, 710(le)
$^{99m}$Tc sestamibi pancreas transplant, 771
single-injection double-phase, Hurthle cell tumor identification, 778
thallium-201Tl bone marrow uptake, nonsecretory myeloma, 250
thymus, $^{111}$In DTPA-arg substance P, 257P(ab)
thallium-201Tl diagnosis, chronic exertional compartment syndrome, 1618
reversal of contrast, myocardial viability in chronic coronary artery disease, 1968
soft-tissue tumors, pediatrics, 1372
tomographic gated blood-pool, left ventricular volume measurement, gradient-echo MRI validation, 131P(ab)
vasoactive intestinal peptide receptor, adenocarcinomas and endocrine tumors, 1732
ventilation-perfusion, low probability, high post-test clinical pulmonary embolism suspicion, 180P(ab)
Scintimammography, see Mammoscintigraphy

Scintimetry, operative probe, preoperative scintigraphy and, $^{99m}$Tc 88BV59, colorectal carcinoma, 738
SDS-CE, size exclusion HPLC and, stannous and UV pretreated MBA-170, behavior differences, causes, 159P(ab)
Seizure, temporal lobe, FDG-PET imaging and Wada test, 84P(ab)
E-Selectin, endothelial activation, inflammatory disorders, imaging of, 24P(ab)
Semiconductor detectors

charge transport modeling in124P(ab), 124P(ab)
SPECT, spatial resolution, 17P(ab)
Sentinel node
detection of, dynamic lymphoscintigraphy, 223P(ab)
radio-guided biopsy, elective lymph node dissection, cutaneous melanoma, 195P(ab)
Serotonin

$^{18}$F labeling of SR 643649, $^{5}$HT2 receptor antagonist, 149P(ab)
high affinity receptor ligand, $^{11}$C org-1352, synthesis and biodistribution, 163P(ab)
$^{5}$HT1A receptor antagonist, evaluation of $^{11}$C WAY 100635, 162P(ab)
Serotonin receptors

ageing effects, cocaine abusers, 10P(ab)
$^{11}$C WAY-100635 for study of, 58P(ab)
PET ligands for study of, 58P(ab)
piracy, PET imaging with $^{18}$F setoperone, 15P(ab)
synthesis and separation of optical isomers of $^{18}$F-labeled MDL-28161 and MDL-100151, 149P(ab)
technetium and rhenium complexes able to bind to, 27P(ab)
technetium complexes binding to, 28P(ab)
Serotonin transporters, density, alteration with impulse violent behavior, 31P(ab)
sFV antibodies, $^{99m}$Tc labeling of, bioengineered peptide chelator, 28P(ab)
Sickle-cell disease, priapism, $^{99m}$Tc pertechnetate and $^{99m}$Tc RBCs pertechnetate scintigraphy, 1404
Sigma receptors

characterization on neural tumor cells, use of radiodinated benzamides, 144P(ab)
ligand, tumor imaging, 6P(ab)
ligands, PET, N-(N-benzylpiperidin-4-yl)-2-$^{18}$F-fluorobenzamide and 4-$^{18}$F-fluoro analog, synthesis and evaluation, 151P(ab)
radiochemicals, breast and melanoma tumor cells, 124P(ab)
selective SPECT imaging, primates, 144P(ab)
Signal amplification, antibody-dependent approach, radiotargeting of tumor xenografts, 212P(ab)
Signaling, receptor mechanism for, growth hormone-receptor complex structure and, 145
Signal-to-noise, improvement, PET activation studies, with $^{18}$O water or $^{18}$O butanol, 307
Single chain Fv, protein-A IgG binding domain cloned with, development of novel immunoassay, 209P(ab)
Single-photon emission computed tomography (SPECT)

abdominal blood-pool, portal hypertension, 218P(ab)
acetazolamide loading, brain perfusion reserve, 243P(ab)
activation study, cerebral blood flow, post-traumatic stress, 85P(ab)
amphetamine challenge, dopamine release after, 10P(ab)
AsF sampling, attenuation maps obtained, analysis of noise characteristics, 169P(ab)
SPECT transmission scans, ratios for sequential application, 169P(ab)
attenuation correction

myocardial, comparison, 50P(ab), 51P(ab)
nonuniform, projection domain method, 50P(ab)
normal database variability, 45P(ab)
active audio CBF, clicking sounds in, 245P(ab)
benzodiazepine receptor measurement, 123P(ab)
imipramine, human brain, reproducibility, 167
benzodiazepine receptors
dementia of Alzheimer type, 236P(ab)
schizophrenia, 248P(ab)
bone
evaluation of low back pain, 236P(ab)
lumbar spine, dual-head circular orbit acquisition, 236P(ab)
successful face joint injection, 26P(ab)
three-dimensional display, 236P(ab)
bone imaging, low back pain, clinical efficacy, 1707
brain
acetazolamide rest, cerebrovascular disease, 62P(ab)
acetazolamide stress, vasomotor reserve, 62P(ab)
attention deficit hyperactivity disorder, children, 246P(ab)
carotid occlusion, 53P(ab)
cognitive activation, 63P(ab)
dementia, meta-analysis of, 107P(ab)
functional MRI and, Alzheimer’s disease, 107P(ab)
interictal, frontal epilepsy, 73P(ab)
neuroacanthocytosis, 244P(ab)
quantitation, abnormality integral, 170P(ab)
seasonal affective disorder, blood flow changes, 43P(ab)
study of blood flow, reproducible kinetic phantom, 173P(ab)
$^{99m}$Tc HMPAO dementia comparison, 108P(ab)
schizophrenia, 43P(ab)
$^{99m}$Tc HMPAO and $^{99m}$Tc ECD comparison, Alzheimer’s, 108P(ab)
visual cortex evaluation, amylobya, 1170
Bremstrahlung, body contour determination and validation, 171P(ab)
cardiac

attenuation correction without transmission measurement, 506
$^{111}$In BMIPP, myocardial viability evaluation, 1022
$^{99m}$Tc teboroxime, liver-heart artifact, 133
three-dimensional displays, left ventricular epicardial surface, 697
central nervous system, neuroradiologic applications of, 272P(ab)
cerebral blood flow
acute intracerebral hemorrhage, 52P(ab)
after electroconvulsive therapy, 248P(ab)
Subject Index • 1995

Single-photon emission computed tomography (SPECT)

- diagnosis of dementia, 108P(ab)
- ipspironone challenge in depression, 247P(ab)
- cerebral hemodynamic change, after PTA, 62P(ab)
- cerebrovascular, schizophrenic and depression, 248P(ab)
- cerebral perfusion imaging, tracers, 359
- combined rest 201Tl/stress 99mTc tetrofosmin, feasibility and diagnostic accuracy of 90-minute protocol, 932
- CT and, image registration using external fiducial band and three-dimensional surface fitting, metastatic thyroid cancer, 100
- diamox, Doppler and, blood flow measurements, 243P(ab)
- diamond HMPAO, transient ischemic attack, 63P(ab)
- DISA 99mTc MIBI, with parallel-hole and fanbeam collimators, 167P(ab)
- dobutamine, combined function-perfusion imaging, 77P(ab)
- Doppler ultrasound and, cerebral blood flow and perfusion reserve capacity, hemodynamic carotid transient ischemic attacks, innominate artery stenosis, 1268
- drug therapy and cerebral perfusion, obsessive-compulsive disorder, 2234
- dual-head coincidence imaging, preliminary investigation, 175P(ab)
- nonuniform sources, transmission imaging, 170P(ab)
- dual-isotope late redistribution imaging in, 13P(ab)
- vector Wiener filter, 173P(ab)
- dynamic
- slow injection of 99mTc ECD, regional cerebral blood flow measurement, 170P(ab)
- 99mTc ECD, discordant brain distribution, 244P(ab)
- energy-weighted acquisition, Compton scatter reduction, receiver operating characteristics analysis, 2352
- fanbeam, three-dimensional motion correction in, 18P(ab)
- fanbeam cardiac, reconstruction using exact body contour, effect on defect detection, 168P(ab)
- fast sequential scanning system, effect of registration error between transmission and emission scans, 174P(ab)
- FASTSPECT, stationary brain SPECT system, 268P(ab)
- FDG
dual-isotope, myocardial ischemia, 35P(ab)
- PET comparison, viable myocardial segments, 3P(ab)
- FDG/TI
prediction of improvement of left ventricular function, 35P(ab)
prediction of reversibility of regional wall motion, 36P(ab)
spontaneous improvement after myocardial infarction, 36P(ab)
11C distribution with, 18P(ab)
18F FDG cardiac and oncologic practice, 273P(ab)
correlation with 18F FDG PET, 988 versus 18F PET, detection of malignancies, 194P(ab)
image reconstruction, use of geometric point response correction, 167P(ab)
511-keV annihilation photons, 1472
- PET versus, 267P(ab)
- 18F FDG and 99mTc MIBI, simultaneous dual-isotope acquisition, rest myocardial perfusion/metabolism imaging, 2110
- 18F PET and, comparison of interpretation, 140P(ab)
- 67Ga citrate, detection of primary breast lymphoma, 236
gated, left ventricular wall thickening from, 8P(ab)
gated blood-pool three-dimensional analysis of, 12P(ab)
volume determinations, 262P(ab)
gated myocardial perfusion studies, validation, beating-heart phantom, 177P(ab)
heart artifacts caused by the liver, 29P(ab)
Asx transmission scan for attenuation correction of, 40P(ab)
attenuation artifacts from wrap-around lung, 111P(ab)
attribution compensation in, 50P(ab)
combined scatter and attenuation compensation in, 60P(ab)
correction of patient motion, selective linogram use, 168P(ab)
liver activity and quantitative analysis, 46P(ab)
motion correction algorithms for, 59P(ab)
single and dual 90SD detector, motion artifact differences, 168P(ab)
high-resolution, hippocampal perfusion assessment, neuropsychiatric disorders, 1163
- 123I beta-CIT
simultaneous multidose preparation, dopamine transporter marker, 525
striatal dopamine transporter binding, age-related decline, 1175
- 123I BMIPP
after elective coronary angioplasty, stunned myocardium detection, 134P(ab)
vasopastic angina, diagnosis and follow-up, comparison with 201Tl and 99mTc MIBI, 1934
tectal perfusion, comparison with FDG PET, epilepsy, 84P(ab)
- 123I gb-CIT
disease severity in Parkinson's, 59P(ab)
dopaminergic degeneration, Parkinson's, 99P(ab)
- 123I gb-CIT-FE, dopamine transporters, 118P(ab)
- 123I IBF, extrapyramidal disease evaluation, dopamine D2 receptors, 1196
- 123I IBZM, striatal dopamine release, after amphetamine challenge, 1182
- 123I IBZM uptake, basal ganglia lateralized differences, asymmetric Parkinson's disease, 1216
- 123I IDEX, for cholinergic muscularic neuroreceptors, dosimetry and biodistribution, 1332
- 123I IMP
benzodiazepine receptors in Parkinson's, 241P(ab)
cerebral blood flow measurement, 257P(ab)
calibrated standard input function and venous blood sampling, 2339
cerebral blood flow sequential measurement, double-injection method, 1339
crossed cerebellar diaschisis, analysis, 399
human primary motor cortex, super-early imaging, 2180
rapid calculation of regional cerebral blood flow and distribution volume, 531
- 123I IMZ
brain benzodiazepine receptors, 239P(ab)
quantitative analysis, use of arterial sampling and octanol extraction, 167P(ab)
- 123I iodobenzamide and, dopamine D2 receptor regional analysis, in Parkinson's disease, 384
- 123I iomazenil benzodiazepine receptor binding and ligand transport, simple quantification, 1201
cerebral infarction evaluation, 2154
psychotic symptoms in schizophrenia and, 20P(ab)
- 123I ionic, potential imaging agent for opiate receptors, 166P(ab)
- 123I IPPA, left ventricular function improvement prediction, after coronary revascularization, 1987
- 123I IPT
aging effects on dopamine reuptake transporter, 32P(ab)
dopamine transporter binding patterns, brain, 125P(ab)
metabolite analysis of, 124P(ab)
striatal dopamine transporter, nonhuman primates, 2290
- 123I 5-I-R91150, new tracer for serotonin 5HT2A receptors, 164P(ab)
image reconstruction of PET images, accelerated conjugate gradient preconditioners, 184P(ab)
- 123I MIBG
normal myocardial adrenergic neuronal function evaluation, age and gender differences, 969
reduced uptake regions, atrophic nerve fibers in, doroobasic caridiomyopathy, 2060
- 123I MIBG/201Tl, 123I BMIPP, perioperative coronary vasospsms detection, 2050
- 123I 2-ISP, dopamine D2 receptors, 1191
- 123I sigma receptor ligands, high cortical uptake, 124P(ab)
- 111In pentetetide and 201Tl, MRI and, comparison, intra-axial brain tumors, 537
511 keV, feasibility, scattered background, 174P(ab)
kidney, function with UP1 obstruction, 233P(ab)
large females, iterative Chang algorithm use in, 40P(ab)
- liver
colorectal cancer metastases, 107P(ab)
99mTc DTPA-galactosyl human serum albumin, 75P(ab)
McSPECT II, clinical brain imaging system, performances, 166P(ab)
MRI combined with, Alzheimer's disease, 237P(ab)
multilhead system, attenuation-correction for, 11P(ab)
muscarinic receptors, ligand 123I-4-IQB-N in blood, 255P(ab)
myocardial
breast attenuation and defect size measurement in, 40P(ab)
circular versus noncircular orbit, 263P(ab)
different body characteristics and, 41P(ab)
emission-based attenuation correction technique for, 18P(ab)
- 123I IFPA, shorter imaging protocol feasibility, 138P(ab)
noncircular versus circular orbits of, 46P(ab)
operatorless processing, 2127
scatter and attenuation compensation, four energy window acquisition, 136P(ab)
simultaneous transmission-emission, 12P(ab)
Single-photon emission computed tomography (SPECT)

myocardial infarction size measurement, effects of scatter correction, cardiac phantom studies, 2080
myocardial perfusion after coronary bypass surgery, 13P(ab)
new evaluation program, software validation and quality assurance, 169P(ab)
normal distributions, correlative evaluation method, 122P(ab)
360SD and short scan reconstruction algorithms, phantom evaluation, 174P(ab)
technical maturation, art becoming science, 905

201Tl/adenosine 99mTc sestamibi, diagnostic accuracy in women, coronary artery disease, 135P(ab)
new radionuclide synthesis of 123I QNB, brain, 6P(ab)
opioid receptor mapping, new radiolabeled 7g.0-O-iodoallyl diprenorphine for, 163P(ab)
pentavalent 99mTc DMSA, primary lung cancer, 202
perfusion, left ventricular volumes and mass, 12P(ab)
versus PET; brain, distinguishing radiation necrosis from tumor recurrence, 159
PET and myocardial, artificial inhomogeneities in normal subjects, 188
sinograms, calculation of three-dimensional spatial coordinates, 179P(ab)

PET or FIDA-2 and, dopamine D2/D3 receptor antagonist, 1322
with 123I or 11C, R)-FIDA2 imaging agent, in vitro and in vivo binding properties, 1282
physically acquired data, anatomical information and, 208P(ab)
pinhole, ultra-high-resolution, small animal studies, 2287(ed)
planar and high-resolution bone imaging, diagnosis of facet syndrome, 37
planar versus reprojected, gated blood-pool ejection fraction, 60P(ab)
postictal 99mTc HMPAO, transient lobe seizure, 73P(ab)
prostate cancer, 111In monoclonal antibody CYT-356 use in, 9P(ab)
quantification, software package for, 270P(ab)
quantitative
dual fanbeam gamma-ray transmission data acquisition, proposal, 172P(ab)
gated wall thickening, 55P(ab)
myocardial 201Tl, impact of reorientation algorithms, 173P(ab)
quantitative imaging, review and recommendations, Focus Committee of the SNM Computer and Instrumentation Council, 1489
reconstruction artifactual decreased myocardial wall uptake, 30P(ab)
hybrid-grid parameterization method, 173P(ab)
versus renal planar imaging, after acute pyelonephritis, infants, 33P(ab)
sцинтillation cameras, recursive two-dimensional maximum likelihood estimator, implementation, 172P(ab)
semiconductor arrays for, spatial resolution, 17P(ab)
semiconductor detector arrays, charge transport modeling in, 124P(ab)
separate-day, 99mTc sestamibi, fast stress and rest acquisitions, 569
sequential, acetazolamide enhancement, brain, 242P(ab)
serial scanning, cortical blindness after symptomatic hypertension correction, dynamic cerebral dysfunction, 1272
sigma subtype receptors, primates, 144P(ab)
signal-to-noise ratio in, improvement, 29P(ab)
simultaneous dual-isotope imaging, with projection-dependent spillover correction factor, 160P(ab)
simultaneous 201Tl/99mTc MIBI convolution cross-talk correction technique, dogs, 179P(ab)
TEW scatter compensation for spectral crossover, experimental evaluation, 168P(ab)
SPRINT and ASP, parallel plate and fanbeam collimators, design and construction techniques, 167P(ab)
table attenuation, prone and supine cardiac imaging, 1102

99mTc quantification distribution evaluation, canine myocardium, 278
scatter correction techniques, comparative assessment by spectral analysis using Monte Carlo simulations, 1476
99mTc BW431/26, anti-CEA MAb tumor uptake, colorectal carcinoma, 679

99mTc DMSA detection of patient motion during, 33P(ab)
renal cortical defects, 32P(ab)
99mTc ECD
cerebral blood flow, microsphere model, 254P(ab)
cerebral blood flow during sleep, 245P(ab)
childhood epilepsy, 84P(ab)
measurements of cerebral blood flow, 247P(ab)
99mTc ECD brain, early and delayed, in stroke, 712P(ab)
reply, 713P(ab)
99mTc HMPAO and 201Tl chloride, skull-base invasion, head and neck tumors, 1740

99mTc HMPAO
activation studies, epilepsy in children, 84P(ab)
autistic disorder functional deficits by, 1156
brain anatomical image standardization, aged and young normal patients, 171P(ab)
practical cortical quantitative normalization method, 171P(ab)
cerebral blood flow, REM sleep in narcoleptics, 1150
cerebral blood flow study, children with craniosynostosis, 394
cerebral lesions in alcohol abusers, 249P(ab)
chronic cocaine polydrug users treated with buprenorphine, improved regional cerebral blood flow, 1211
Creutzfeld-Jacob disease diagnosis, 616
evaluation of regional cerebral blood flow, massive intracerebral calcifications, 610
ictal and 6-hour postictal comparison, epilepsy, 73P(ab)
ictal and interictal, difference images from, epilepsy, 684
language processing, 251P(ab)
motor efferent pathway activation, 245P(ab)
obsessive-compulsive disorder, 248P(ab)
opiate-dependent subjects, 248P(ab)
rest and dexam stress, stroke penubra, 63P(ab)
reversible hyperperfusion of cerebral cortex, in hydrocephalus, after shunt operation, 470
three-dimensional surface cortical perfusion display, Alzheimer's disease assessment, 690
uptake increase, brain SPECT, grade II astrocytoma, 804
video EEG and, epilepsy, 73P(ab)
99mTc MDP, spine, 122P(ab)
99mTc MIBI
myocardial dynamic exercise and dipiridamole stress, reverse redistribution, 2053
role in mediastinal lymph node metastases detection and monitoring of pulmonary mediastinal lesions, 159P(ab)
99mTc nitroimidazole ligand, ischemic myocardium, 1445
99mTc sestamibi
comparison of STEP with parallel hole SPECT, PET validation, 169P(ab)
double-phase, ectopic parathyroid adenoma localization, 1840
fast acquisition, 1723P(ab)
fixed myocardial defects, infarct or artifact characterization, 952
gated myocardial perfusion, automatic ejection fraction quantification, 2138
myocardial, three-dimensional mapping of specific coronary arteries, 2120
myocardial stress and rest, automated alignment and sizing to three-dimensional templates, image registration algorithm, 1115
parathyroid adenomas, 228P(ab)
tetrofosmin and, chest pain patients, 88P(ab)
99mTc sestamibi myocardial, infarct sizing, multencel trial feasibility, cardiac phantom evaluation, 1130
99mTc sulfur colloid, suspected heterotaxy syndrome, infants, 1368
99mTc tetrofosmin and 201Tl, myocardial viability assessment, coronary artery disease, 1961
99mTc tetrofosmin versus 99mTc sestamibi, with dipiridamole, myocardial stress imaging, 2009
thalium, MRI comparison, brain tumor from radiation necrosis, 95P(ab)
thalium/insulin/potassium/glucone infusion, hibernated myocardium detection, 1377
three-dimensional bone, failed back evaluation, 122P(ab)
iterative reconstruction for, 29P(ab)
options and potential, 273P(ab)
three-dimensional activity map, dosimetry for radioimmunotherapy, 1885
three-dimensional transaxial myocardial perfusion, automatic reorientation, 1107
three-vessel CAD, individual arterial stenoses with, 111P(ab)
201Tl
cardiac polar maps, 12P(ab)
coronary artery disease in women, 78P(ab)
18F FDG PET and, value in detection of pancreatic cancer, 229
myocardial perfusion imaging, patient motion prevention during, 2001
preoperative supratentorial glioma, 96P(ab)
role in differential diagnosis, intracerebral space occupying lesions, HIV+e patients, 192P(ab)
sequential use, viable myocardium identification, superiority over single tests, 143P(ab)
simultaneous transmission-emission, attenuation correction effect on myocardial tracer distribution, 921 single-vessel coronary artery disease and, implications of normal anatomy variability, 944 201Tl and 123I MIHA, defect reversibility analysis, myocardial infarction, 1561 201Tl 99mTc, estimate of contamination, 60P(ab) 201Tl SPECT, myocardial bridging, 1031 transmission imaging, temporal resolution effects, 50P(ab) triple-headed, 123I IPT, activity measurements of in vivo monkey brain, 178P(ab) truncation in, conjugate views for correction, 40P(ab) ultrafast, ventricular assist device, 17P(ab) ultra-high resolution, pinhole collimators, small animal studies, 2282 x-ray CT imaging combined, animal studies, 18P(ab) Skeletal imaging, granulocyte-colony-stimulating factor, 235P(ab) Skeletal muscle, viability assessment, 19F PET, 140G(ab) Skeletal tumor, metastatic, from 186ReSn(5) HEDP, Monte Carlo model for radiation dose, 336 Skull-base invasion, head and neck tumors, 99mTc HMDF and 201Tl chloride SPECT, 1740 Smoking, effects on bronchial clearance, 99mTc DTPA and 111In DTPA scintigraphy, 1569 Sn-117m(4) DTPA, pharmacokinetics of, multiple metastatic bone pain, 30P(ab), 31P(ab) Society of Nuclear Medicine Focus Committee, Computer and Instrumentation Council, Quantitative SPECT imaging, review and recommendations, 1489 government relations committee, strong voice to influence changes, 28N (11) NRC, breaking away from, 34N(9) Soft tissue buttocks trauma, clarification, 709(e) reply, 709(e) tumors, protein synthesis rate in, measured with 11C TYR, 217P(ab) Software, see Computers Somatostatin analogs 111In-labeled, radiolabeled of somatostatin-receptor-positive tumors, 214P(ab) imaging of prostate cancer, 92P(ab) radiolabeled, scintigraphy, in differentiated thyroid carcinoma, 807 Somatostatin receptors demonstration using 111In DTPA-D-Phe1-octreotide scintigraphy, lymphoma and lymphadenopathy, 13 density glomus tumors, successful pentetreotide therapy and, 42P(ab) pituitary macroadenomas, 205P(ab) 123I and 111In-octreotides in, imaging of small-cell lung cancer, 72P(ab) imaging, 99mTc P829 use in, 91P(ab) imaging in malignant lymphomas, 19(ed) 111In DTPA-D-Phe1-octreotide intravenous injection, activity concentration in tumor effects, 50P(ab) 111In DTPA-D-Phe1-octreotide scintigraphy, central nervous system tumors, blood-brain barrier permeability role, 403 111In pentetreotide imaging, in gastroenteropancreatic neuroendocrine tumors, safety/efficacy/impact on management, 542 111In pentetreotide scintigraphy, effect of dose and specific activity on tissue distribution, rats, 623 perioperative radiodetection of endocrine tumors, hand-held gamma probe, 202P(ab) radiotherapy mediated by, cancer, 114P(ab) scintigraphy bone scintigraphy comparison, 127P(ab) differentiated thyroid cancer tumor sites, 14P(ab) endocrine and exocrine pancreatic tumors, 126P(ab) Hodgkin- and non-Hodgkin lymphoma, 199P(ab) 99mTc-labeled, imaging of tumors expressing specific receptors, 126P(ab) tissues positive for, 111In DTPA-octreotide uptake, 113P(ab) SPECT, see Single-photon emission computed tomography Spectral analysis, Monte Carlo simulations, scatter correction techniques, comparative assessment, 99mTc SPECT, 1476 Spectroscopy, magnetic resonance, graft viability and neural degeneration, 87P(ab) Spinal deformity, prediction, index of bone mineral density, 235P(ab) Spleen, liver and, and scintigrams, interpretation improvement by fuzzy logic, 1415 99mTc sulfur colloid SPECT, infantile heterotaxy syndrome, 1368 Spondyloolithiasis, diagnosis, radiolabeled IgG, 708(e) Squamous-cell carcinoma, head and neck cell proliferation kinetics and initiated FDG and methionine uptake, in vitro comparison, 252 detection of lymph node metastases, 19F FDG PET and MRI, 211 staging, 19F FDG PET/MRI/endoscopy comparison, 1747 Standard uptake values 19F FDG, total body weight and, 201(ab) quantitation, PET, standard or silly, 1836 Stannous chloride, treatment evaluation, biological effect on a plasmid DNA, 148P(ab) Steal phenomenon, 15O water PET, acetazolamide effects, 241P(ab) Stereotaxy foci intensity, location of activation areas, comparison with PET, 93P(ab) SPECT and PET sinograms, calculation of three-dimensional spatial coordinates, 179P(ab) Steroid receptors, radiotracer design, breast and prostate tumor imaging, 85 Steroids, rheumatin complexes that mimic, 68P(ab) Streptavidin biotin binding, pretargeting protocols based on, direct antibody targeting, pharmacokinetic comparison, 867 111In in avidin and, human breast tumor xenograft, localization, 188P(ab) 111In in biotin and, bacterial endocarditis detection, rats, 137P(ab) radiolabeled, improved targeting, pretargeted tumors, biotinylated MABs through avidin chase, 837 Stress, fast and rest acquisitions, 99mTc sestamibi separate-day SPECT, 569 Stress test, noninvasive, cardiology, information boodoodle assessment, 1009(ed) Stress testing, pharmacologic, modified approaches, effects on hyperemic myocardial blood flow, 575 Stroke ischemic acute stage, increased 99mTc HMPAO uptake, predictive value for brain survival/necrosis, 2392(le) 55Co PET in, 239P(ab) penumbra characterization, 99mTc HMPAO rest and diamsx stress SPECT in, 63P(ab) prediction of outcome, 99mTc HMPAO hyperfixation in, 238P(ab) Strontium-89, bone metastasis study in multidisciplinary pain clinic, 30P(ab) toxic effects, 30P(ab) Strontium-89 chloride, wipe tests, sodium iodide well counter for, 126P(ab) Strontium-90, applicator, human lens dose rates, Monte Carlo computer model, 182P(ab) Subcellular distribution, 99mTc N-NOEt, myocardium, rat, 2075 Substance abuse, cocaine, radiopharmaceuticals and emission computed tomography, neurochemistry of addiction, 1298(ed) Surface charge, relationship between benzodiazepine ligand and receptor, investigation, 155P(ab) Surgery biliary-enteric bypass, 99mTc scintigraphy study after, positional biliary stasis, 104 breast cancer, 19F FDG-guided, positron-sensitive probe, 1869 Sympathetic innervation, anterior and inferior walls of left ventricle, difference in 123I MIHG uptake, 134P(ab) Sympathetic nervous system atrioventricular node, adrenergic activity, MIHG as index, 1096 maturation of innervation time, developing heart, 89P(ab) Synovectomy, 135mI PHVP radiation, for chronic knee synovitis, biodistribution data, 51 Synovium, parathyroid hormone-related peptides in, osteoarthritis and rheumatoid arthritis patients, 209P(ab) Systemic sclerosis, esophageal scintigraphy of, 1533 T TAC extraction, blood, factor analysis, dynamic PET studies, small cardiac chambers relative to resolution, 185P(ab) Tamoxifen estrogen receptor-rich tissues after treatment, FDG and FES uptake in, 39P(ab) high-dose, brain tumor, serial PET scans in, 225P(ab) Teaching, Internet file, nuclear medicine, 1520 Technegas, transition to pertechnegas, 267 Technetium, xenon and, binding to serotonin receptor, 27P(ab) Technetium-99m, 99mTc and, gamma imaging, design study, 180P(ab) Technetium-99m antibody photolabeling, preclinical testing, 160(ab) antigranulocyte Fab fragment, binding characteristics of, 208(ab) binding to serotonin receptors, 28P(ab) charge measurement of complexes, gel electrophoresis, 147P(ab)
chelates of novel amines and carboxylates, 146P(ab)
complexing, 
sTcO reducing and, use of new neutral water soluble phosphine ligand, 146P(ab)
detector at nanoscale level, potential tool for preclinical pharmacology applications, 154P(ab)
development of novel brain agents, mixed ligand approach, biology and radiochemistry, 145P(ab)
different labeling methods, anti-Tac disulfide stabilized Fv fragments, tumor detection, comparative studies, 160P(ab)
DNA oligonucleotide labeling, 2306
DTPA and HMPAO radioaerosol inhalation lung scintigraphy, alveolar integrity in pulmonary emphysma, 68
19F and, labeled dextran transport, in situ rabbit lung, 1436
hepatobiliary scintigraphy, positional biliary stasis, findings after biliary-enteric bypass surgery, 104
HMPAO SPECT
autistic disorder functional deficits by, 1156
cerebral blood flow, REM sleep in narcoleptics, 1151
labeled anti-CEA MAb's, complete versus fragmented, immunoscintigraphy in colorectal cancer, 430
labeled antigranulocyte antibody, bone marrow scintigraphy, 1800
labeled biotin-bearing liposome, avidin and, rapid tumor imaging using, 146P(ab)
labeled chimeric ZD3 antibody Fab, experimental atherosclerotic lesion localization, 138P(ab)
labeled hydrazinonicotinamide conjugated chemotactic peptides, formulation studies to control radiolabeled speciation, 148P(ab)
labeled IgM, binding to human neutrophils, 156P(ab)
labeled nitroheterocycle, hypoxic infarct border zone ex vivo delineation by, canine infarct model, 137P(ab)
labeled synthetic peptide, breast cancer imaging, 195P(ab)
labeled synthetic peptide P280, deep venous thrombosis detection, 1384
labeling
site-specific dihydralazine conjugation to antibody for, 147P(ab)
three anticancer MAb's, stability/pharmacokinetics/aging, 842
labeling of single-chain antibodies, bioengineered peptide chelator, 28P(ab)
MAb direct labeling, photoactivation, 1913
measurement of red cell mass, 23P(ab)
new Q-series complexes with ester functionality, synthesis and biodistribution, 146P(ab)
red blood cells, penile hemodynamics, measurement with nonimaging stcilliation probe, 2345
scintigraphy, salivary gland disorders, 220P(ab)
solid-phase technology, 27P(ab)
SPECT quantification distribution evaluation, canine blood pool, 278
scatter correction techniques, comparative assessment by spectral analysis using Monte Carlo simulations, 1476
Tc and, gamma imaging, design study, 180P(ab)
transchelation agents, nonspecific labeling, quantitative study, 159P(ab)
Tc aerosol, central and peripheral distribution, normal and deep breathing, 34P(ab)
Tc albumin comparison with 6Ga citrate, lung scanning, HIV-positive patients, 208P(ab)
lymphatic mapping with, early stage melanoma, 223P(ab)
Tc anti-CDA, Fab fragments, adjuvant arthritis, rats, 2268
Tc antisense, preparation, distribution and, 113P(ab)
Tc 88BV59, preoperative scintigraphy and operative probe scintimetry, colorectal carcinoma, 738
Tc DACH, renal allograft function, 233P(ab)
Tc dithydoxamamide, new tetratendate ligand, preparation and characterization, 146P(ab)
Tc DISIDA, hepatobiliary scintigraphy, hepatic lobar infarction, in cholangiocarcinoma, 474
Tc DMP HSA kit-prepared, in vitro labeled Tc RBC substitute, radionuclide ventriculography, 158P(ab)
preparation, one-step labeling kit, substitute for Tc RBC in radionuclide ventriculography, 156P(ab)
Tc DMS enhancement of tumor accumulation, glucose-mediated acidification effect on, 145P(ab)
tumor accumulation, glucose-mediated acidification effect, 28P(ab)
Tc DMSA accumulation in experimental abscesses, 147P(ab)
pentavalent, SPECT, primary lung cancer, 202
renal scintigraphy, vesicoureteral reflux in children, long-term effects, 259P(ab)
SPECT detection of patient motion during, 33P(ab)
renal cortical defects, 32P(ab)
Tc pertechnetate and, tubular reabsorption, kidney, 1654
Tc DNA pharmacokinetics, properties of phosphodiester and phosphorothioate, 103P(ab)
probe, thrombin binding and imaging, cardiopulmonary bypass, 16P(ab)
Tc DTPA clearance, radiodiode dosage effects index, pulmonary alveolar-capillary membrane integrity, pulmonary metastases in thyroid cancer, 783
dynamic renal images with, estimation of glomerular filtration index, 231P(ab)
Gastrointestinal permeability study, 219P(ab)
111In in DTPA and, scintigraphy, effects of smoking on bronchial clearance, 1569
lung clearance, effect of inhaled fuosamide, 73
MPEG-PL, preclinical testing, polymer based blood pool imaging, 164P(ab)
onthermal skeletal muscle injury, electric shock, 235P(ab)
plasma volume product assessment, for glomerular filtration rate calculation, 1602
prostaglandin and cytokine release stimulated by, polymorphonuclear leukocytes, 250P(ab)
Tc MAA and, PIOPED scintigraphic criteria, lung scan, 1573
Tc DTPA-galactosyl, human serum albumin, regional hepatic function, 75P(ab)
Tc EC renal disorders, evaluation, extraction ratio determination, 1398
Tc MAG3, 111 In OIH and, clinical comparison, in renal disorders, 224
Tc ECD brain SPECT, early and delayed, in stroke, 712(le)
reply, 713(le)
cost-effective preparation, freezing excess ligand, 88P(ab)
dynamic SPECT, compared with 15O water PET, cerebral blood flow measurements, 254P(ab)
nature of cellular retention, 254P(ab)
preclinical evaluation, cerebral perfusion reserve, 242P(ab)
cCBF brain SPECT, temporal and frontal lobe epilepsy, 72P(ab)
renal scanning agent, 232P(ab)
reperfusion hyperemia, 240P(ab)
slow injection, regional cerebral blood flow, dynamic SPECT, 170P(ab)
SPECT cerebral blood flow, microsphere model, 254P(ab)
Tc HMPAO and, discordant brain distribution, 244P(ab)
Tc HMPAO and, flow distribution mismatch, brain SPECT, CBF PET study versus, 243P(ab)
in vivo stability, in human brain, SPECT evaluation, 166P(ab)
Tc enema, ileo-rectal anastomosis assessed by, rectal motility after, 220P(ab)
Tc galactosyl-neoglycoalbumin, 123I
Tyr(A14)-insulin and, hepatocellular carcinoma visualization, 1875
Tc GLA, biodistribution pharmacokinetics and radiation dosimetry, humans, 183P(ab)
Tc glucarate recognition, myocardial necrosis, 47P(ab)
subcellular distribution, acute myocardial infarction, 47P(ab)
Tc GSA, evaluation of liver function, hepatocellular carcinoma, 219P(ab)
Tc HDP abdominal uptake, after colectomy, Gardner's syndrome, 1611
uptake, nonskeletal abnormalities and artifacts, 273P(ab)
Tc HIDA, hepatobiliary scintigraphy, hepatic arterial embolization in hepatocellular carcinoma, 1590
Tc HMDP bone scintigraphy, growth hormone-secreting pulmonary cancer and hypertrophic osteoarthropathy, 822
Tl chloride and, SPECT, skull-base invasion, head and neck tumors, 1740
Tc HMPAO absolute cortical uptake, body weight, blood pressure, and age effects, 255P(ab)
brain, survival imaging, 244P(ab)
brain SPECT
Alzheimer's and microangiopathy dementia, comparison, 108P(ab)
impaired cognitive function, 108P(ab)
physiological and cognitive activation measured by, 63P(ab)
cerebral blood flow, diabetes patients, 240P(ab)
cerebral blood flow and static imaging, determination of
brain death, 267P(ab)
cerebral vasculitis, 240P(ab)
hypercification, predictor of stroke outcome,
measured by, 238P(ab)
imaging of glutathione localization in brain, 147P(ab)
increased uptake, acute stage ischemic stroke, predictive value for brain
survival/necrosis, 2392(le)
intracranial plasmacytoma uptake, during
carotid balloon test occlusion, 800
lung clearance, staging of pulmonary
hypertension, congenital heart disease,
22P(ab)
nature of cellular retention, 254P(ab)
radiochemical purity quality control, dependence
on specific activity, 706(e)
rest and stress SPECT, stroke
penumbra, 63P(ab)
retention, adriamycin-sensitive and -resistant
MCF-7 cells, 197P(ab)
SPECT
Alzheimer's disease assessment, three-
dimensional surface cortical perfusion
display, 690
brain
children with attention deficit hyperactivity
disorder, 246P(ab)
neuroacanthocytosis, 244P(ab)
neuroophthalmology in schizophrenia, 43P(ab)
perfusion, laminar heterotopia, 238
cerebral blood flow changes during
electroconvulsive therapy, 244P(ab)
cerebral blood flow study, children with
cranioyostosis, 394
chronic cocaine polydrug users treated with
buprenorphine, improved regional
cerebral blood flow, 1211
Cerebral vasculopathy diagnosis, 616
evaluation of regional cerebral blood flow, massive
intracerebral calcifications, 610
fibromyalgia syndrome, 247P(ab)
hypermnla and hyperfixation in subacute
ischemic stroke, 54P(ab)
ictal and interictal, difference images from,
epilepsy, 684
measurement of cerebral blood flow, obsessive-compulsive disorder, 20P(ab)
motor effenter pathway activation, 245P(ab)
reversive hyperperfusion of cerebral cortex, in
hydrocephalus, after shunt operation, 470
99mTc ECD and, flow distribution mismatch,
brain SPECT, CBF PET study versus, 243P(ab)
201TI chloride and, brain tumor imaging,
274P(ab)
uptake increase, brain SPECT, grade II
astrocytoma, 804
Technetium-99m HSA, intestinal loss of protein,
scrub typhus patients, 226P(ab)
Technetium-99m hynic HSA, 99mTc MAG, HSA
and, as possible blood-pool agents,
comparative evaluation, 146P(ab)
Technetium-99m IgG, hydrazino nicotinamide,
infection imaging with, 233P(ab)
Technetium-99m interleukin-2, targeting activated
lymphocytes with, 228P(ab)

Technetium-99m isotopes, synthesis and
characterization, multidrug resistance,
27P(ab)
Technetium-99m leukocyte, osteomyelitis, 24P(ab)
Technetium-99m MAA
scintigraphy, after endovascular stenting of
pulmonary artery stenosis, 2006
99mTc DTPA and, PIOPED scintigraphic
criteria, lung scan, 1573
Technetium-99m MAG3
clearance
children, 258P(ab)
measurement improvement, camera-based
method, 1689
51Cr EDTA and, simultaneous glomerular
filtration and tubular excretion rate, renal
plasma flow, 1701
diuretic renogram, neonatal period, utility, 2214
urinary tract obstruction, children, 33P(ab)
131I OH and, single-injection renal clearance
methods, with and without urine collection,
603 renal
clearance
normal values, 706(e)
whole-body geometry and gamma camera
ROI-technique, 45P(ab)
renal scintigraphy with
acute renal failure patients, 232P(ab)
renal artery stenosis, 234P(ab)
renal transplant patients, 233P(ab)
99mTc EC-131 OH and, clinical comparison,
 renal disorders, 224
99mTc hynic HSA and, as possible blood-pool
agents, comparative evaluation, 146P(ab)
Technetium-99m MDP
bone scan and radiography findings, osseous and
central nervous system sarcoidosis, 464
bone scintigraphy, localized clear-cell epithelial
tumor, diffuse renal retention, 817
scintimammography, primary breast cancer, 718
SPECT, spine, 122P(ab)
versus 201TI uptake, in cosmophilic granuloma
of the frontal bone, 107
uptake, axillary lymph nodes, 1797
Technetium-99m methylene diphosphonate,
sцинтigraphy, enhanced bone metabolism
induction by acupuncture, 2246
Technetium-99m MHI-Fab, pulmonary embolism,
dep deep venous thrombosis and, 34P(ab)
Technetium-99m MIBI
breast cancer detection, nonpalpable primary
malignancies, 194P(ab)
breast imaging, upright position, masses,
194P(ab)
18F FDG and, SPECT, simultaneous dual-
isotope acquisition, rest myocardial
perfusion/metabolism imaging, 2110
infusion imaging, viable myocardium
identification, 1037
mammocintigraphy, suspicious breast tumors,
51P(ab)
myocardial SPECT, dynamic exercise and
dipyridamole stress, reverse redistribution, 2053
nitré administration, enhanced viable
myocardium detection, chronic coronary
artery disease, 1945
ontocintigraphy, differentiated thyroid cancer,
204P(ab)
rapid washout
large parathyroid adenoma, 241
parathyroid adenoma, 1928(e)
reply, 1928(e)
redistribution, myocardial viability index, chronic
coronary artery disease, 1953
scintigraphy, bone lesion detection, multiple
myeloma, 1903P(ab)
scintimammography, advanced breast cancer,
tumor monitoring, 193P(ab)
SPECT
mediastinal lymph node metastases detection
and pulmonary mediastinal lesions,
195P(ab)
myocardial wall motion analysis, correlation with
echocardiography, 90P(ab)
201TI and comparison with 123I BMIPP SPECT,
diagnosis and follow-up of vasospastic
angiina, 1934
uptake and release in HeLa cells, 201P(ab)
uptake
intracoronary Doppler flow measurements
and, intermediate coronary artery stenosis
assessment, 136P(ab)
recurrent parathyroid carcinoma and brown
tumors, 811
Technetium-99m (MPEG-PL-DTPA), infection imaging with, 11In IgG comparison,
205P(ab)
Technetium-99m nitroimidazole
biologic activity of, 17P(ab)
BMS181321, detection of hypoxia in tumors,
71P(ab)
ligand, SPECT, ischemic myocardium, 1445
myocardial ischemia detection, 1078
renal artery stenosis, acute renal ischemia and,
animal model, 45P(ab)
retention, effect of graded hypoxia on, perfused
rat heart, 632
Technetium-99m NOET
myocardial perfusion imaging, comparison with
201TI and coronary angiography, 936
regional myocardial blood flow tracer, kinetics,
1069
subcellular distribution, myocardium, rat, 2075
Technetium-99m oxodionate, pinhole bone
scintigraphy, Paget's disease of the bone,
1421
Technetium-99m P280
biodistribution and dosimetry, phase I study,
183P(ab)
detection of venous thrombosis, 89P(ab)
Technetium-99m P748
imaging, activated platelets, 16P(ab)
synthetic peptide, imaging of pulmonary
embolism, 34P(ab)
thrombus imaging, canine model, 103P(ab)
Technetium-99m PB29
somatostatin receptor binding, imaging
somatostatin receptors, 91P(ab)
somatostatin receptor binding technetium,
tumor uptake, comparison with 111In DTPA,
pancreatic tumor, rats, 192P(ab)
Technetium-99m peptide
activated platelet imaging, 16P(ab)
thrombus imaging, 16P(ab)
Technetium-99m pertechnetates, ventilation
imaging, washout clearance patterns in
pulmonary embolism, 250P(ab)
Technetium-99m pertechnetate
in argon-oxygen solution, transition from
technegas to pertechnetes, 267
18F FDG/111 sodium iodide and, PET, cervical
lymph node metastasis of thyroid
papillary carcinoma, 1843
99mTc DMSA and, tubular reabsorption, kidney,
1654

Subject Index • 1995
2449
Technetium-99m phytate

\(^{99m} \text{Tc}\) RBCs and, penile scintigraphy, priapism in sickle-cell disease, 1404

\(^{201} \text{TI}\) chloride and \(^{99m} \text{Tc}\) sestamibi, scintigraphic pitfalls, enlarged parathyroid glands, 467

Technetium-99m phytate

liver scintigraphy by fuzzy reasoning, chronic liver disease diagnosis, 593

subtraction liver imaging, \(^{201} \text{TI}\) SPECT and, pancreatic cancer evaluation, 762

Technetium-99m PIP

nonthermal skeletal muscle injury, electric shock, 235P(ab)

skeletal muscle imaging, nonthermal electrical injury, 122P(ab)

Technetium-99m pyrophosphate, scintigraphy, intestinal perforation, dermatomyositis, 1615

Technetium-99m Q12, kinetics, effects of no flow and reperfusion on, 2103

Technetium-99m Q complexes, multidrug resistance and, 130P(ab)

Technetium-99m Q-series, ester functionality, heart imaging, 17P(ab)

Technetium-99m RBC

cavernosal blood volume, blood flow and, flaccid penis, 55P(ab)

scintigraphy, in liver metastasis, 709(le)

reply, 710(le)

\(^{99m} \text{Tc}\) pertechnetate and, penile scintigraphy, priapism in sickle-cell disease, 1404

three-dimensional display, hepatic hemangiomata, 227P(ab)

Technetium-99m RC-160, prostate cancer imaging, 92P(ab)

Technetium-99m RGD, acute renal ischemia, 45P(ab)

Technetium-99m RP128, imaging of colitis model, 114P(ab)

Technetium-99m SC, oral hard gelatin capsules, gastric residence time, 64P(ab)

Technetium-99m sestamibi

attenuation correction of cardiac SPECT, coronary artery disease, 132P(ab)

\(^{11} \text{C}\) deoxyglucose and, autoradiography and radioscinhtigraphy, breast tumors in \(\text{c-neu}\) transgenic mice, 1862

comparison with \(^{18} \text{FDG}\), whole-body scans, differentiated thyroid cancer, 200P(ab)

detection of multidrug resistance, 129P(ab)

evaluation of tumor response, preoperative chemosarcoma, bone and soft tissue sarcomas, 129P(ab)

gated correlates, myocardial viability rest/delayed \(^{201} \text{TI}\) SPECT, 56P(ab)

sublingual nitroglycerin administration and, 56P(ab)

gated perfusion images, wall motion and thickening evaluation, new quantitative method, 139P(ab)

gated SPECT, fixed myocardial defects, infarct or artifact characterization, 952

intracoronary, myocardial risk area determination, 111P(ab)

lung uptake evaluation, correlation with left ventricular function, 58

lymphoma evaluation, comparison with \(^{67} \text{Ga}\) citrate, 117P(ab)

mammoscintigraphy with breast cancer, effect of dense breasts, 52P(ab)

primary breast cancer and axillary lymph node involvement, 52P(ab)

multidrug resistance P-glycoprotein-mediated transport, effects of extracellular ATP, chloride, cell volume and PKC modulation on, 196P(ab)

myocardial perfusion imaging comparison with echocardiography, with arbutamine stress testing, 132P(ab)

defect assessment, three-dimensional template-based region-growing technique, 171P(ab)

myocardial SPECT, infarct sizing, multicenter trial feasibility, cardiac phantom evaluation, 1130

nongeometric mean region of interest method, assessment of pulmonary masses, 261P(ab)

perfusion tomography, with nitrate infusion, viable hibernating myocardium detection, postvascularization recovery prediction, 1994

P-glycoprotein expression and, breast cancer, 129P(ab)

primary hyperparathyroidism, imaging before reoperation, 2186

prone scintimammography, primary breast cancer and axillary lymph node involvement detection, 1758

pulmonary uptake, in early-stress post-images, ROC analysis and comparison to \(^{201} \text{TI}\), 135P(ab)

reconstitution and fractionalization of Cardiolite kit, cost saving, 80P(ab)

scintigraphic assessment, pancreas transplant, 771

scintigraphy

parathyroid, 202P(ab)

single-injection double-phase, Hurlhcell cancer tumor identification, 778

scintimammography, breast cancer, clinical and pathological follow-up, 1784

semi-automated computation, left ventricular ejection fraction, 56P(ab)

semiquantitative, versus dynamic MRI, breast tumors, 51P(ab)

SPECT

brain tumor local relapse detection, 196P(ab)

double-phase, localization of ectopic parathyroid adenoma, 1840

fast acquisition, 1723(le)

myocardial, three-dimensional mapping of specific coronary arteries, 2120

myocardial perfusion imaging, automatic ejection fraction quantification, 2138

myocardial stress and rest, automated alignment and sizing to three-dimensional templates, image registration algorithm, 1115

parathyroid adenomas, 228P(ab), 229P(ab)

prediction of cardiac events, chest pain patients, 88P(ab)

separate-day, fast stress and rest acquisitions, 569

\(^{99m} \text{Tc}\) tetrofosmin and, SPECT, with dipiridamole, myocardial stress imaging, 2009

thallium comparison, acute coronary reperfusion, 101P(ab)

\(^{201} \text{TI}\) and, SPECT, myocardium viability assessment, coronary artery disease, 1961

total-body imaging, differentiated mixed thyroid cancer, 2248

uptake, breast cancer, 83P(ab)

Technetium-99m Tc2Gis antil fibrin, scintigraphy, deep venous thrombosis, computer processing, 2326

Tests

cancer, metastatic, \(^{18} \text{FDG}\) PET therapy control of, 198P(ab)

human, \(^{201} \text{TI}\) kinetics and dosimetry, 607

Tetralogy of Fallot, pulmonary artery stenosis, endovascular stenting, \(^{99m} \text{Tc}\) MAA scintigraphy, 2006

Thallium, viability, late redistribution, exercise dual-isotope SPECT, 14P(ab)

Thallium-201

accumulation, in myositis ossificans and juxta-articular ossification, 2239

BMIPP and, percutaneous transluminal coronary angioplasty, improved myocardial fatty acid utilization, 1605

brain SPECT, role in differential diagnosis, intracerebral space occupying lesions, HIVve patients, 192P(ab)
brain tumors
99mTc-MIBI and CT/MRI comparison, 96P(ab)
prooperative supratentorial glioma, 96P(ab)
brain tumors and, relation between tumor cell activity in astrocytic tumors and proliferating cell nuclear antigen, 2201
childhood brain tumors, value over 18F FDG, 222P(ab)
coronary angiography and, comparison with 99mTc Te NOET myocardial perfusion imaging, 936
dipyridamole, myocardial SPECT, Kawasaki disease, 13P(ab)
exercise myocardial SPECT, reverse redistribution on 24-hour delayed imaging, comparison with myocardial 18F FDG PET and ventricular wall motion, 66*
67Ga and, accumulation in pediatric neuroectodermal tumor, chest wall, 814
123I BMIPP and, comparison, myocardial hyperperfusion, 1645
123I MIBG/124I BMIPP and, myocardial SPECT, perioperative coronary vasospasm detection, 2050
123I MIHA and, SPECT, defect reversibility analysis, myocardial infarction, 1561
insulin/potassium/glucose and, SPECT, hibernated myocardium detection, 1377
kinetics and dosimetry, in human tests, 607
myocardial perfusion SPECT, choice of collimators for, 47P(ab)
neural network analysis in conjunction with, renal transplant candidates, 14P(ab)
prediction of functional recovery, hibernating myocardium, 121P(ab)
quantitative myocardial SPECT, impact of reorientation algorithms, 173P(ab)
regional blood flow and, comparison to myocardial 99mTc teboroxime uptake during hyperemia, dogs with coronary stenosis, 476
reinjection or rest-redistribution, myocardial viability in chronic coronary artery disease, 1968
rest/restredistribution/reinjection protocol, myocardial viability, 121P(ab)
rest SPECT, comparison with 18F FDG SPECT and 18F FDG PET, myocardial viability detection, 176
reverse redistribution, in coronary artery disease, 1019
scintigraphy diagnosis, chronic exertional compartment syndrome, 1618
salivary gland disorders, 220P(ab)
soft-tissue tumors, pediatrics, 1372
severe conventionally fixed defects, coronary artery disease, 120P(ab)
SPECT
cardiac polar maps, 12P(ab)
early myocardial perfusion data, predictor of PTCA results, 135P(ab)
18F FDG PET and, value in detection of pancreatic cancer, 229
myocardial, glucose loading, detection of myocardial viability, 121P(ab)
myocardial bridging, 1031
myocardial perfusion imaging, patient motion prevention during, 2001
single-vessel coronary artery disease and, implications of normal anatomy variability, 944
99mTc phytate subtraction liver imaging and, pancreatic cancer evaluation, 762
SPECT and PET, sequential use, viable myocardium identification, 143P(ab)
stress, resting cardioidile and, simultaneous tomographic imaging, 46P(ab)
stress SPECT, diagnostic accuracy in left ventricular hypertrophy, 110P(ab)
99mTc MIBI and, uptake and release in HeLa cells, 201P(ab)
99mTc tescambitii and, craniocaudal mammoscinntigntura, limitations, 1696
mismatch, thyroid and parathyroid adenoma in chronic renal failure, 526
myocardial scintigraphy VEX test, effect on abdominal background activity, 914
99mTc technetium stenosis, myocardial viability assessment, coronary artery disease, 1961
unexpected bone marrow uptake, nonsecretory myeloma, 250
uptake after high-dose radiation for high-grade gliomas, 96P(ab)
lung cancer, 1514
tests, radiation dosimetry, 97P(ab)
uptake in esoplastic granuloma of frontal bone, comparison with 99mTc MDP imaging, 107
Thallium-201 chloride assessment of chemotherapy effects, osteosarcoma, 129P(ab)
123I MIBG and, scintigraphy, primary thymic carcinoid tumor, presurgical diagnosis, 2243
99mTc HMPAO and, SPECT, skull-base invasion, head and neck tumors, 1740
99mTc HMPAO SPECT and, brain tumor imaging, 174P(ab)
99mTc pertechnetate and 99mTc sestamibi, scintigraphic pitfalls, enlarged parathyroid glands, 467
Thiennylsiperos, radiofluorinated, synthesis, tissue distribution and primate imaging, D2 receptor site mapping, PET, 151P(ab)
Therapeutic nuclear medicine, somatostatin-receptor-positive tumors, 131I-labeled somatostatin analogs for, 214P(ab)
Thermal injury, acute bacterial infection in, 111In IgG use in, 256P(ab)
Thiaminocerecytes, evaluation, high specific 107Rh BFCA formation, 155P(ab)
Thorax, CT and PET, thorax, retrospective image registration, 2333
Three-dimensional analysis gated blood-pool SPECT, 12P(ab)
myocardial perfusion imaging, 12P(ab)
Three-dimensional displays left-ventricular epicardial surface, standard cardiac SPECT, 697
nuclear medicine, depiction of reality or superficial rendering, 703(ab)
surface cortical perfusion, Alzheimer's disease assessment, 99mTc HMPAO SPECT, 690
Thrombin, binding, during cardiopulmonary bypass, 99mTc DNA probe for, 16P(ab)
Thrombolytic therapy pulmonary embolism, lung scan evaluation, 364
pulmonary embolism management, role definition, 369(ab)
Thrombolysis deep venous contrast venography versus other imaging methods, 273P(ab)
detection with 99mTc-labeled synthetic peptide P280, 1384
lower limb, radiolabeled thrombus specific agent, 89P(ab)
pulmonary embolism and, detection with 99mTc MIH1-Fab, 34P(ab)
RP31 as potential imaging agent, 16P(ab)
99mTc P280-labeled synthetic peptide use in detection, 89P(ab)
99mTc TcT2G1s antifibrin scintigraphy, computer processing, 2326
graft, 11In platelets for, 102P(ab)
Thrombus disease, PET imaging with radiolabeled anti-tissue factor antibody, 149P(ab)
imaging radiolabeled Fab(ab), and FAB fragments of fibrin-specific GC4 MAb, 164P(ab)
RP31 in, 16P(ab)
99mTc-labeled peptides, 16P(ab)
99mTc TcP748 for, 103P(ab)
radiolabeled specific agent, lower limb deep venous thrombosis, 89P(ab)
Thymidine, cardiac retention, humans and primates, new metabolic pathway, 143P(ab)
Thymus primary carcinoid tumor, presurgical diagnosis, 123I MIBG and 201T chloride scintigraphy, 2243
scintigraphy 11In in DTPA, immune disease patients, 207P(ab)
11In in DTPA-arg substance P, 257P(ab)
Thyroglobulin, human, diagnosis of thyroid cancer, 15P(ab)
Thyroid autonomous nodule, 131I therapy, patients with or without visible extranodular activity, 217
cancer children of Belarus after Chernobyl, radiiodine treatment, 42P(ab)
differentiated hTG for diagnosis of, 15P(ab)
metastatic, lithium in radiiodine therapy of, 15P(ab)
somatostatin receptor scintigraphy, 14P(ab)
99mTc MIBI onconscintigraphy in, 204P(ab)
without external radiation therapy, 204P(ab)
differentiated mixed, total-body imaging, 47P(ab)
123I tetrofosmin, 2248
female fertility and carcinogenesis assessment, after 131I therapy, 21
131I therapy, patient safety, 27
metastatic follicular, reappearance of radiiodine uptake, 613
near total thyroidectomy, ablation of iodine avid tissue after, 111I use, 203(ab)
pulmonary metastases, alveolar-capillary membrane integrity, 99mTc DTPA clearance as radioidine dosage index, 783
radioimmunotherapy in, 41P(ab)
recurrent metastatic differentiated, 18F FDG and 18F comparison, 203(ab)
TFn-177m(4) DTPA

remnant ablation in, optimal dose of 131I, 41P(ab)
tumoroidal cytokine enhancement of radiodiode uptake, 204P(ab)
differentiated carcinoma, 111In pentetreotide scintigraphy in, 807
18F PET imaging, in concurrent 131I therapy patients, 197P(ab)
function, fetal, Compound W as marker in maternal urine, 210P(ab)
mediullary carcinoma anti-CEA/anti-DTPA immunoconjugate injection, 225P(ab)
bspecific antibody and 111I-labeled bivalent hapten for, 211P(ab)
111In octreotide scintigraphy in detection of, 203P(ab)
metastatic cancer, SPECT and CT image registration using external fiduciary band and three-dimensional surface fitting, 100
papillary carcinoma, cervical lymph node metastasis of, imaged by 18F FDG/111In pertechnetate/131I sodium iodide PET, 1843
parathyroid and, adenoma, in chronic renal failure, 99mTc sestamibi and 201TI mismatch, 826
primary and metastatic cancer, 18F FDG PET, diagnostic value, 196P(ab)
thyroxine binding globulin, correction of triiodothyronine uptake distortion, 209P(ab)
Tfn-1177m(4) DTPA, pain palliation, osseous metastases, pilot study, 725
Tomographic table, attenuation, prone and supine cardiac SPECT, 1102
Total-body imaging, 99mTc tetrofosmin, differentiated mixed thyroid cancer, 2248
Tracer activity, PET, correction for, 115(ab)
Tracer kinetic modeling, data fitting, multiple brain regions, parameter estimate stability increases, 187P(ab)
Transferrin, 18F-labeled, measuring tumor metabolism, 38P(ab)
Transient ischemic attack, diamox HMPAO cerebral perfusion stress test in, 63P(ab)
Transmission-compensated tomography (TCT) attenuation compensation, use of flood source and TET scatter, 166P(ab)
data from scanning line source, uniformity correction and calibration method, 173P(ab)
fast data, collimated scanning line source for, 41P(ab)
fast sequential, attenuation-map determination based on 133CsGd for, 50P(ab)
fast sequential SPECT/TCT data acquisition method, for attenuation correction in cardiac SPECT, 169P(ab)
Transmission/scintillation imaging, SPECT, temporal resolution effects, 50P(ab)
Transplantation
fetal mesencephalic, dopamine transporter after, graft function in Parkinson's disease, 87P(ab)
heart allograft rejection, 111In monoclonal antibody imaging, 102P(ab)
coronary artery disease detection after, 13N ammonia PET/coronary angiography comparison, 982
coronary vasomotion and vasodilatory capacity after, 3P(ab), 78P(ab)
decreased alveolar permeability after, 5P(ab)
kidney allograft function, 99mTc DACH, 233P(ab)
dipyrindamole 201TI scintigraphy use in preoperative assessment, 77P(ab)
measurement of GFR in patients, 231P(ab)
network analysis with 201TI stress imaging, 14P(ab)
prognostic utility of 111In MAG3, 233P(ab)
nuclear medicine methods for evaluation of, 272P(ab)
real-time monitoring of renal function after, 54P(ab)
right and left ventricular contractile reserve, 218P(ab)
thyroid imaging, scintigraphy in, 251P(ab)
18F PET, 224P(ab)
Transplantation, imaging, PET/CT after, 87P(ab)
localization, three agents for lymphoscintigraphy, 199P(ab)
neuroendocrine, somatostatin receptor scintigraphy, 188P(ab)
noval glycosaminoglycans, rapid tumor delivery of radionuclides, neovascular endothelium, 69P(ab)
organ masses and, dose calculations, generalized approach, 1923
ovarian, 111C methionine PET, metabolic imaging, 2196
pancreatic, FDG PET, 224P(ab)
pretargeting, 876(ed)
radioiodinated EGF receptor ligands as tumor probes, MDA-468 cancer cells, 71P(ab)
sigma receptor ligand for, 6P(ab)
size and curability relationship, beta-emitting radionuclides, targeted radioimmunotherapy, 1902
soft-tissue, 201TI scintigraphy, pediatrics, 1372
specific receptor expression, 99mTc-labeled somatostatin receptors, 126P(ab)
thymus, primary carcinoid, presurgical diagnosis, 121I MIBG and 201TI chloride scintigraphy, 2243
using 99mTc-labeled ibotenic-bearing liposome and avidin, 146P(ab)
vasoactive intestinal peptide-receptors, in vitro identification, 71P(ab)
Tumor markers, elevated, suspected recurrent cancer, whole-body PET in, 57P(ab)
Tumor-seeking agents
radiiodinated phospholipid ether analog, breast cancer, 103P(ab)
substance P receptors, human primary neoplasms, 71P(ab)

U
Ultrasound, Doppler, SPECT and, cerebral blood flow and perfusion reserve capacity, hemodynamic carotid transient ischemic attacks, innominate artery stenosis, 1268
Upright position, breast masses, 99mTc MIBI imaging, 194P(ab)
Uracil, 18F-labeled adenosine and, assessment of tumor proliferation rate, 148P(ab)
Urea breath test, 14C-dosimetry and reproducibility of, 98P(ab)
H. pylori gastritis, 227P(ab)
Urinary tract, obstruction, 99mTc MAG3 diuretic renography, children, 33P(ab)

Urine collection, single-injection renal clearance methods with and without, 99mTc MAG3 and 131I OIH, 603
measurement accuracy, dual-isotope Schilling test, multicenter study, 1654
Uterus, carcinoma, postradiation vesicocutaneous fistulas, detection by 111In leukocytes, 618

V
Varical sclerosis therapy, endoscopic, effect on esophageal motor function and gastroesophageal reflex, 1363
Vascular disease, peripheral, skeletal muscle viability assessment, 18F PET, 1408
Vascular permeability, lung, measurement, 1442(ed)
Vascular surgery, cardiac events after, 82Rb PET for prediction of, 78P(ab)
Vasculitis, cerebral, diagnosis by 99mTc HMPAO, 240P(ab)
Vasomotor reserve measurement of, acetalozamide stress brain SPECT, 62P(ab)
venous, presurgical, cerebrovascular disease patients, 53P(ab)
Venography, contrast, deep venous thrombosis, other imaging comparisons, 273P(ab)
Ventilation decreased, decreased perfusion response to, autoregulation effects, lung, 5P(ab)
normal and deep breathing, central and peripheral distribution of radioaerosol, 34P(ab)
regional deterioration of, beta stimulant inhalation therapy and, 35P(ab)
Ventilation-perfusion mismatch, idopathic peripheral pulmonary artery stenosis, 1608
Ventilation-perfusion scanning diagnostic accuracy, acute pulmonary embolism, 112P(ab)
impact of results, on pulmonary angiography, 250P(ab)
interpretation prior cardiopulmonary disease and pulmonary embolism, 112P(ab)
very low probability scan pattern, 113P(ab)
low probability, pulmonary angiography in, 250P(ab)
lung, interpretation criteria, PIOPED study, pulmonary embolism, comprehensive results analysis, 2380
neural network interpretation of, 112P(ab)
reverse mismatches, pulmonary hypertension, 251P(ab)
Ventricular assist device, ultrafast tomographic imaging of, 17P(ab)
Ventricular function asymptomatic aortic regurgitation, radionuclide cineangiography in, 65P(ab)
ejection fraction measurement, myocardial perfusion 82Rb PET imaging, 91P(ab)
first-pass determination, 82Rb PET myocardial perfusion imaging, 141P(ab)
hibernating myocardium, 201TI prediction of functional recovery, 121P(ab)
left assessment, by 99mTc tetrofosmin, correlation with cine-MRI, 135P(ab)

Wada test, FDG-PET imaging versus, temporal lobe seizures, 84P(ab)

Y
Yohimbine, cerebral metabolic correlates of, post-traumatic stress syndrome, PET measurement, 43P(ab)
Yttrium-90 antibody streptavidin pretargeting, performance of, 225P(ab)
BCL2 antisense oligodeoxynucleotide probes labeled with, tumor cell killing, 212P(ab)
111In and, intraperitoneal labeled human IgM, nude mice with peritoneal carcinomatosis, 160P(ab)
labeled HMFG1 MAbs, anti-chelate body response, ovarian cancer therapy, 746
new labeled DOTA-biotin, characterization for pretargeting, 154P(ab)
single-dose pretargeted, breast, lung and colon tumor xenograft regression with, 217P(ab)
Yttrium-90 DOTA 111In and, peptide, conjugation from chimeric L6 MAbs, pharmacokinetics, tumor-bearing mice, 829
peptide, radioimmunotherapy, breast cancer, 97P(ab)
Yttrium-90 KC4, treatment of refractory prostate carcinoma, 213P(ab)
Yttrium-90 lipiodol biodistribution, after hepatic arterial injection, rats with liver tumor, 162P(ab)
preparation and biodistribution, after hepatic arterial injection, rats, 163P(ab)

Wall motion, thickening and, gated sestamibi perfusion images, new quantitative method, 139P(ab)
Washout, 99mTc MIBI, large parathyroid adenoma, 241
Watershed infarct, brain, assessment with 123I IMP SPECT, 242P(ab)
Weighted-integration method cerebral glucose utilization change mapping, 18F FDG double injection, 187P(ab)
rapid calculation of regional cerebral blood flow and distribution volume, 123I IMP and dynamic SPECT, 531
Wiener filter, vector, dual-isotope SPECT, 173P(ab)
World-Wide-Web, See also Computers; Internet teaching file, nuclear medicine, 1520
X
Xenon-133 radiation exposure from, human trachea, 1458
single-breath washin, patients with extensive obstructive airway disease, perfusion and ventilation scans, 64
X-ray, dual-energy absorptiometry, comparative study of body composition, 1392

Yohimbine, cerebral metabolic correlates of, post-traumatic stress syndrome, PET measurement, 43P(ab)

Yttrium-90 antibody streptavidin pretargeting, performance of, 225P(ab)
BCL2 antisense oligodeoxynucleotide probes labeled with, tumor cell killing, 212P(ab)
111In and, intraperitoneal labeled human IgM, nude mice with peritoneal carcinomatosis, 160P(ab)
labeled HMFG1 MAbs, anti-chelate body response, ovarian cancer therapy, 746
new labeled DOTA-biotin, characterization for pretargeting, 154P(ab)
single-dose pretargeted, breast, lung and colon tumor xenograft regression with, 217P(ab)
Yttrium-90 DOTA 111In and, peptide, conjugation from chimeric L6 MAbs, pharmacokinetics, tumor-bearing mice, 829
peptide, radioimmunotherapy, breast cancer, 97P(ab)
Yttrium-90 KC4, treatment of refractory prostate carcinoma, 213P(ab)
Yttrium-90 lipiodol biodistribution, after hepatic arterial injection, rats with liver tumor, 162P(ab)
preparation and biodistribution, after hepatic arterial injection, rats, 163P(ab)
Listed below are the companies that have advertised in this issue. Simply circle the numbers of those companies you are interested in, fill out the information below, and mail or FAX this to the Society of Nuclear Medicine, Advertising Department, 1850 Samuel Morse Drive, Reston, VA 22090-5316, Fax 703-708-9015. We will forward this information to the advertiser(s).

Deadline for response is: February 15, 1996.